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THESIS SUMMARY 
 
In this thesis, presented in the “thesis by publication” format, we have performed a 
systematic evaluation of iron and copper homeostasis in senescent cells. Senescent 
cells are non-dividing cells that enter a state of permanent replicative arrest in 
response to cellular stress (e.g. ionizing radiation, oncogene activation, oxidants). 
Senescent cells are known to accumulate in tissues with age and are implicated in 
various age-related pathologies. 
 We first review the important findings that establish a link between iron, 
organismal ageing and cellular senescence. We discuss our work in the context of 
recent findings that indicate metal dyshomestasis in senescent cells. This thesis 
introduction is being prepared for publication in the journal Metallomics to be 
communicated after publication of our primary research findings.  We also 
previously reviewed the implications of copper in cancer and malignancy that was 
published in the journal Metallomics (Denoyer et al., 2015) (Please find attached in 
Appendices). 
Manuscript 1, prepared as an original research article titled “Iron 
accumulation in senescent cells is coupled with impaired ferritinophagy and 
inhibition of ferroptosis”, is communicated to the journal eLife. This thesis section 
provides a thorough inquiry of the perturbations in iron homeostasis in senescent 
cells. We described the profound accumulation of iron in senescent cells of different 
origins [mouse embryonic fibroblasts (MEFs), human diploid fibroblasts (HDFs) and 
human prostate epithelial cells (PrECs)] produced through different means 
[replicative exhaustion, gamma irradiation (IR), oncogene induction]. Changes in the 
key proteins involved in iron uptake [transferrin receptor 1 (TfR1)], storage (ferritin), 
regulation [iron responsive proteins (IRP1 and IRP2))] and the mislocalization of the 
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iron export protein, ferroportin, is described in further detail in senescent irradiated 
MEFs. We determined that the iron accumulation is a consequence of senescence and 
is associated with impaired ferritinophagy (autophagy of ferritin) leading to a 
functional iron deficiency in these cells and resistance to a novel iron-dependant cell 
death pathway termed ferroptosis. Lastly, we provide in vivo evidence of senescence-
associated increase in iron and ferritin in livers of aged mice and discuss the potential 
use of these findings.  
 Manuscript 2, prepared as an original research article titled “Copper 
elevation in senescent cells through altered cuproproteins and glutathione 
homeostasis” will be communicated to the journal Metallomics after publication of 
manuscript 1. This thesis section describes the accumulation of copper in senescent 
cells of different origins (MEFs, HDFs, PrECs) produced through various means 
[replicative exhaustion, IR, oncogene induction]. Here, we described the changes in 
the copper import (Ctr1) and export proteins (Atp7a) that resulted in elevated copper. 
We explored the effect of senescence in intracellular metal buffering via glutathione, 
changes in copper dependent enzyme SOD1, as well as the copper chaperone for 
SOD1 (CCS). Furthermore, we studied the link between copper accumulation and 
functional Atp7a, the principle copper export protein, using MEFs produced from the 
Brindled mutant mouse with significantly reduced Atp7a function and trafficking. 
We finally describe the connection between the breakdown in lysosomal function of 
senescent cells and their inability to export copper causing it to accumulate. We 
confirm this by preventing the copper accumulation phenotype in senescent MEFs 
through the preservation of lysosomal function as well as by producing this 
phenotype in non-senescent primary cells by limiting their lysosomal function.  
  
 
  
3 
 
Additional works describing the role of copper in malignant transformation 
that I co-authored during this project were published in the journals Prostate and 
Oncotarget. These can be found in the thesis appendices.   
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1.1 Introduction 
Ageing in multicellular organisms eventually leads to deterioration in tissue 
function, promotes chronic inflammation and frailty, and heightens the risk of 
developing degenerative pathologies including dementias (e.g. Alzheimer’s 
and Parkinson’s) and hyperplastic diseases (e.g. cancers) [reviewed in 
(Campisi, 2013, Campisi and Robert, 2014, van Deursen, 2014)]. Modern 
theories of ageing are broadly classified under two categories: programmed 
theories, where ageing is considered a program hardwired into the biology of 
the organism, and error theories, claiming that ageing occurs as a consequence 
of accumulating erroneous molecules and damaged biological processes (Jin, 
2010). These theories are however not mutually exclusive and indeed share 
fundamental processes driving the various effectors that promote ageing (Jin, 
2010, Maklakov et al., 2015). Several important biological functions altered 
during ageing and which contribute to ageing, include cellular senescence 
(Baker et al., 2016, Baker et al., 2011), stem cell function (Oh et al., 2014) 
and cellular reprogramming (Ocampo et al., 2016). Modulation of these 
biological functions can impact upon the progression of normal ageing and 
alter the onset of age-related pathologies (Niccoli and Partridge, 2012, Baker 
et al., 2016, Baker et al., 2011, Oh et al., 2014, Ocampo et al., 2016).  
It has been proposed that ageing itself may be considered a 
pathological condition that might potentially be alleviated with therapeutic 
interventions (Bulterijs et al., 2015, Gems, 2015, Kirkland, 2013, Caplan, 
2005). However, a much better understanding of the cellular biochemistry and 
determinants of ageing is required to provide the means to effectively 
ameliorate ageing and related diseases. Research focused on ageing is 
  6 
becoming increasingly more critical, as projections forecast that by the year 
2030 most countries will experience an unprecedented rise in the percentage 
of people aged 60 years or older (Bloom et al., 2015). A larger aged 
population will require greater medical input for health and long-term care 
and thus will create considerable socio-economic pressure (Bloom et al., 
2015). Therefore, emphasis has been placed on enhancing the productive 
healthy lifespan (healthspan) by reducing the effects and health risks 
associated with ageing (Bloom et al., 2015). For example, one intensely 
studied approach that has been demonstrated to significantly extend 
healthspan in both primates and rodents is calorie restriction (Kemnitz, 2011, 
Boily et al., 2008).  
Calorie restriction activates what have been dubbed ‘survival genes’, 
including sirtuins that encode for NAD+-dependent protein deacylases. These 
genes have been associated with extended healthspan, and longevity, in many 
organisms from yeast (S. cerevisiae) through to mice (Anderson et al., 2003, 
Boily et al., 2008, Lin et al., 2000, Rogina and Helfand, 2004, Wang and 
Tissenbaum, 2006). How sirtuins positively influence healthspan is unclear, 
but is thought to involve a myriad of pathways including promoting 
mitochondrial biogenesis, enhancing stress tolerance and improving fat 
metabolism (Guarente, 2013).  
The most marked healthspan increase provided by calorie restriction 
was seen in rats, resulting in a 45% increase in their median lifespan 
(Swindell, 2012). Calorie restriction has also been correlated with enhanced 
healthspan in humans, the best example of which is the long-live population 
of Okinawa, Japan, where below-average food intake is prevalent (de Cabo et 
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al., 2014). Nevertheless, it is doubtful that most humans would adopt a calorie 
restriction lifestyle and our enjoyment of food would likely create compliance 
issues. Compounds that activate sirtuins to mimic the beneficial effects of 
calorie restriction are currently being assessed in humans for their safety and 
pharmacokinetics (Hubbard and Sinclair, 2014, Mercken et al., 2014, Libri et 
al., 2012, Bonkowski and Sinclair, 2016). 
Another promising approach to improve healthspan has recently 
emerged and involves the selective targeting and clearance of senescent cells, 
which accumulate in tissues with age and contribute to chronic diseases and 
age-related dysfunctions. Clearance of senescent cells in aged mice (progeroid 
or normal) showed remarkable health benefits and limited the progression of 
age-related dysfunctions of adipose tissue, eyes, skeletal muscles and reduced 
frailty and sarcopenia (loss of muscle mass) (Baker et al., 2016, Baker et al., 
2011). The clearance was controlled by activating (drug mediated) a transgene 
product selectively expressed in senescent cells, driven by the p16 promoter [a 
“suicide protein” (ATTAC)]. Furthermore, life-long clearance of senescent 
cells in mice delayed the establishment of age-related debilitating conditions 
(Baker et al., 2016, Baker et al., 2011). Chemotherapeutic approaches 
targeting senescent cells to prevent and halt age-related pathologies have been 
developed and their remarkable effectiveness demonstrated in several mouse 
models (Zhu et al., 2015, Baar et al., 2017). This has ushered a new class of 
drugs called “senolytics” that target and eliminate senescent cells through 
various mechanisms (Zhu et al., 2015, Baar et al., 2017). Preclinical studies in 
mice have shown that senolytics mitigate age-related pathologies associated 
with cardiovascular, renal, pulmonary, neurological and motor function and 
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reduce side effects incurred through radiation and chemotherapy (Baar et al., 
2017, Chang et al., 2016, Schafer et al., 2017, Xu et al., 2015, Zhu et al., 
2015, Childs et al., 2016, Kirkland and Tchkonia, 2017, Roos et al., 2016). 
Together, these studies have unequivocally demonstrated the importance of 
senescent cells in ageing and in the establishment of age-related pathologies. 
Furthermore, given the promising preclinical studies establishing senolytic 
utility in mice, human clinical trials are now being devised by the Geroscience 
Network, a consortium of NIH funded gerontology centres, to translate lead 
compounds (Kirkland and Tchkonia, 2017). However, the successful clinical 
translation of senolytics would require a better understanding of the 
biochemistry of senescent cell and how they exert their 
physiological/pathological influence. This would be essential for determining 
potential side effects of any such intervention and for establishing treatment 
regimen (Kirkland and Tchkonia, 2017).  
1.2 Senescence phenotype: A brief overview 
Primary cells isolated from mammalian tissue, with the exception of 
embryonic cells and transformed cells, have a finite replicative potential and 
subsequently they enter an irreversible state of cell cycle arrest characterized 
as cellular senescence (Miura et al., 2004, Hayflick and Moorhead, 1961). It 
has been over 50 years since Hayflick hypothesized that this limited 
replicative potential is an expression of ageing (or senescence) at the cellular 
level (Hayflick, 1965, Hayflick and Moorhead, 1961). Telomeres, the 
protective ends of chromosomes that shorten with every successive cell 
division, were then described as the molecular clocks that determined the 
replicative potential of primary cells (Harley et al., 1990). Telomere attrition 
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invokes a DNA damage response (DDR) that may ultimately lead to 
establishing cellular senescence. It was subsequently found that various forms 
of stress, such as oxidants (e.g. peroxides), ionizing radiation (e.g. gamma 
radiation) and certain cytotoxic drugs (e.g. doxorubicin) can also contribute to 
the DDR and lead to premature senescence. Certain key proteins that were 
known to be important mediators of genomic stability were subsequently 
linked to senescence induced by these stressors, or through replicative 
exhaustion. These were p53, its downstream mediators (e.g. p21) and the Rb 
protein and its associated signalling protein p16, which were found to be the 
critical mediators of the senescent phenotype (Ben-Porath and Weinberg, 
2005, Shay et al., 1991, van Deursen, 2014). For details on the molecular 
players involved in the induction and maintenance of cellular senescence the 
reader is referred to the following excellent reviews (Campisi, 2013, van 
Deursen, 2014, Childs et al., 2014) 
 Senescence can also be triggered in non-immortalized cells through 
the activation of certain oncoproteins (e.g. H-RasV12 and B-RafE600), a 
phenomenon dubbed as oncogene-induced senescence (OIS). OIS is 
considered as a mechanism for preventing cancer development (uncontrolled 
proliferation) and for facilitating the timely clearance of damaged (mutated) 
cells from the body (Michaloglou et al., 2008, Serrano et al., 1997).  
 Replicative and the various forms of premature senescence have been 
well characterized in vitro with the aid of multiple senescence biomarkers. 
Senescent cells display a characteristic flat-cell phenotype, where cells appear 
enlarged and flattened compared to their proliferative counterparts. Another 
widely used biomarker is the substantially increased lysosomal β-
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galactosidase enzyme, which is referred to as senescence-associated β-
galactosidase activity (SA-βgal). Senescent cells also display alterations in 
chromatin structure, resulting in the appearance of identifiable senescence-
associated heterochromatic foci (SAHF). An important ‘functional feature’ of 
cellular senescence is the change in their secretory components. Senescent 
cells secrete a unique mixture of proteins, including pro-inflammatory 
mediators (cytokines and chemokines) to elicit immunological self-clearance 
(Campisi and Robert, 2014, van Deursen, 2014). The accumulation of 
senescent cells in tissues and organs with age is thought to contribute to age-
related pathologies and dysfunctions, in part, through promoting chronic 
inflammation (van Deursen, 2014, Campisi and Robert, 2014).  
Senescence and the senescence-associated secretory phenotype 
(SASP) were until very recently well described only in vitro (Coppé et al., 
2010, Naylor et al., 2013). In vivo detection of senescent cells had initially 
been problematic due to lack of a reliable biomarker and because genetic 
manipulation of the pathways responsible for senescence, such as those 
involving p53 and p16, invariably led to confounding abnormalities including 
cancer and early death of the organism (Sherr, 2000, Baker et al., 2008, van 
Deursen, 2014). However, over the last 2 decades increasing evidence of 
cellular senescence in vivo has amassed, particularly in association with 
pathologies (Baker et al., 2016, Baker et al., 2011, Erusalimsky and Kurz, 
2005, Xu et al., 2015, Zhu et al., 2015). For example, senescent cells have 
been identified at sites of hyperplastic disease and in tissues following 
chemotherapy (Dimri et al., 1995, Choi et al., 2000, te Poele et al., 2002). 
Other notable examples include the observation of abundant SA-βgal positive 
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endothelial cells, with morphological traits consistent with senescence, in 
atherosclerotic lesions of the aorta, coronary and carotid artery (Vasile et al., 
2001, Minamino et al., 2002). Senescent vascular smooth muscle cells have 
also been identified in arteries of patients with atherosclerosis (Minamino et 
al., 2002).  
These finding corroborate observations made in the senescence-
accelerated mouse model (SAM-P/8) that are predisposed to atherogenesis 
and which display premature senescence in various tissue, including 
throughout the vasculature (Fenton et al., 2004). The enrichment of senescent 
cells in diseased tissue has also been correlated with disease severity (Baker et 
al., 2016, Baker et al., 2011, Erusalimsky and Kurz, 2005, Xu et al., 2015, 
Zhu et al., 2015). For example, senescent hepatocytes have been enumerated 
in liver cirrhosis with their enrichment positively correlated to increased 
fibrosis (Wiemann et al., 2002). 
Recent findings have however led to the re-examination of the role of 
senescence in the context of malignant transformation and tumour 
development. The role of cellular senescence in malignant transformation in 
now described as being antagonistic pleiotropy; performing certain beneficial 
functions in young individuals, but ultimately becoming harmful to older 
individuals (Campisi, 2013). The secretion various pro-inflammatory factors, 
chemokines and proteins by senescent cells (SASP) plays a beneficial role in 
wound healing (Demaria et al., 2014), tissue reorganization (during 
embryogenesis) and in maintaining tissue homeostasis, by facilitating the 
immunological clearance of damaged cells in early life (Campisi, 2013). 
However, the accumulation of senescent cells with age leads to SASP-
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mediated chronic inflammation that is associated with the development of 
malignancies and other age-related pathologies (Campisi, 2013). Given the 
deleterious role senescent cells play in age-related pathologies methods for 
their detection and removal in vivo are being developed (Sharpless and Sherr, 
2015, Biran et al., 2017).  
 
1.3 Senescent cells and age-related pathologies 
The enrichment of senescent cells in various tissues with age is now largely 
accepted and was powerfully demonstrated in the luciferase knock-in mouse 
(p16LUC), where age-dependent accumulation of senescent cells was directly 
observed in vivo (Burd et al., 2013, Yamakoshi et al., 2009). Further studies 
using BubR1 progeroid mice demonstrated the deleterious effects of senescent 
cells in age-related pathologies and frailty (loss of muscle mass) (Baker et al., 
2011, Baker et al., 2008, Baker et al., 2004). BubR1 hypomorphic (BubR1H/H) 
mice express reduced levels of the spindle checkpoint protein BubR1 and 
consequently have features of accelerated ageing including a short lifespan, 
sarcopaenia, arterial hardening, cataracts, loss of subcutaneous fat and 
impaired wound healing (Baker et al., 2008, Baker et al., 2004). These 
features were all reversed through the inactivation of p16 (Baker et al., 2008, 
Baker et al., 2004). Importantly, the beneficial effect of p16 inactivation was 
contingent on reducing the senescent cell burden in the corresponding affected 
tissues (Baker et al., 2008). The related INK-ATTAC transgenic progeroid 
model, developed by introduction of a novel transgene INK-ATTAC in BubR1 
mice provided a means of selectively eliminating p16 expressing cells (Baker 
et al., 2011). Lifelong clearance of p16 expressing senescent cells in this 
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mouse model delayed the onset of age-related pathologies, and for the first 
time, powerfully placed senescent cells as a direct cause of age-related 
diseases (Baker et al., 2011). Interestingly, the clearance of these cells even 
post-establishment of age-related pathologies led to a substantial decrease in 
their severity with improved healthspan (Baker et al., 2011). Therefore, the 
INK-ATTAC transgenic progeroid model provided an important proof of 
principal for the concept of delaying ageing and improving healthspan by 
targeting senescent cells. More recently, by utilizing the INK-ATTAC 
transgene in a normal ageing (non-progeroid) mouse model, the deleterious 
effect of accumulated in ageing tissues was firmly established in the context 
of age-related disease in normal (chronological) ageing (Baker et al., 2016).  
Since these findings, several groups have shown prevention or remediation of 
several tissue dysfunctions by using “senolytic” treatments, including small 
molecule combinations (dasatinib + quercetin) (Zhu et al., 2015), JAK 
inhibitors (Xu et al., 2015), Bcl-Xl inhibitors (Chang et al., 2016), and p53-
FOXO4 interfering peptide (Baar et al., 2017). In each case, ablation of 
senescent cells led to a consistent and significant improvement in disease 
outcome regardless of the mode of action of the senolytic agent. Therefore, 
senolytic treatments have the potential to prevent and/or treat a wide range of 
age-related pathologies (Kirkland and Tchkonia, 2017).  
 
1.4 Role of iron in ageing and senescence  
1.4.1 Iron homeostasis: A brief overview 
Iron mediates critical biological functions including, but not limited to, 
cellular respiration, oxygen transport, biogenesis of DNA and serves as an 
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important functional constituent in numerous proteins.  Mammalian cells have 
evolved intricate iron homeostasis mechanisms to prevent disorders of iron 
deficiency (anaemia) or excess (e.g. haemochromatosis) (Pantopoulos et al., 
2012, Ganz, 2013, Rouault, 2006). In the human body, iron levels are 
maintained through efficient absorptional control over dietary iron uptake and 
iron recycling primarily through the reticuloendothelial system (Ganz, 2013). 
The average human body maintains ~4-5 g of iron, of which, 1-2 mg is lost 
per day through skin desquamation and overall iron is maintained by dietary 
absorption (Pantopoulos et al., 2012, Ganz, 2013, Wang and Pantopoulos, 
2011). No other specific mode of iron excretion, in addition to desquamation, 
is known to exist. The major iron expense in the body is haemoglobin 
synthesis (20-30 mg of iron per day), which is sustained predominantly 
through  phagocytosis of old and/or damaged red blood cells by macrophages; 
a process that contributes towards 90% of total iron through recycling (Wang 
and Pantopoulos, 2011).  
 The absorption of dietary iron occurs in the duodenum (McKie et al., 
2000). Iron (III) is converted to its reduced form iron (II) by the action of 
duodenal cytochrome-b ferrireductase (Dcytb) and then taken up by the 
enterocytes through the divalent metal transporter 1 (DMT1) (Ganz, 2013). 
Iron is bound by transferrin (Tf) and transported via the hepatic portal vein to 
the liver, the major iron storage organ (Ganz, 2013). Circulating iron exists as 
soluble Tf-bound iron (III), which is bound and internalized into cells by 
transferrin receptor 1 (TfR1). Iron is subsequently utilized chiefly for the 
synthesis of iron-sulfur clusters (catalyzed by the iron-sulfur cluster assembly 
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enzyme (ISCU), synthesis of heme (a complex of iron-porphyrin), or stored in 
multimeric ferritin cages (Rouault, 2006, Ganz, 2013).  
 Cellular iron homeostasis is orchestrated through the activites of iron 
regulatory proteins (IRPs). IRPs interact with iron responsive elements (IREs) 
found in mRNA encoding for various iron homeostasis proteins (Rouault, 
2006). In iron depleted conditions, IRPs bind to IREs in the 5’UTR regions of 
ferritin mRNA, limiting ferritin synthesis. Conversely IRPs binds to and 
stabilize the mRNA of TfR1 by binding to 3’UTR, leading to enhanced TfR1 
expression and cellular iron uptake (Rouault, 2006). In conditions of iron 
excess, IRPs do not bind to IREs leading to reduction in TfR1 levels and 
production of ferritin for iron storage and detoxification. Stored iron in ferritin 
cages can in turn be used for cellular requirements in conditions of low iron 
availablity (Rouault, 2006).  
 STEAP3, a ferrireductase facilitates the reduction of iron (III) to iron 
(II) upon its internalization, which is required for iron delivery to the 
mitochondria for heme synthesis and for iron-sulfur clusters (Ganz, 2013). 
The export of excess cellular iron is mediated by ferroportin (FPN) and aided 
by either the multicopper protein hephaestin or ceruloplasmin that, through 
their ferroxidase activity, facilitate the binding of exported iron to Tf (Ganz, 
2013).  
 The liver plays a central role in iron homeostasis through the 
production of ceruloplasmin, Tf, and provides an iron storage site (Anderson 
and Shah, 2013). In addition to these functions, systemic iron homeostasis is 
regulated by the peptide hormone, hepcidin, produced primarily by the liver 
(Nemeth et al., 2004). Hepcidin regulates iron uptake by binding to and 
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internalising FPN resulting in its degradation and consequently causing an 
increase in intracellular iron to occur (Nemeth et al., 2004). In the duodenum, 
this results in reduced dietary iron uptake and in macrophages this process 
limits the recycling of heme bound iron derived from red blood cells (Ganz, 
2013). The hepcidin-mediated regulation allows for robust systemic control of 
circulating iron.  
 
1.4.2 Role of iron in organismal ageing 
Iron dyshomeostasis and iron-mediated oxidative stress are implicated in 
tissue and organismal ageing. The intralysosomal “age pigment” lipofuscin, 
considered a hallmark of ageing tissue, is produced by iron catalysed 
oxidative processes and contains considerable amounts of iron (Brunk and 
Terman, 2002). The link between dietary iron and organismal ageing and 
lifespan is well established in several lower organisms. For example, in fruit 
fly an increase in iron intake decreased lifespan, while lifespan was prolonged 
by the inhibition of dietary iron absorption (Massie et al., 1993, Massie et al., 
1985). Similarly, in the nematode a supraphysiological increase in iron led to 
a reduction in lifespan (Valentini et al., 2012). Furthermore, nematodes 
display an age-associated accumulation of iron, where levels positively 
correlated with increased protein aggregation (Klang et al., 2014) and resulted 
from inefficient loading of iron onto its principle storage protein complex, 
ferritin (James et al., 2015). Age-associated accumulation of iron is also 
observed in tissues of mice and rats (Hahn et al., 2009, Arruda et al., 2013, 
Massie et al., 1983).  
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 In the context of human ageing, dysfunctional iron homeostasis is 
indicated by the conspicuously higher prevalence of both anaemia and iron 
overload in older individuals (Fairweather-Tait et al., 2014, Xu et al., 2012). 
Furthermore, the form of anaemia common in older individuals is anaemia of 
chronic disease, which is associated with iron dyshomeostasis rather than 
deficiency (Xu et al., 2012). Older individuals also display organ specific 
build-up of iron (Fairweather-Tait et al., 2014, Xu et al., 2012).  The age-
associated build-up of iron in brain tissue is especially deleterious and is 
thought to promote proteinopathies leading to debilitating age-associated 
pathologies such as Alzheimer’s and Parkinson’s disease (Connor et al., 1992, 
Ward et al., 2014, Zhu et al., 2009, Smith et al., 2007, Bartzokis et al., 2004). 
Furthermore, elevated iron can be used as a means of assessing risk of these 
disorders and has emerged as an important modifiable age-related risk factor 
(Bush, 2013, Bartzokis et al., 2004).  
 
1.4.3 Iron dysfunction in senescent cells   
We have shown that cellular senescence is accompanied by robust and 
consistent changes in the intracellular level and homeostatic regulation of iron 
(please refer Manuscript 1).  Previously, Killilea et al described iron 
accumulation in human fibroblasts made senescent through replicative 
exhaustion or oxidative stress (Killilea et al., 2003, Killilea et al., 2004). We 
confirmed these findings and further established that iron accumulation is a 
universal feature of senescent cells irrespective of the pro-senescence stimuli, 
cell specialization or species of origin (please refer Manuscript 1). The iron 
accumulation phenotype we further demonstrated related to changes in the 
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expression of homeostatic proteins, causing enhanced iron uptake and storage 
and resistance to iron-mediate toxicity (please refer Manuscript 1). For a 
detailed account of the changes to iron homeostasis proteins that occurred as a 
result of cellular senescence the reader is referred to Manuscript 1. The iron 
accumulation in senescent cells and the associated changes to iron 
homeostasis proteins, were found to be intrinsically linked to an impairment 
of autophagy/lysosomal function in senescent cells (Ott et al., 2016, Tai et al., 
2017, Han et al., 2016). Ultimately, an inability of senescent cells to degrade 
ferritin via lysosomes (ferritinophagy) promotes ferritin build-up and iron 
becomes trapped creating a perceived cellular iron deficiency (please refer 
Manuscript 1). Consistently, recent reports have described senescent cells as 
having impaired lysosomal function and that senescent human fibroblasts 
display elevated ferritin as a result of this dysfunction (Ott et al., 2016, Tai et 
al., 2017, Han et al., 2016). We used rapamycin to either preserve or restore 
lysosomal activity in senescent cells, which reduced the accumulation of iron 
by increasing ferritin turnover. Rapamycin is known to enhance autophagy in 
senescent cells through the inhibition of mTOR, a negative regulator of 
autophagy (Ott et al., 2016, Tai et al., 2017, Han et al., 2016). In Manuscript 
1, we propose a well-reasoned model for senescence-associated iron 
accumulation, covering the notion that an established state of functional iron 
deficiency drives profound iron accumulation (Schematic of model shown in 
Fig.1). Furthermore, we quantified the enrichment of senescent cells in 
hepatic tissue from aged mice, which positively correlated with an increase in 
iron and tissue ferritin.  
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Figure 1: Proposed model for senescence-associated iron accumulation 
Impaired ferritin degradation due to autophagic/lysosomal dysfunction traps 
intracellular iron (Fe) creating a perceived cellular deficiency, which in turn 
causes concomitant changes in the expression profile of iron regulatory 
proteins. Elevated Iron regulated protein 2 (IRP2) levels are indicative of 
cellular iron deficiency and stabilizes Transferrin receptor 1 (TfR1) mRNA 
(via binding to 3’ IRE) increasing its expression to upregulate cellular iron 
uptake. Imported iron (III) [Fe(III)] is reduced to iron (II) [Fe(II)] by the 
metalloreductase STEAP3 and exported across the endosomal compartment 
by the divalent metal transporter 1 (DMT1). Iron (II) is subsequently loaded 
into ferritin cages following oxidation by the action of Poly(rC) binding 
protein (PCBP). Ferritin cages are directed to autophagosomes by the 
specialised cargo receptor Nuclear Receptor Coactivator 4 (NCOA4) where it 
builds-up due to impaired lysosomal function. This scenario accounts for the 
profound iron accumulation observed in senescent cells (up to 20-fold) and 
for their capacity to extract further iron from enriched media. IRP2, which can 
mediate the degradation of ferritin and ferroportin, mRNA in primary cells is 
insufficient to prevent their biosynthesis in the context of senescent cells. 
Ferritin and ferroportin (FPN) can be regulated through mRNA stability or 
post-translationally through protein turnover. Ferritin may be upregulated in 
response to inflammatory cytokines of the senescence-associated secretory 
phenotype (SASP) (such as IL1 & IL6) that drive translation through an 
“acute phase box” (APB) in the 5’ region of ferritin transcript. Ferroportin 
predominantly localized at a large intracellular compartment in senescent 
cells, possibly representing built-up autophagosomes.  
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1.5 Conclusion 
Ageing is a complex process that leads to tissue dyshomeostasis and disease 
in almost all multicellular organisms. The role of iron in ageing remains 
obscure despite a strong association between iron dyshomeostasis and age-
related disorders. The recent establishment of senescent cells as key drivers of 
ageing and of age-related disorders, coupled with the remarkable success in 
their selective targeting with senolytic agents, has provided a promising 
avenue for the enhancement of the human healthspan.  The discovery that 
senescent cells have altered iron homeostasis conceivably accounts for the 
increased iron observed in aged tissues and in organs affected by age-related 
pathologies. Our findings furthermore provide a possible aetiological link 
between both iron dyshomeostasis and senescent cell enrichment, both of 
which occur at the sites of age-related pathologies.   
The biology of senescent cells, while being intensely studied, remains 
largely unknown. One major research focus, the evasion of programmed cell 
death, is of great importance for determining the pathways that lead to the 
origin and persistence of senescent cells in ageing tissue. Ascertaining the 
means to re-initiate programmed cell death pathways for the selective 
elimination of senescent cells is the cornerstone for developing senolytic 
approaches. One possible approach to induce programmed cell death in 
senescent cells is the iron-dependant cell death pathway, ferroptosis. We have 
shown that senescent cells, through harboring imparied ferritinophagy, are 
highly resistant to ferroptosis. The substantial build-up of iron in senescent 
cells compared to their precursor, may provide a therapeutic window to 
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selectively ablate senescent cells if iron can be exploited to somehow elicit 
ferroptosis.  This is the subject of current research.  
 It is also important to explore the importance of iron in the 
development of the various features of senescence, such as SASP, and to 
determine whether iron redistribution/chelation may be sufficient to mitigate 
some of their deleterious effects. If realised, this could be transformational for 
current approaches for alleviating age-associated disorder.   
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Abstract 
Cellular senescence is characterized by the irreversible arrest of proliferation, a 
pro-inflammatory secretory phenotype and evasion of programmed cell death 
mechanisms. We report that senescence alters cellular iron acquisition and storage 
and also impedes iron-mediated cell death pathways. Senescent cells, regardless 
of stimuli (irradiation, replicative or oncogenic), accumulate vast amounts of 
intracellular iron (up to 30-fold) with concomitant changes in the levels of iron 
homeostasis proteins. For instance, ferritin (iron storage) levels provided a robust 
biomarker of cellular senescence and for associated iron accumulation and 
conferred resistance to iron induced toxicity. Cellular senescence preceded iron 
accumulation and was not perturbed by sustained iron chelation (deferiprone). 
Iron accumulation in senescent cells was driven by impaired ferritinophagy, the 
process of ferritin being delivered to lysosomes (via autophagosomes) for 
degradation. Lysosomal dysfunction in senescent cells was confirmed through 
several markers, including the build-up of microtubule-associated protein light 
chain 3 (LC3-II) in autophagosomes. Impaired ferritin degradation rationalises the 
iron accumulation phenotype of senescent cells, whereby iron is effectively 
trapped in ferritin creating a perceived cellular deficiency. Consistently, senescent 
cells were highly resistant to ferroptosis, an autophagic cell death process reliant 
on bioavailable iron. Promoting ferritin degradation by using the autophagy 
activator rapamycin averted the iron accumulation phenotype of senescent cells, 
preventing the increase of TfR1, ferritin and intracellular iron, but failed to re-
sensitize these cells to ferroptosis. Finally, the enrichment of senescent cells in 
mouse ageing hepatic tissue was found to accompany iron accumulation, an 
elevation in ferritin and mirrored our observations using cultured senescent cells.  
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Introduction 
Cellular senescence refers to cells that have undergone irreversible growth arrest 
through replicative exhaustion, or in response to a variety of pro-oncogenic 
cellular stresses (e.g. oncogenes, oxidants, and radiation) (Campisi and Robert, 
2014, van Deursen, 2014). Irrespective of the stimulus, senescence safeguards 
against the unrestricted growth of damaged cells and promotes cellular clearance 
through eliciting the immune system. However, senescent cells accumulate with 
age and contribute to chronic diseases and age-related dysfunctions, in part, 
through the pro-inflammatory factors (e.g. cytokines & chemokines) they secrete 
(senescence-associated secretory phenotype; SASP) (Campisi and Robert, 2014, 
van Deursen, 2014). Senescent cells and SASP have been linked with chronic 
inflammation that is often observed during ageing in tissues in the absence of 
obvious infection (van Deursen, 2014).  
The clearance of senescent cells in mice, using a novel transgene (INK-
ATTAC) that allows for selective apoptosis of p16-positive senescent cells in vivo, 
improved healthspan by attenuating age-related pathologies both prophylactically 
and as treatment (Baker et al., 2016, Baker et al., 2011). Removal of p16-positive 
senescent cells in ageing mice delayed tumourigenesis and attenuated age-related 
deterioration of several organs, including kidney, heart and adipose tissue, 
without adverse side effects (Baker et al., 2016). Furthermore, a median lifespan 
extension was observed, indicating that p16-positive senescent cells negatively 
impact longevity (Baker et al., 2016). Senolytic (anti-senescence) treatment is 
also sought-after for cancer therapy, as current chemotherapeutics (e.g. DNA 
damaging agents) can cause cancer cells to become senescent (Roninson, 2003, 
Baar et al., 2017, Sanoff et al., 2014, Ewald et al., 2010). Senescent cells are 
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linked with cancer drug resistance and recurrence (Demaria et al., 2017, Sun et 
al., 2012). Recently, a novel senolytic agent (FOXO4-p53 interfering peptide) has 
shown considerable promise in mice, promoting apoptosis of doxorubicin-induced 
senescent cells, neutralizing doxorubicin-induced toxicity and improving overall 
healthspan (Baar et al., 2017). Together, these studies demonstrate tangible health 
benefits for targeting senescent cells and thereby identify senescent cells as being 
integral to many age-related pathologies and dysfunctions.  
Several reports have alluded to a dysfunction in iron homeostasis either 
systemically with ageing (Fairweather-Tait et al., 2014, Xu et al., 2012), or in 
specific organ systems affected by age-related pathologies (Puxeddu et al., 2014, 
Ogilvie-Harris and Fornaiser, 1980, Morris et al., 1986). The accumulation of iron 
in various tissues with ageing has been reported separately to the enrichment of 
senescent cells (Fairweather-Tait et al., 2014, Xu et al., 2012, Hahn et al., 2009, 
Connor et al., 1992, Hahn et al., 2006, Cook and Yu, 1998). Nevertheless, many 
diseases associated with the accumulation of senescent cells, such as dementias 
(Alzheimer’s and Parkinson’s) (Chinta et al., 2015, Bhat et al., 2012, Chinta et al., 
2013), osteoarthritis (Rose et al., 2012, Philipot et al., 2014) and idiopathic 
pulmonary fibrosis (Schafer et al., 2017), also exhibit iron dyshomeostasis where 
often iron positively correlates with disease severity (Ward et al., 2014, Zhu et al., 
2009, Bartzokis et al., 2004, Ayton et al., 2014, Dexter et al., 1987, Lhermitte et 
al., 1924, Ogilvie-Harris and Fornaiser, 1980, Morris et al., 1986, Fritz et al., 
1996, Camacho et al., 2016, Chandler et al., 1988). Iron accumulation occurs in 
replicative senescent fibroblasts in vitro (Killilea et al., 2003) and the iron storage 
protein ferritin is enriched in ageing tissues (Ott et al., 2016a, DeRuisseau et al., 
2013). However, a relationship between senescent cells and iron dyshomeostasis 
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in ageing, or in age-related pathologies and dysfunctions, has not been shown. We 
therefore investigated whether altered iron homeostasis is a characteristic of 
senescent cells using mammalian cell culture models and aged wild-type (wt) 
C57BL/6 mice. The aim was to determine if the senescence phenotype is 
intrinsically linked with changes to cellular iron homeostasis and related cell 
death pathways. 
 
Results 
Senescent cells accumulate marked amounts of intracellular iron  
Inducing senescence in mouse embryonic fibroblasts (MEFs) by using sublethal 
gamma irradiation is a well-established technique (Freund et al., 2012, Cmielova 
et al., 2012). The DNA damage incurred sequentially activates the p53-p21 and 
p16-RB effector pathways, representing distinct phases from early to full 
senescence (Childs et al., 2015, van Deursen, 2014). We initially chose this mode 
of induction to determine whether cellular senescence is associated with any 
change in the level of intracellular iron (Fig. 1A). When cultured for a minimum 
of 10 days, more than 80% of irradiated MEFs (MEF IR) stained positive for 
senescence associated beta-galactosidase (SA-βgal) activity (Fig. 1A(i), Fig. 
S1A). Senescent MEFs remain viable (Fig. S1B) and can be metabolically active 
in culture for many months (van Deursen, 2014). To permit sufficient time for a 
net change in intracellular iron to occur, we cultured irradiated MEFs (MEF IR) 
for 21 days, by which time they had increased p53 and p16 protein expression 
consistent with senescence incurred through DNA damage (Fig. 1A(ii)). 
Senescent markers, p16, p21 and IL-6 were also increased at the transcript level 
(Fig. S1C). Intracellular iron was measured by inductively-coupled plasma mass 
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spectrometry (ICP-MS) and at 21 days post-irradiation senescent MEFs (MEF IR) 
accumulated a vast amount of iron (~20-fold) when compared to primary non-
irradiated MEFs (MEF PRI) (Fig. 1A(iii)). The iron accumulation was reliant on 
p53-mediated senescence induction and was not indirectly caused by irradiation 
(Fig. S1E). One consequence of cellular senescence is the reported morphological 
change in cell size (flat-cell phenotype) (Kuilman et al., 2010), which is an 
important factor to consider when quantifying intracellular metals. Consistent 
with previous reports (Kuilman et al., 2010), the diameter of adhered senescent 
MEFs (at 21 days post-irradiation) was approximately twice that of primary non-
irradiated MEFs (MEF PRI) (Fig. S1F). However, diameters of suspended cells 
measured following dissociation of adherent cells were closely aligned (Fig. 
S1G). Cellular protein content is considered a surrogate marker for overall cell 
size, increasing roughly linearly with cell mass and volume (Milo, 2013). Total 
cellular protein was slightly elevated (~1.3-fold) in senescent MEFs (MEF IR) 
(Fig. S1G), but could not account for the magnitude of increased intracellular iron 
(~20-fold) (Fig. 1A(iii)).  
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Figure 1. Senescent MEFs accumulate marked amounts of intracellular iron.  
(A) Induction of senescence in MEFs by sublethal gamma irradiation (10 Gy) 
caused intracellular iron accumulation. (i) Percentage of senescent MEFs in 
primary (MEF PRI) and irradiated (MEF IR) cultures as determined by SA-βgal 
activity. The majority (>80%) of MEFs displayed positive SA-βgal activity 10 
days post-irradiation (IR) (blue staining). Images were taken at 100X 
magnification. (ii) Western blot analyses of molecular markers of senescence, p53 
and p16, in primary (PRI) and irradiated (IR) MEFs. Senescent MEFs (MEF IR) 
had elevated levels of both p53 and p16 at 21 days post-irradiation (10 Gy). β-
actin was detected as a loading control. (iii) ICP-MS analyses demonstrated that 
senescent MEFs (MEF IR) accumulated intracellular iron (~20-fold) at 21 days 
post-irradiation (10 Gy). Note that media were replenished weekly. 
(B) Induction of senescence in MEFs by replicative exhaustion caused 
intracellular iron accumulation. (i) Percentage of senescent MEFs in primary 
(MEF PRI), replicative senescent (MEF REP) and senescence-bypassed 
NIH(3T3) cultures. The majority (>80%) of MEFs became replicative senescent 
(REP) at passage 7 (10-days post seeding), being positive for SA-βgal activity 
(blue staining). Senescence-bypassed NIH(3T3) cells had no detectable SA-βgal 
activity. Images were taken at 100X magnification. (ii) Western blot analyses of 
molecular markers of senescence, p53 and p16, in primary (MEF PRI), replicative 
senescent (MEF REP) and senescence-bypassed [NIH(3T3)] MEFs. Replicative 
senescent MEFs (MEF REP) when cultured for 21 days at passage 7 had elevated 
levels of both p53 and p16. β-actin was detected as a loading control. (iii) ICP-
MS analyses demonstrated that replicative senescent MEFs (REP) when cultured 
for 21 days at passage 7 accumulated intracellular iron (~20-fold). MEFs that 
underwent senescence-bypass [NIH(3T3)] had intracellular iron levels 
comparable to that of primary MEFs (MEF PRI). (iv) ICP-MS analyses 
demonstrated that isogenic MEFs that we aided to spontaneously bypass 
senescent [ISO(3T3)] also had intracellular iron level comparable to that of 
primary MEFs (MEF PRI). (v) Primary MEFs were immortalised with virus 
containing the SV40 large T antigen (LT). Western blot analyses confirmed LT 
expression at passage 7 post-immortalisation. β-actin was detected as a loading 
control. (vi) ICP-MS analyses demonstrated that immortalised MEFs (MEF LT) 
at passage 7 had intracellular iron levels comparable to that of primary MEFs 
(MEF PRI). 
(C) Induction of senescence in MEFs with virus containing the oncogene H-
RasV12 caused intracellular iron accumulation. (i) Percentage of senescent MEFs 
in primary (PRI) and oncogenic-induced senescent MEFs (OIS) as determined by 
SA-βgal activity. MEFs transduced with virus containing H-RasV12 (OIS) were 
enriched for SA-βgal positive cells (>50%) at 8 days post-transduction in 
comparison to MEFs transduced with control virus (VC) (<5%). Images were 
taken at 100X magnification. (ii) ICP-MS analyses demonstrated that oncogenic-
induced senescent MEFs (OIS) accumulated intracellular iron (~4.5-fold) at 8 
days post-transduction with virus containing H-RasV12. Immortalised MEFs 
[LT(SV40)] transduced with virus containing H-RasV12 (MEF LT Ras) had 
intracellular iron levels comparable to that of primary MEFs (PRI). 
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3).  
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To ascertain whether intracellular iron accumulation occurs when 
senescence is induced through other stimuli, not just through irradiation, we 
measured iron in MEFs that underwent replicative senescence (REP), or oncogene 
(HRasV12) induced senescence (OIS). In our hands, replicative senescence in 
primary MEFs occurred at passage 7 (P7), as established through staining for SA-
βgal activity (10 days post-seeding) (Fig. 1B(i)) and was accompanied with 
termination of their replicative potential [population doubling limit (PDL) < 0.2] 
(Fig. S1H). When MEFs at passage 7 were sustained in culture for 21 days they 
had increased p53 and p16 expression (Fig. 1B(ii)). Concurrently, these 
replicative senescent MEFs (MEF REP), analogous to irradiation-induced 
senescent MEFs (MEF IR) (Fig. 1A), accumulated a vast amount of intracellular 
iron (~20-fold) (Fig. 1B(iii)). Variation in cell diameter or total cellular protein 
content between primary (MEF PRI) and replicative senescent MEFs (MEF REP) 
did not account for the degree of increased intracellular iron (Fig. S1F, G). In 
contrast, the well-characterised NIH(3T3) MEF line that spontaneously bypassed 
senescence (Todaro and Green, 1963), had intracellular iron levels more 
comparable to that of primary MEFs (MEF PRI) (Fig. 1B(iii)). Similarly, isogenic 
MEFs (our embryo lineage) that we aided to spontaneously bypass senescence 
using the 3T3 culturing method [ISO(3T3)] (Todaro and Green, 1963), had 
minimal change in their cellular iron content (Fig. 1B(iv)). Furthermore, primary 
MEFs immortalised with retrovirus containing SV40 large T antigen (LT) (at 
passage 5) (Fig. 1B(v)), which evaded replicative senescence and continually 
proliferated, also had intracellular iron levels comparable to that of primary MEFs 
(MEF PRI) (Fig. 1B(vi)). Therefore, iron accumulation is associated with 
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replicative senescence in MEFs and is not a feature of MEFs that have either 
spontaneously bypassed senescence or were immortalised.  
Oncogene-induced senescence (OIS) was produced in MEFs by using 
retroviruses containing HRasV12 (Fig. 1C). HRasV12 directly causes senescence by 
activating the MAPK pathway in murine fibroblasts, arresting cells at the G1 cell 
cycle stage and is accompanied by an accumulation of p53 and p16 (Serrano et 
al., 1997). Oncogene-induced senescence has also been linked to the reactivation 
of programmed developmental senescence involving p21 and p15 and thus has 
certain molecular distinctions from replicative and irradiation-induced senescence 
that emanate from DNA damage response (DDR) mechanisms (Storer et al., 
2013). Senescent MEFs (MEF OIS) were determined by SA-βgal activity 8 days 
after retroviral transduction with HRasV12 and represented approximately 50% of 
the cell population (Fig. 1C(i)). Despite the limited percentage of senescent cells 
the accumulation of intracellular iron (~4.5-fold) was still evident when compared 
to MEFs transduced with control retroviruses (Fig. 1C(ii)). Immortalised primary 
MEFs (MEF-LT) transduced with retroviruses containing HRasV12 showed no 
signs of cellular senescence and accordingly no iron accumulation (Fig. 1C(ii)).  
Cellular senescence can be induced by different molecular mechanisms 
depending upon the cell type and species of origin (van Deursen, 2014). We 
therefore further demonstrated that human primary diploid fibroblast (HDFs) and 
prostate epithelial cells (PrECs), analogous to MEFs, also accumulated 
intracellular iron following senescence induction through either irradiation (IR) 
(Fig. 2A) or replicative exhaustion (REP) (Fig. 2B). Taken together, these results 
demonstrate that intracellular iron accumulates in senescent cells irrespective of 
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stimuli, or cell origin (mouse vs. human; fibroblast vs. epithelial) and is therefore 
likely a universal feature.  
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Figure 2. Human senescent cells from different linages (fibroblast or epithelial) 
accumulate vast amounts of intracellular iron. 
(A) Induction of senescence in human diploid fibroblasts and human prostate 
epithelial cells by irradiation (IR, 10 Gy) caused intracellular iron accumulation. 
(i) Percentage of senescent diploid fibroblasts in primary (HDF PRI) and 
irradiated (HDF IR) cultures as determined by SA-βgal activity. The majority 
(>80%) of diploid fibroblasts displayed positive SA-βgal activity 10 days post-
irradiation (blue staining). Images were taken at 100X magnification. (ii) ICP-MS 
analyses demonstrated that senescent diploid fibroblasts (HDF IR) accumulated 
intracellular iron (~3.6-fold) at 21 days post-irradiation. (iii) Percentage of 
senescent human prostate epithelial cells in primary (PrEC PRI) and irradiated 
(PrEC IR) cultures as determined by SA-βgal activity. The majority (>80%) of 
prostate epithelial cells displayed positive SA-βgal activity 10 days post-
irradiation (blue staining). Images were taken at 100X magnification. (iv) ICP-
MS analyses demonstrated that senescent prostate epithelial cells (PrEC IR) 
accumulated intracellular iron (~8.4-fold) at 21 days post-irradiation. 
(B) Induction of senescence in human diploid fibroblasts and human prostate 
epithelial cells by replicative exhaustion caused intracellular iron accumulation. 
(i) Percentage of senescent diploid fibroblasts in primary (HDF PRI) and 
replicatively exhausted (HDF REP) cultures as determined by SA-βgal activity. 
The majority (>80%) of diploid fibroblasts became replicative senescent (HDF 
REP) at passage 29, being positive for SA-βgal activity (blue staining). Images 
were taken at 100X magnification. (ii) ICP-MS analyses demonstrated that 
senescent diploid fibroblasts (HDF REP) when cultured for 21 days at passage 29 
accumulated intracellular iron (~3.3-fold). (iii) Percentage of senescent prostate 
epithelial cells in primary (PrEC PRI) and replicatively exhausted (PrEC REP) 
cultures as determined by SA-βgal activity. The majority (>80%) of prostate 
epithelial cells became replicative senescent (PrEC REP) at passage 6, being 
positive for SA-βgal activity (blue staining). Images were taken at 100X 
magnification. (ii) ICP-MS analyses demonstrated that senescent prostate 
epithelial cells (PrEC REP) when cultured for 21 days at passage 6 accumulated 
intracellular iron (~7.3-fold).  
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3).  
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Altered iron homeostatic mechanisms drive senescent cells to acquire 
profound levels of intracellular iron  
The considerable increase in intracellular iron in senescent cells would 
conceivably necessitate numerous adaptive changes by the cell. Iron represents a 
double-edged sword, as its redox property that is utilised by many biochemical 
reactions also renders it potentially toxic. Iron can catalyse the production of 
reactive oxygen species (ROS) and free radicals, including the highly reactive 
hydroxyl radical (Dixon and Stockwell, 2014). We therefore investigated the 
levels of key cellular iron homeostasis proteins in senescent MEFs (21 days post-
irradiation) (Fig. 3). Western blot analyses revealed that senescent MEFs (MEFs 
IR) had significantly elevated levels of transferrin receptor 1 (TfR1), the principle 
protein responsible for the cellular uptake of iron via transferrin (Fe3+-transferrin) 
(Fig. 3A). The divalent metal transporter 1 (DMT1) protein, which is involved in 
transport of iron (Fe2+) from endosomes to cytoplasm, did not significantly 
change (Fig. 3A). Ferroportin was also increased in senescent cells (Fig. 3A) and 
can function to efflux iron from the cell under certain conditions. However, 
ferroportin predominantly localized to an intracellular compartment and not at the 
plasma membrane in senescent cells (Fig. S2A-C) and therefore is unlikely to 
partake in effective iron efflux. Strikingly, the cellular iron storage protein, 
ferritin, was elevated more than 10-fold in senescent cells (Fig. 3A). Considering 
that each ferritin complex is capable of coordinating up to 4500 atoms of iron 
(MacKenzie et al., 2008, Rouault, 2006), a 10-fold increase in protein levels could 
easily account for the iron accumulation in senescent cells and for its 
detoxification. To ascertain whether ferritin also increased markedly in senescent 
cells of other origins, we utilized both human primary diploid fibroblast (HDFs) 
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and prostate epithelial cells (PrECs). When senescent (21 days post-irradiation), 
these human cell lines both displayed a substantial increase in intracellular ferritin 
(Fig. 3B(i),(ii)), consistent with concurrent iron accumulation as previously 
observed in these cells (Fig. 2). Additionally, when senescence in MEFs was 
induced through continual passaging (REP), there was likewise iron accumulation 
(Fig. 1B) and correspondingly a marked elevation in ferritin (Fig. 3B(iii)). 
Therefore, ferritin is a reliable marker of cellular senescence and associated iron 
accumulation. 
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Figure 3. Altered iron homeostatic mechanisms drive senescent cells to acquire 
intracellular iron.  
(A) Expression of key iron homeostasis proteins was analysed in senescent MEFs 
(IR) at 21 days post-irradiation (10 Gy) by western blot and densitometry. The 
levels of transferrin receptor 1 (TfR1) [main iron (Fe3+) importer], divalent metal 
transporter 1 (DMT1) (cytosolic iron importer), ferroportin (iron exporter) and 
ferritin (intracellular iron storage) were measured in comparison to primary (PRI) 
MEFs. β-actin was detected as a loading control.  
(B) Western blot analyses and densitometry confirm elevated expression of 
ferritin in (i) senescent human diploid fibroblasts (HDF IR) and in (ii) senescent 
human prostate epithelial cells (PrEC IR), both at 21 days post-irradiation (10 
Gy). Furthermore, elevated ferritin expression was confirmed in (iii) replicative 
senescent MEFs (P7) cultured for 21 days. β-actin was detected as loading 
controls.  
(C) Expression of key regulatory proteins of iron homeostasis was analysed in 
senescent MEFs (IR) at day 21 post-irradiation (10 Gy) by western blot and 
densitometry. The levels of iron regulatory protein 1 (IRP1) and iron-sulfur 
cluster assembly enzyme (ISCU) were found significantly lower than those in 
primary (PRI) MEFs, while IRP2 was significantly elevated. β-actin was detected 
as a loading control. Statistical analysis was performed by student-t test: 
significant (*p<0.05, **p<0.01, ***p<0.001). Data represented as mean ± SD (n 
= 3).  
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The principle regulators of cellular iron homeostasis are the iron 
regulatory proteins (IRPs), IRP1 and IRP2. These proteins bind to iron-responsive 
elements (IRE) situated in mRNAs of key iron homeostasis proteins. During iron 
deficiency, IRPs bind to ferritin and ferroportin mRNAs to repress translation and 
to TfR1 mRNAs to block its degradation. In excess iron, IRPs do not bind, 
increasing the expression of ferritin and ferroportin while promoting TfR1 mRNA 
degradation (Rouault, 2006). Senescent MEFs (MEFs IR) had significantly lower 
levels of both IRP1 and its regulator the iron-sulfur cluster enzyme (ISCU) (Fig. 
3C), which is required for iron-sulfur cluster biogenesis (Funauchi et al., 2015, 
Rouault, 2006, Rouault, 2015). IRP1 when bound with an iron-sulfur (4Fe-4S) 
cluster functions as a cytosolic aconitase instead of a translational regulator 
(Funauchi et al., 2015, Rouault, 2006). However, senescent MEFs (MEF IR) had 
markedly elevated IRP2 expression, consistent with having elevated TfR1 but not 
with elevated ferritin and ferroportin (Fig. 3A). Unlike IRP1, IRP2 is regulated 
via iron-dependent degradation and acts as a sensor for cellular iron 
bioavailability (Rouault, 2006). Furthermore, the IRE-binding activity of IRP2 
correlates with its protein level (Asano et al., 2011, Iwai et al., 1995, Rouault, 
2006). Therefore, high levels of IRP2 are usually indicative of decreased cellular 
iron bioavailability. Taken together, these results demonstrate that iron 
accumulation in senescent cells is associated with dramatic changes in the levels 
of relevant homeostatic proteins; with a paradoxical increase in both TfR1 and 
ferritin coupled with internalized ferroportin.  
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Cellular senescence precedes iron accumulation and provides resistance to 
iron induced toxicity 
We next sought to determine the timeframe between cellular senescence 
development and iron accumulation and whether augmented iron levels are 
maintained in metabolically active senescent cells. Occurrence of the senescence 
phenotype (SA-βgal activity) and iron accumulation was surveyed in MEFs 
following irradiation across different subsequent culturing time points (1, 7, 14 
and 21 days) (Fig. 4A, B). Note that media were replenished weekly for each time 
point. The accumulation of intracellular iron (Fig. 4B) occurred in parallel with 
the formation of senescent cells and reflected the percentage of senescent cells at 
days 7 (>50%) and 14 (>80%) post-irradiation (Fig. 4A). However, the amount of 
accumulated iron between days 14 and 21 had somewhat plateaued but was 
maintained, indicating that a possible upper threshold had been reached. A similar 
limit for iron accumulation was demonstrated in replicative senescent MEFs (Fig. 
S3). This upper threshold was reflected by the protein levels of both TfR1 and 
ferritin, which increased until and peaked at 14 days post-irradiation (Fig 4C). To 
establish whether the level of iron accumulation at 14 days post-irradiation 
represented sequestration capacity, we treated senescent MEFs (MEF IR) at this 
time point with either basal medium or media supplemented with 5 µM or 40 µM 
iron [as ferric ammonium citrate (FAC)] for 24 hours (Fig. 4D(ii)). Primary non-
irradiated MEFs (MEF PRI) were treated equivalently as a control (Fig. 4D(i)). 
Remarkably, there was a further dose-dependent increase in the capacity of 
senescent MEFs to accumulate iron, with cells accumulating up to ~3-fold more 
(with 40 µM FAC) when compared with senescent cells cultured in basal medium 
and ~30-fold more when compared with primary MEFs (Fig. 4D(i)).  
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Analogous to the response documented in most cell types, primary MEFs 
with augmented intracellular iron (following 24 hour FAC treatments) (Fig. 
4D(i)) had reduced TfR1 and upregulated ferritin in order to counteract toxicity 
(Fig. 4E(i)). However under the same treatment conditions, senescent MEFs (14 
days post-irradiation) further increased TfR1 (5 µM FAC) and likewise ferritin 
(Fig. 4E(ii)). Ferritin continued to increased even when senescent MEFs, already 
laden with intracellular iron, were exposed to media containing pathological 
levels of iron (40 µM FAC). These extraordinary ferritin dynamics seen in 
senescent MEFs would conceivably enhance resistance to iron. Consistent with 
this idea, senescent MEFs (14 days post-irradiation) were substantially less 
vulnerable to iron induced toxicity than primary non-irradiated MEFs (MEF PRI) 
(Fig. 4F). Therefore, homeostatic mechanisms in senescent MEFs are geared for 
continual uptake and sequestration of milieu iron and afford cells enhanced 
tolerance to iron. 
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Figure 4.  Cellular senescence precedes iron accumulation and provides 
resistance to iron induced toxicity.  
(A) Percentage of senescent MEFs (MEF IR) post-irradiation (10 Gy) over the 
culturing time points indicated (day 1, 7, 14 and 21), as determined by SA-βgal 
activity (blue staining). Images were taken at 100X magnification.  
(B) ICP-MS analyses demonstrated cumulative intracellular iron accumulation in 
irradiated (10 Gy) senescent MEFs (MEF IR) over the culturing time points 
indicated (day 1, 7, 14 and 21). Note that iron accumulation somewhat plateaued 
after day 14, but was maintained. Baseline intracellular iron level in primary 
MEFs (MEF PRI) is also shown.  
(C) Expression of iron uptake and storage proteins was analysed in senescent 
MEFs (IR) post-irradiation (10 Gy) over the culturing time points indicated (day 
1, 7, 14 and 21) by western blot. The levels of transferrin receptor 1 (TfR1) [main 
iron (Fe3+) importer] and ferritin (intracellular iron storage) were determined in 
comparison to primary (PRI) MEFs. β-actin was detected as a loading control. 
(D) Capacity of senescent MEFs to accumulate iron is dependent on milieu iron 
concentration. (i) Primary (PRI) MEFs were cultured for 24 hours in basal 
medium, or media supplemented with either 5 µM or 40 µM iron (FAC). ICP-MS 
analyses revealed a dose-dependent increase in accumulated iron in primary 
MEFs following iron treatment. (ii) Irradiated (10 Gy) senescent MEFs (IR) were 
first cultured for 14 days, then for 24 hours in basal medium, or media 
supplemented with either 5 µM or 40 µM iron (FAC). ICP-MS analyses revealed 
a dose-dependent increase in accumulated iron in senescent MEFs following iron 
treatment. Baseline intracellular iron level in primary (PRI) MEFs is also shown. 
(E) Senescent MEFs are geared to sequester milieu iron. (i) Western blot analyses 
and densitometry demonstrated that TfR1 was downregulated and ferritin 
upregulated when primary MEFs (MEF PRI) were cultured for 24 h in media 
supplemented with either 5 µM or 40 µM iron (FAC). (ii) Western blot analyses 
and densitometry demonstrated that TfR1 and ferritin are further upregulated 
when senescent cells (14 days post-irradiation) were cultured for 24 h in media 
supplemented with either 5 µM or 40 µM iron (FAC). β-actin was detected as 
loading controls.  
(F) Senescent MEFs possess enhanced resistance to elevated iron. The viability of 
iron treated primary and senescent MEFs was determined by propidium iodide 
and flow cytometry. Note that an extremely high concentration of iron (500 µM) 
was used as a positive control.  
(G) Chelation reduced intracellular iron and ferritin accumulation in irradiated 
MEFs. Primary MEFs were treated with the cell-permeable iron chelator 
deferiprone (Dfp) (50 µM) while irradiated (10 Gy) to become senescent and then 
subsequently for 10 days in culture. Primary MEFs irradiated and cultured in 
basal medium served as a control. (i) ICP-MS analyses demonstrated that 
sustained Dfp treatment prevented iron accumulation in irradiated MEFs. 
Baseline intracellular iron level in primary MEFs (MEF PRI) is also shown. (ii) 
Western blot analyses and densitometry demonstrated that sustained Dfp 
treatment prevented ferritin accumulation in irradiated MEFs. β-actin was 
detected as a loading control.  
(H) Percentage of senescent MEFs following sustained Dfp treatment. Primary 
MEFs were treated with Dfp (50 µM) while irradiated (10 Gy) to become 
senescent and then subsequently for 10 days in culture. Primary MEFs irradiated 
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and cultured in basal medium served as a control. The majority (>80%) of treated 
MEFs become senescent, staining positive for SA-βgal activity (blue staining). 
(I) Stored iron in senescent MEFs once accumulated is highly resistant to 
chelation. Senescent MEFs (21 days post-irradiation) treated with Dfp (50 µM) 
for 24 hours showed (i) only a marginal decrease in intracellular iron as 
determined by ICP-MS. (ii) Western blot analyses and densitometry showed a 
negligible effect of Dfp treatment on ferritin level of senescent MEFs. β-actin was 
detected as a loading control.  
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3).  
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We next ascertained whether iron accumulation is important for the 
induction of cellular senescence (Fig. 4G-H). Primary MEFs were treated with 
the cell-permeable iron chelator deferiprone (Dfp) (50 µM) while irradiated (10 
Gy) to become senescent and then subsequently for 10 days in culture. Note that 
10 days in culture is required for >80% of irradiated MEFs (MEF IR) to stain 
positive for SA-βgal activity (Fig. 1A(i), 4A). Sustained Dfp treatment inhibited 
both intracellular iron accumulation and ferritin upregulation in the irradiated 
MEFs (MEF IR) (Fig. 4G(i),(ii)), but did not obstruct cellular senescence 
development (Fig. 4H). Once senescence was fully established (21 days post-
irradiation) Dfp treatment (50 µM for 24 hours) could only marginally decrease 
intracellular iron and consequently had a negligible effect on ferritin level (Fig. 
4I(i), (ii)). Stored iron in senescent cells once accumulated is therefore highly 
resistant to chelation. Taken together, these results demonstrate that dose-
dependent iron accumulation occurs post senescence development and is 
associated with remarkable ferritin dynamics that confer resistance to iron 
induced toxicity.  
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Iron accumulation in senescent MEFs is associated with impaired 
ferritinophagy and inhibition of ferroptosis 
Ferritinophagy, the process of ferritin being sequestered into autophagosomes and 
delivered to lysosomes for degradation, is important for liberating iron from 
ferritin and thus for maintaining cellular iron homeostasis (Asano et al., 2011, 
Mancias et al., 2014, Kidane et al., 2006, Zhang et al., 2010). We hypothesized 
that impaired ferritin degradation might provide an explanation for the iron 
accumulation phenotype of senescent cells; by effectively trapping iron in ferritin 
and thereby creating a perceived cellular deficiency. To investigate this idea, we 
compared the lysosome-mediated ferritin degradation pathway between primary 
(MEF PRI) and senescent MEFs (MEF IR) (Fig. 5). Primary MEFs (MEF PRI) 
were treated with 40 µM iron (FAC) for 24 hours to increase ferritin (Fig. 5A(i)), 
raising the intracellular iron concentration to that observed in senescent MEFs 
(MEF IR) (14 days post-irradiation) (Fig. 5A(ii)). Ferritin degradation was then 
stimulated with the iron chelator deferoxamine (DFO) (50 µM) as previously 
described (Asano et al., 2011, De Domenico et al., 2009, Mancias et al., 2014) 
and occurred substantially within 6 hours of treatment (Fig. 5A(i)). The acidic 
environment of the lysosome is crucial for iron extraction from ferritin and for 
subsequent ferritin degradation (Asano et al., 2011). Therefore, ferritin 
degradation was inhibited by alkalinisation of the lysosome, with ammonium 
chloride (NH4Cl) (Fig. 5A(i)). These results are consistent with lysosome-
mediated ferritin degradation in MEFs as previously reported (Asano et al., 2011, 
Kidane et al., 2006, Zhang et al., 2010). However, in senescent MEFs (14 days 
post-irradiation) the equivalent treatment with DFO was insufficient to induce 
ferritin degradation (Fig. 5B), suggesting impairment of this pathway.  
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Figure 5. Iron accumulation in senescent MEFs is associated with impaired 
ferritinophagy. 
(A) Ferritin degradation in primary MEFs (MEF PRI) was inhibited by lysosomal 
acidification.  
(i) Primary MEFs (MEF PRI) were treated with 40 µM iron (FAC) for 24 h to 
increase ferritin expression. Ferritin degradation was stimulated with the iron 
chelator deferoxamine (DFO) (50 µM) and occurred substantially with 6 h of 
treatment, as determined by western blot analyses (ii) ICP-MS analyses confirmed 
that intracellular iron levels increased in primary MEFs following treatment with 
40 µM iron (FAC) for 24 h (PRI Fe), subsequently becoming comparable to iron 
levels observed in senescent MEFs (MEF IR) (14 days post-irradiation). 
(B) Ferritin degradation in senescent MEFs (MEF IR) is impaired. Western blot 
analysis showing no change to ferritin in senescent MEFs (MEF IR) (14 days 
post-irradiation) treated with DFO (50 µM) for 6 h. β-actin was detected as a 
loading control. 
(C) Autophagy in primary MEFs with functional lysosomes can be monitored by 
the LC3-II:LC3-I ratio. The ratio of LC3-II:LC3-I was determined by western 
blot analyses and densitometry and increased in primary MEFs (MEF PRI) treated 
with the autophagy activator rapamycin (100 nM) for 16 h. The ratio of LC3-
II:LC3-I was decreased in primary MEFs (MEF PRI) treated with the autophagy 
inhibitor bafilomycin A1 (100 nM) for 16 h. β-actin was detected as a loading 
control. 
(D) Senescent MEFs (10 days post-irradiation) displayed a large build-up of LC3-
II, indicating impaired lysosomal function, as determined by western blot 
analyses and densitometry. The level of LC3-II protein in primary MEFs (MEF 
PRI) is shown for comparison. β-actin was detected as a loading control. 
(E) Senescent MEFs are highly resistant to ferroptosis. The viability of primary 
and senescent MEFs treated for 24 h with varying concentrations of erastin (0.1-5 
μM) and RSL3 (0.1-5 μM) was determined by propidium iodide and flow 
cytometry.  
(F) Preservation of autophagy averted the accumulation of iron-regulatory 
proteins in irradiated MEFs. Primary MEFs were treated with rapamycin (100 
nM) while irradiated (10 Gy) to become senescent and then subsequently for 10 
days in culture. Western blot analyses demonstrated that sustained rapamycin 
treatment significantly reduced expression of phosphorylated ribosomal protein 
S6 (pS6). LC3-II levels were likewise significantly reduced indicating 
preservation of lysosomal function and permissible LC3-II degradation. 
Rapamycin treatment averted the iron accumulation phenotype of senescent 
MEFs, preventing the accumulation of TfR1 and ferritin (densitometry shown). β-
actin was detected as a loading control.  
(G) Preservation of autophagy averted the iron accumulation in irradiated MEFs. 
Primary MEFs were treated with rapamycin (100 nM) while irradiated (10 Gy) to 
become senescent and then subsequently for 10 days in culture. Primary MEFs 
irradiated and cultured in basal medium served as a control. ICP-MS analyses 
demonstrated that sustained rapamycin treatment averted intracellular iron 
accumulation in irradiated MEFs. 
(H) Percentage of senescent MEFs following sustained rapamycin treatment. 
Primary MEFs were treated with rapamycin (100 nM) while irradiated (10 Gy) to 
become senescent and then subsequently for 10 days in culture. Primary MEFs 
irradiated and cultured in basal medium served as a control. Approximately 50% 
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of treated MEFs became senescent, staining positive for SA-βgal activity as 
established by blue staining. Images were taken at 100X magnification.  
(I) Autophagy activation reduced stored iron in established senescent MEFs. ICP-
MS analyses demonstrated that senescent MEFs (MEF IR) (10 days post-
irradiation) treated for 4 days with rapamycin (100 nM) showed a significant 
reduction in intracellular iron when compared to untreated senescent MEFs (MEF 
IR).  
(J) Preservation of autophagy was insufficient to sensitize irradiated MEFs to 
ferroptosis. The viability of primary, senescent, and rapamycin treated irradiated 
MEFs (MEF IR + Rapa) (as described previously in Fig. 5G), treated for 24 h 
with varying concentrations of erastin and RSL3 (0.1-5 μM) was determined by 
propidium iodide and flow cytometry. 
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3).  
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 Lysosomal dysfunction has recently emerged as an important feature of 
oxidative stress-induced senescence and is characterized by the build-up of 
autophagosomes (Tai et al., 2017, Ott et al., 2016a). To confirm that senescent 
MEFs have impaired lysosomal function, we assessed the level of the membrane-
bound form of microtubule-associated protein light chain 3 (LC3-II). LC3-II 
localizes to autophagosomes that ultimately fuse with lysosomes (autolysosomes) 
and is consequently degraded by lysosomal hydrolases (Tanida et al., 2005, 
Mizushima and Yoshimori, 2007). Lysosomal dysfunction causes cells to 
markedly accumulate LC3-II in autophagic structures (Tanida et al., 2005). 
Furthermore, in cells with normal lysosomal activity (turnover) a higher ratio of 
LC3-II to that of its cytosolic (soluble) precursor LC3-I can indicate enhanced 
autophagy, due to greater autophagosome formation (Mizushima and Yoshimori, 
2007, Tanida et al., 2005). Demonstrating enhanced autophagy in primary MEFs 
(MEF PRI), treatment with the autophagy activator, rapamycin (100 nM), 
significantly increased the LC3-II:LC3-I ratio (Fig. 5C). In contrast, treatment 
with bafilomycin A1 (100 nM), an inhibitor of late-phase autophagy (prevents 
fusion of autophagosomes and lysosomes) (Yamamoto et al., 1998), significantly 
reduced the LC3-II:LC3-I ratio (Fig. 5C). In senescent MEFs (10 days post-
irradiation) there was a large build-up of LC3-II, consistent with impaired 
lysosomal function (Fig. 5D). In fact, the level of LC3-II that accumulated in 
senescent MEFs (Fig. 5D) was greater than that observed in primary MEFs 
treated with bafilomycin A1 (Fig. 5C). Note that the LC3-II:LC3-I ratio is a 
reliable indicator of autophagy only in cells possessing functional lysosomes and 
therefore was not evaluated for senescent cells (Tanida et al., 2005). LC3-II also 
accumulated in replicative senescent MEFs (MEF REP), concomitant with 
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elevated ferritin (Fig. S3C). We provided further validation that autophagy 
inhibition exists by demonstrating that senescent cells are highly resistant to 
ferroptosis (Fig. 5E). Ferroptosis is an iron-dependent autophagic cell death 
process (Dixon et al., 2012, Gao et al., 2016, Wolpaw et al., 2011) that can be 
inhibited in MEFs by genetically inactivating autophagy (Hou et al., 2016). We 
treated senescent MEFs (MEF IR and MEF REP) for 24 h with varying 
concentrations of erastin and RSL3 (0.1-5 μM), two structurally different inducers 
of ferroptosis that affect distinct pathways (Yang and Stockwell, 2008). Senescent 
MEFs, both irradiated (MEF IR) and replicatively exhausted (MEF REP) were 
extremely resistant to ferroptosis in comparison to primary MEFs (MEF PRI) 
(Fig. 5E(i)). Taken together, these results demonstrate that lysosomal impairment 
is a feature of cellular senescence and is associated with ferritin accumulation 
(impaired ferritinophagy) and resistance to ferroptosis.  
We next established whether preserving lysosomal function in senescent 
cells would prevent the iron accumulation phenotype. Rapamycin selectively 
activates autophagy through inhibiting the mTOR pathway (Sarkar et al., 2009) 
and has been shown to restore lysosomal function in senescent cells (Tai et al., 
2017). The mTOR pathway is a negative regulator of autophagy and intriguingly, 
is involved in cellular senescence (Xu et al., 2014). mTOR signalling has been 
linked to several senescence features, most notably SA-βgal activity and the 
expression of p16 and p21 markers and is a critical driver of SASP (Laberge et 
al., 2015, Xu et al., 2014). Primary MEFs were treated with rapamycin (100 nM) 
while irradiated (10 Gy) to induce senescence and then subsequently for 10 days 
in culture (Fig. 5F). An important substrate used as a marker for mTOR activity, 
phosphorylated ribosomal protein S6 (pS6), was significantly reduced in 
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rapamycin treated cells (Fig. 5F). Inhibition of pS6 promotes autophagosome 
formation (Blommaart et al., 1995). Furthermore, sustained rapamycin treatment 
was associated with a reduction in LC3-II, indicating preservation of lysosomal 
function and permissible LC3-II degradation (Fig. 5F). Moreover, rapamycin 
treatment averted the iron accumulation phenotype of senescent MEFs, 
preventing the accumulation of TfR1, ferritin (Fig. 5F) and intracellular iron (Fig. 
5G). Consistent with previous reports (Laberge et al., 2015), sustained rapamycin 
treatment was associated with diminished SA-βgal activity (~50%) (Fig. 5H), 
although cells did remain in a non-proliferative state (Fig. S4A). Additionally, 
once senescence was fully established (10 days post-irradiation) subsequent 
rapamycin treatment (100 nM for 4 days) significantly reverted the intracellular 
accumulation of iron (Fig. 5I) without affecting SA-βgal activity (Fig. S4B). 
Torin 1, another inhibitor of mTOR with a different mode of action to rapamycin 
(Kim and Guan, 2015), showed a similar capacity to reduce iron accumulation 
(Fig. S4C). Together these results demonstrate that cellular senescence is 
associated with autophagy dysfunction that impedes ferritinophagy, providing a 
rationale for the associated iron-accumulation phenotype. 
We next explored whether averting the iron accumulation phenotype 
through rapamycin treatment (Fig. 5F,G) would sensitize senescent MEFs (MEFs 
IR) to ferroptosis (Fig. 5J). As above, primary MEFs were treated with rapamycin 
(100 nM) while irradiated (10 Gy) to induce senescence and then subsequently for 
10 days in culture. Subsequently, these cells were treated for 24 h with varying 
concentrations of both ferroptosis inducers erastin and RSL3 (0.1-5 μM) (Fig. 
5J). However, rapamycin treatment, and thus preserving lysosomal function 
(ferritinophagy), was insufficient to sensitize senescent cells to ferroptosis and 
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therefore other overriding factors are involved in impeding ferroptosis in 
senescent cells.  
 
Ageing mice accumulate senescent liver cells with iron and ferritin 
After establishing that senescent cells in vitro accumulate vast amounts of iron, 
we next investigated whether similar changes occur in ageing mice, which have 
previously been reported to accumulate senescent cells in various organs/tissues 
(Baker et al., 2016). We focused on the ageing mouse liver, as senescence within 
this organ has been well characterised and detection through SA-βgal activity was 
shown to have negligible background (Freund et al., 2012). Consistent with 
previous reports, there was a significant increase (~10-fold) in the percentage of 
SA-βgal positive cells in histological liver sections of 30 month-old mice (Aged) 
(C57BL/6; n = 4), when compared to 3 month-old mice (Young) (C57BL/6; n = 
4) (Fig. 6A). ICP-MS analyses demonstrated that aged mouse livers, in addition 
to accumulating senescent cells, also accumulated iron (~2.6-fold) (Fig. 6B). 
Western blot analyses revealed that in senescence-enriched aged livers, in 
accordance with there being elevated iron levels, there was also elevated levels of 
the iron-storage protein, ferritin (Fig. 6C(i)). The increase in ferritin in aged livers 
positively correlated with increased p16 protein and transcript levels (Fig. 
6C(i),(ii)), which served as a further marker for cellular senescence in addition to 
SA-βgal activity staining (Fig. 6A). Serial histological liver sections from both 
young (n = 3) and aged mice (n = 3) were then stained for cellular senescence 
(SA-βgal activity) and ferritin (Fig. 6D). Consistent with the western blot 
analyses (Fig. 6C), there was augmented levels of ferritin in histological liver 
sections of aged mice when compared to young mice (Fig. 6D). Note that the 
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ferritin antibody was diluted in these experiments to facilitate the exclusive 
detection of ferritin overexpressing cells. Additionally, the percentage of ferritin-
enriched cells within aged livers (~10%) (Fig. 6D) corresponded well with the 
percentage of SA-βgal positive senescent cells (~11%) (Fig. 6A). Taken together, 
the enrichment of senescent cells in ageing hepatic tissue was found to 
accompany iron accumulation, an elevation in the iron-storage ferritin protein and 
mirrored our observations in vitro using cultured senescent cells.  
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Figure 6.  The enrichment of senescent cells in ageing mouse liver is 
accompanied by iron accumulation and elevated ferritin. 
 (A) Senescent cells are markedly enriched in the livers of aged mice. Percentage 
of senescent cells in serial histological liver sections from both young (3 month; n 
= 4) and aged mice (30 month; n = 4) as determined by SA-βgal activity (blue 
staining).  
(B) ICP-MS analyses demonstrated a significant increase in iron (~2.5-fold) in 
liver tissues harvested from aged mice (30 month; n = 4) when compared to liver 
tissues harvested from young mice (3 month; n = 4).  
(C) The iron-storage protein ferritin and the senescence marker p16 were 
significantly elevated in livers of aged mice. (i) Western blot analyses and 
densitometry demonstrated that ferritin and p16 expression are increased in liver 
tissues harvested from aged mice (30 month; n = 3) when compared to liver 
tissues harvested from young mice (3 month; n = 3). β-actin was detected as a 
loading control. (ii) Quantitative real-time PCR analysis confirmed increased p16 
transcript levels in liver tissues harvested from aged mice (30 months, n = 3), 
when compared to liver tissues from young mice (3 months, n = 3) 
(D) The percentage of ferritin-enriched cells within aged livers matched the 
percentage of SA-βgal positive senescent cells. Serial histological liver sections 
from both young (n = 3) and aged mice (n = 3) were stained for either SA-βgal 
activity or for ferritin. Images are representative of the mean percentage of either 
SA-βgal activity or ferritin staining from each mouse liver, as determined by 
observing 4 independent fields of view at a magnification of 400X using OlyVIA 
viewer software (ver2.4).  
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Discussion 
Senescent cells can have profound in vivo effects despite their relatively low 
abundance in ageing or diseased tissue (maximum of 15 percent of cellular 
content) (Baker et al., 2011, Baker et al., 2016). However, how senescent cells 
exert both physiological and pathological influence is poorly understood. We 
have provided mechanistic insight into a novel biological activity of senescent 
cells, relating to altered iron acquisition and storage. Intracellular iron 
accumulation was identified a hallmark of cellular senescence irrespective of the 
inducing stimuli (IR, REP or OIS) (Fig. 1) and occurred across species (human 
and mouse) and cell specialisation (fibroblast or epithelial) (Fig. 2). Always 
concomitant was a notable increase in ferritin, which provided a robust biomarker 
for cellular senescence and for associated iron accumulation (Fig. 3A,B, 4C,E, 
6C,D). In mammalian cells, ferritins assemble to form large (480 kDa) complexes 
with cavities capable of accommodating up to 4500 atoms of iron and function to 
modulate iron bioavailability and detoxification within cells (MacKenzie et al., 
2008). Increased cellular iron uptake positively regulates ferritin expression, both 
at the transcriptional and translational levels, to afford protection from labile iron-
mediated oxidative stress (Freund et al., 2012). Most cells subsequently down-
regulate iron uptake mechanisms, particularly TfR1 and up-regulate iron efflux 
via ferroportin in order to regain homeostatic levels (Fig. 4E(i)) (MacKenzie et 
al., 2008). However, senescent cells have altered iron homeostatic mechanisms 
driving both iron acquisition and sustained storage. Senescent cells paradoxically 
had increased TfR1 and ferritin, coupled with reduced ferroportin at the plasma 
membrane (Fig. 3A, Fig. S2,S3C). Ferroportin is therefore unlikely to participate 
in effective iron efflux and consequently iron accumulation prevails through 
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enhanced uptake and sequestration. Senescent cells indeed have an unusual 
appetite for iron acquisition and can amass considerable amounts of intracellular 
iron in comparison to proliferative cells (up to 30-fold increase) (Fig. 4E(ii),F).  
We established that iron accumulation in senescent cells was associated 
with autophagic/lysosomal dysfunction (Fig. 5). Autophagy involves the delivery 
of cytoplasmic substrates (cellular proteins and damaged organelles) to lysosomes 
for degradation and impairment of this process is associated with premature 
ageing and age-associated decline in tissue function (Rubinsztein et al., 2011, 
Tanida et al., 2005). Autophagy impairment incurred through lysosomal 
dysfunction has recently been described in cellular senescence and shown to 
regulate SASP (Tai et al., 2017, Han et al., 2016, Kang et al., 2011, Lin et al., 
2015, Mizunoe et al., 2017). Consistent with our findings (Fig. 5, Fig.S3), 
lysosomal dysfunction has been documented in replicative (Lin et al., 2015) and 
oxidative stress-induced senescence (Tai et al., 2017) and in both cases was 
associated with the buildup of autophagosomes and related markers (e.g. LC3-II, 
p62). Additionally, lysosomal dysfunction can precede senescence development 
and drive the associated phenotypic changes (Kang et al., 2011, Tai et al., 2017). 
Depletion of lysosomal-associated membrane protein 2 (LAMP2), which is 
critical for fusion between autophagosomes and lysosomes, can induce cellular 
senescence (Kang et al., 2011, Tai et al., 2017), as can pharmacological inhibition 
of lysosomal activity (hydroxychloroquine & leupeptin treatment) (Tai et al., 
2017). Furthermore, proteins known to turnover through autophagic degradation 
accumulate in senescent cells, including the GATA4 transcription factor, an 
important regulator of SASP (Kang et al., 2015). GATA4 in turn activates the 
NF-kB transcription factor to initiate SASP and facilitate senescence progression. 
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Coincidently, impaired autophagy in senescent cells has previously been shown to 
reduce ferritin turnover, but in this study intracellular iron levels or the levels of 
major iron homeostasis proteins were not evaluated (Ott et al., 2016b). Ferritin is 
selectively targeted for autophagic/lysosomal degradation by the cargo receptor 
NCOA4 (Mancias et al., 2014), a process required for liberating iron making it 
bioavailable to the cell (Asano et al., 2011, Hou et al., 2016, Mancias et al., 
2014). This process has recently been dubbed ferritinophagy (Hou et al., 2016, 
Mancias et al., 2014). Promoting ferritin degradation by using the autophagy 
activator rapamycin averted the iron accumulation phenotype of senescent cells, 
preventing the increase of TfR1, ferritin and intracellular iron (Fig. 5F,G). 
Rapamycin selectively activates autophagy through inhibiting the mTOR pathway 
(Sarkar et al., 2009) and can extend the lifespan of mice (Harrison et al., 2009).  
Ferroptosis, a unique cell death pathway distinct from apoptosis (Dixon et 
al., 2012, Yagoda et al., 2007, Yang and Stockwell, 2008), is reliant on the 
availability of iron (Dixon et al., 2012, Reed and Pellecchia, 2012, Yang and 
Stockwell, 2008) liberated through ferritinophagy (Gao et al., 2016). Cells are 
also desensitized to ferroptosis through genetic silencing of iron uptake (TfR1), 
metabolism (IRP2 and ISCU) and storage (ferritin) genes (Yang and Stockwell, 
2008, Dixon et al., 2012, Cao and Dixon, 2016), or through depletion of 
transferrin in the extracellular environment (Gao et al., 2015). Cell death elicited 
by ferroptosis-inducing compounds (FINs) (e.g. erastin and RSL3) can also be 
mitigated through various iron chelators (DFO, 2,2-bipyridile or compound 311) 
(Dixon et al., 2012, Reed and Pellecchia, 2012, Yang and Stockwell, 2008). 
Distinctly, ferroptosis can be initiated through repression of the p53 target, 
SLC7A11, which encodes a component of the cysteine/glutamate antiporter 
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(system Xc-), resulting in iron-dependent accumulation of ROS and glutathione 
(antioxidant) depletion (Dixon et al., 2012, Cao and Dixon, 2016). Erastin induces 
ferroptosis through silencing SLC7A11 (Dixon et al., 2014) and was recently 
demonstrated to enhance iron bioavailability through autophagic/lysosomal 
degradation of ferritin and its cargo receptor NCOA4 (Gao et al., 2016). We 
established that senescent cells were highly resistant to erastin-induced ferroptosis 
(Fig. 5E) and remained refractory despite rapamycin treatment preserving 
ferritinophagy (Fig. 5J). Likewise, senescent cells were also markedly resistant to 
RSL3 (Fig. 5E,J), which in contrast to erastin induces ferroptosis through direct 
inhibition of glutathione peroxidase 4 (GPX4) without dependance upon system 
Xc- inhibition or glutathione depletion (Cao and Dixon, 2016). What 
mechanism(s) underpin senescent cell resistance to ferroptosis is under further 
investigation.  
Based on our results we propose the following model to explain iron 
accumulation in senescent cells. Impaired ferritinophagy traps iron in ferritin 
creating a perceived cellular deficiency, which in turn causes concomitant 
changes in the levels of iron regulatory proteins. Elevated IRP2 levels (Fig. 3C) 
are indicative of cellular iron deficiency and stabilizes TfR1 mRNA (via binding 
to 3’ IRE) increasing its expression to up-regulate cellular iron uptake (Rouault, 
2006). However, senescent cells having perturbed ferritin degradation sequester 
iron (trapped in ferritin), creating a perpetual state of deficiency and a cycle 
promoting continual iron acquisition. This scenario accounts for the profound iron 
accumulation observed in senescent cells (up to 20-fold) and for their capacity to 
extract further iron from enriched media (Fig. 4E(ii)). While IRP2 can mediate 
the degradation of ferritin and ferroportin mRNA (Rouault, 2006), this must be 
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insufficient to prevent their biosynthesis in the context of senescent cells. 
Furthermore, ferritin levels remained responsive in senescent cells, further 
increasing in iron supplemented media and affording greater tolerance to iron-
induced toxicity (Fig. 4E(ii), F). Ferritin and ferroportin can be regulated through 
mRNA stability or post-translationally through protein turnover (Ward and 
Kaplan, 2012, Drysdale and Munro, 1966). Interestingly, ferritin can be 
upregulated in response to inflammatory cytokines of the SASP (such as IL1 & 
IL6) that drive translation through an “acute phase box” in the 5’ region of ferritin 
transcripts (Wessling-Resnick, 2010, Kobune et al., 1994). Nonetheless, 
lysosomal dysfunction in senescent cells can account for ferritin and ferroportin 
accumulation, as both proteins are degraded through the autophagic pathway 
(Asano et al., 2011, Nemeth et al., 2004). Consistently, ferroportin predominantly 
localized at a large intracellular compartment in senescent cells, possibly 
representing built-up autophagosomes (Fig. S2A). We provided further evidence 
that senescent cells have a functional iron deficiency, in addition to the 
observation that they were highly resistant to ferroptosis (Fig. 5E). Additionally, 
ISCU levels are suppressed by iron deprivation, to decrease iron utilization by 
curtailing iron-sulfur cluster biogenesis (Tong and Rouault, 2006). In this 
situation, IRP1 usually loses its iron-sulfur cluster and aconitase activity and 
binds IREs with high affinity (Rouault, 2006, Rouault, 2015). However, while 
senescent cells had barely detectable ISCU, consistent with deficient cellular iron, 
this was coupled with markedly reduced IRP1 and therefore this pathway is 
unlikely influencing iron regulatory proteins (Fig. 3C).  
Future studies are required to determine both physiological and 
pathological roles for iron accumulating in senescent cells. We speculate on one 
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possible physiological function; a probable role in delivering anaemia of 
inflammation (AI) (a hypoferremic environment) at the site of 
injury/inflammation to help impede infection (Wessling-Resnick, 2010, Ganz and 
Nemeth, 2015). The subsequent clearance of iron-laden senescent cells by 
macrophages (Munoz-Espin et al., 2013, Storer et al., 2013) would then maintain 
the protective AI and facilitate iron recycling through the reticuloendothelial 
system (Ganz and Nemeth, 2015, Ganz, 2012). Nevertheless, the ramifications of 
accumulating iron in ageing tissues where senescent cell are enriched would be 
profound. Conceivably, senescent cells account for the increased iron observed in 
aged tissues (Fairweather-Tait et al., 2014, Xu et al., 2012) and similarly in 
organs affected by age-related pathologies (Puxeddu et al., 2014, Ogilvie-Harris 
and Fornaiser, 1980, Morris et al., 1986). Furthermore, our findings provide a 
plausible aetiological link between both senescent cell enrichment and iron 
dyshomeostasis occurring at the site of age-related pathologies.   
 
Materials and Methods 
Chemicals and reagents 
Rapamycin was purchased from Thermo Fischer Scientific (Cat#FSBBP2963-1). 
Torin 1 was purchased from Cell Signalling Technologies (Cat#14379S). RSL3 
was purchased from Jomar Bioscience (Cat# S8155). Erastin (Cat#E7881), ferric 
ammonium citrate (FAC) (Cat#F5879), deferoxamine mesylate salt (DFO) 
(Cat#D9533), deferiprone (Dfp) (Cat#379409), bafilomycin A1 (Baf) (Cat# 
B1793) and MG-132 (ready made solution) (Cat# M7449) were purchased from 
Sigma Aldrich. All other reagents were purchased from Sigma Aldrich unless 
otherwise stated.  
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Isolation and culturing of primary mouse and human cells 
Primary mouse embryonic fibroblasts (MEFs) were collected from sacrificed 
pregnant wild-type or Li-Fraumeni syndrome C57BL/6 mice at day 13 post-
coitum, using a protocol modified from that described previously (Todaro and 
Green, 1963). The Li-Fraumeni syndrome C57BL/6 mice, which carry a germline 
mutation in TP53 (G515A nucleotide mutation), were a kind gift from Prof. 
Guillermina Lozano (University of Texas) (Lang et al., 2004). This study was 
approved by the Deakin University Animal Ethics Committee (AEC) (Id#G01-
2014). In brief, intact uteri were removed, washed with cold phosphate-buffered 
saline (PBS) (without Ca2+Mg2+) (Life Technologies, Cat#10010049), and each 
embryo individually prepared by removing appendages including the head and 
red organs. A surgical scalpel blade (Size 11, Livingstone) was used to finely 
mince the remaining tissue, which was then applied through an 18-gauge needle 
using a 5 mL syringe. Suspended cells derived from each embryo were seeded 
into separate 10 cm (55 cm2) dishes (Cellstar®, Cat#664160) and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies, 
Cat#11965118) supplemented with 10% FBS, penicillin (20 U/mL), streptomycin 
(20 μg/mL), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES (1 mM) and 
non-essential amino acids (1%). When adherent MEFs reached ~90% confluency 
they were expanded into one 14.5 cm (152 cm2) dish (Catalogue no. 639160, 
Cellstar®), at which stage they were referred to as being passage 2 (P2). Cells 
were further expanded into three 14.5 cm dishes and subsequently cryopreserved 
at passage 3 (P3) in liquid N2. 
 Primary human diploid fibroblasts (HDFs) (S103) isolated from skin by 
the scratch biopsy method, were obtained from the Murdoch Children’s Research 
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Institute, Melbourne, and were collected from healthy control individuals as 
previously described (Michalczyk et al., 2003). HDFs were provided at passage 
14 and were cultured in Basal Eagle’s medium (BME) supplemented with 10% 
FBS, penicillin (20U/mL), streptomycin (20 μg/mL), L-glutamine (4 mM) and 
HEPES (1 mM). Human primary prostate epithelial cells (PrECs) were purchased 
from Lonza (Cat#CC-2555) and cultured in the recommended PrEBM growth 
medium (Cat#CC-3166) and subcultured using reagents provided by the supplier 
(Cat#CC-5034).  All primary cells were incubated at 37°C in 5% CO2. 
 
Senescence induction by ionizing radiation 
Primary mouse and human cell lines (MEFs, HDFs and PRECs) were cultured to 
~90% confluence in 25 or 75 cm2 flasks (Cellstar®, Cat#690175 or 658175, 
respectively) and subjected to 10 Gray (Gy) gamma irradiation using a calibrated 
Cesium-137 source (Gamma Cell 40, Atomic energy of Canada Limited). Primary 
cells were in their respective standard medium as described above during 
irradiation. Control non-irradiated cell lines were cultured to equivalent 
confluence and otherwise handled in the same manner as irradiated cells. Cellular 
senescence was assessed at various time points (in days) post irradiation by 
senescence-associated β-galactosidase (SA-βgal) activity staining, as detailed in 
the Results.  
 
Retrovirus production and transduction of primary MEFs 
HEK293T cells were cultured in DMEM medium supplemented with 10% FBS, 
penicillin (20 U/mL) and streptomycin (20 μg/mL), and were used as a packaging 
cell line for retrovirus production. The cells were seeded at 5 × 106 cells in a 10 
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cm (55 cm2) dish and the following day transfected (in 5 ml of medium) with a 
500 µl mixture containing 15 µg (total) of plasmid DNA, 45 µl of FuGENE® HD 
Transfection Reagent (Promega, Cat#E2311) and Opti-MEM medium (Life 
Technologies, Cat#31985-070). To produce retroviruses containing SV40 Large T 
antigen (SV40 LgT), equimolar amounts of pBabe-neo large TcDNA plasmid 
(Addgene, Cat#1780) along with the packaging plasmid pCl-Eco (Addgene, 
Cat#12371) were used. Retroviruses containing the oncogene H-RasV12 were 
produced with pWZL-hygro H-Ras V12 plasmid (Addgene, Cat#18749), while 
control retroviruses were produced with empty pWZL-hygro plasmid (Addgene, 
Cat#18750). Transfected HEK293T cells were cultured for 24 h before the 
medium was replaced (5 mL) and subsequently collected every 12 h over a 48 h 
timeframe. Viral supernatants were pooled, filtered (0.45 μm filter, Millipore) and 
frozen at -80°C until required. Retroviral transduction of MEFs was achieved by 
culturing 1.2 × 106 cells in a 10 cm (55 cm2) dish overnight, then substituting the 
medium for 3 h with neat viral supernatant (5 mL) together with polybrene (8 
μg/mL). Subsequently, the cells were cultured in fresh medium (10 mL) for 24 h 
before selection agent (G418; 500 µg/mL or hygromycin 100 μg/mL) was 
administered.  
 
Senescence-associated β-galactosidase assay in cells and tissues 
SA-βgal staining of cultured cells was performed using a protocol modified from 
that previously described (Dimri et al., 1995). Adherent cells were washed twice 
with PBS (30 sec each) and then fixed with a PBS solution containing 2% 
formaldehyde and 0.2% glutaraldehyde for 15 min at room temperature. After a 
further two PBS washes (30 sec each) the cells were incubated in staining solution 
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(150 mM NaCl, 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 2.45 mM (1 mg/mL) 5-bromo-4-chloro-3-indolyl-β-D-
thiogalactopyranoside (X-Gal) in phosphate-citrate buffer, pH 6.0) at 37°C 
without CO2 for <12 h (overnight).  The percentage of cells stained for SA-βgal 
activity was determined using an inverted microscope (Olympus IX51), by 
counting cells in four random fields of view at a magnification of 200/400X. 
Images were taken with Canon 1100D digital camera. 
SA-βgal staining of tissue sections was performed using a protocol 
modified from that described previously (Hinkal et al., 2009). Harvested liver 
from young (3 months) and aged (30 months) mice (wild-type C57BL/6) were 
frozen immediately on dry ice and stored at -80°C until required. Tissue 
specimens were first attached to cryostat section disks with a drop of optimal 
cutting temperature compound (OCT) prior to sectioning at -24°C. The cryostat 
was used to cut 5 µm sections, which were then immediately mounted on 
positively charged slides and fixed in 0.5% glutaraldehyde (in PBS) at room 
temperature for 15 min. Sections were then rinsed thrice with PBS (1 min each) 
and incubated in a humidity chamber at 37°C (without CO2) with fresh SA-βgal 
staining solution for 8-12 h. The tissue sections were then dehydrated in 90% 
ethanol (1 min), stained with 1% hematoxylin (1 min) (Thermo Fisher), washed in 
tap water (30 sec) and then rinsed in acidified alcohol (2% 1N HCl in 90% 
ethanol) for 3 sec. Sections were then washed in tap water (30 sec) then in 
deionized water (30 sec) to remove excess stain and rehydrate the samples. 
Following rehydration the sections were stained in eosin (2%) for 4 min and then 
rinsed consecutively in 90% ethanol (30 sec, twice) and then in 100% ethanol (2 
min). Dry sections were then mounted in DPX and a coverslip was applied and 
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the DPX was allowed to dry for 4 h. Using a standard light microscope at a 
magnification of 400X, SA-βgal stained cells were counted in four random fields 
for each section together with the total number of cells as determined by 
haematoxylin stained nuclei. The percentage of senescent cells was determined 
for tissues harvested from 4 mice per group (young vs. aged) and were averaged 
to establish the percent of senescent cells in a given tissue. Images were taken 
with an inverted light microscope (Nikon Eclipse E200) and photographed using 
an imaging system (Nikon digital site, DS-Fi1).  
 
Western blotting analyses 
Cell cultures were washed once and harvested with trypsin-EDTA solution 
(0.025% trypsin with 0.02% EDTA) and pelleted by centrifugation at 5000 × g.  
RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
1% Triton X-100 and a protease inhibitor cocktail tablet (Roche)) was then used 
to lyse the cell pellet (5 × 105 cells per 150 µL of RIPA buffer), which was 
incubated on ice for 10 min before being centrifuged at 10,000 × g for 10 min at 4 
°C to remove insoluble cell debris. Protein concentration was determined by the 
BCA protein assay kit (Thermo Scientific) as per the manufacturer’s instructions. 
Total cell lysates were made up in SDS protein sample buffer (final 
concentrations: 50 mM Tris/HCl, 2% (w/v) SDS, 0.1% Bromophenol Blue, 10% 
glycerol and 10% β-mercaptoethanol). NP-40 insoluble fractions were prepared as 
described previously (Cater and Haupt, 2011). To obtain enriched plasma 
membrane fractions, cell pellets were suspended in 500 µL of homogenization 
buffer (250 mM sucrose, 10 mM HEPES pH 7.5 with protease inhibitor cocktail 
tablet), followed by sonication (Fisher Scientific Model 550 Sonic Dismembrator) 
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using a microtip probe (amplitude setting 2, two cycles of 15 sec). Samples were 
then centrifuged at 1500 × g for 15 min at 4 °C to remove insoluble cell debris. 
Supernatant was transferred to 4.7 mL polyallomer centrifuge tubes with plugs 
(OptiSealTM tubes, Beckman Coulter) and filled with excess homogenization 
buffer and centrifuged at 48,000 × g for 1 h at 4 °C. The plasma membrane pellet 
obtained was then resuspended in 100 µL solubilisation buffer (62.5 mM Tris-
HCl pH 6.8, 5% SDS) by heating to 50 °C. Protein concentration was determined 
as described above. Plasma membrane enriched lysates were made up in SDS 
protein sample buffer.  
Freshly harvested liver tissues were frozen on dry ice and stored at -80°C 
until required. Each tissue was ground using a pre-chilled (in liquid N2) mortar 
and pestle as previously described (Ke et al., 2006). Resultant dry powder was 
then transferred to pre-chilled 1.5 mL microcentrifuge tubes. Powdered tissue (50 
mg) was then lysed in RIPA buffer (500 µL) and incubated on ice for 10 min. 
Tissue lysate was homogenized by passing consecutively through 25 and 21 
gauge needles and then by sonication (Fisher Scientific Model 550 Sonic 
Dismembrator) using a microtip probe (amplitude setting 2, two cycles of 15 sec). 
The lysate was then centrifuged at 12000 × g for 10 min to remove insoluble 
debris and either frozen at -80°C or used immediately for protein estimation 
(BCA method) and western blotting.  
Proteins samples (30-50 µg) were fractionated using the Novex Bolt® 
Mini-Gel system (Bio-Rad Technologies) on Bolt® 4-12% Bis-Tris Plus precast 
gels and transferred to nitrocellulose membrane using Bolt® transfer system and 
buffer containing Tris-HCl (25mM), glycine (192 mM) and 15% methanol (10% 
for IRP2). Membranes were blocked for 1 h at room temperature using 5% (w/v) 
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skimmed milk in wash (TBS-T) buffer containing Tris-HCl [10mM, pH 8.0), 
NaCl (150mM) and 0.1% Tween-20]. The following antibody dilutions were 
used: Anti-p16 (Cat#sc-1207, 1:1000), was purchased from Santa Cruz 
Biotechnology, USA. Anti-β-actin (Cat#A5441, 1:10000), anti-LC3B 
(Cat#L7543, 1:1000) and HRP conjugated anti-goat IgG (Cat#A5420, 1:5000) 
were purchased from Sigma Aldrich. Anti-SV40 Large T antigen 
(Cat#MABF121, 1:4000) was purchased from Merck Millipore. Anti-ferritin 
(Cat#EPR3004Y, 1:1000), anti-IRP1 (Cat#EPR7225, 1:1000) and anti-p53 
(Cat#PAb 240, 1:1000) were purchased from Abcam. Anti-TfR1 (H68.4, 1:1000) 
was purchased from Invitrogen. Anti-IRP2 (Cat#NB100-1798, 1:1000) was 
purchased from Novus Biologicals. Anti-DMT1 (Cat#NRAMP21-P, 1:1000) was 
purchased from Alpha Diagnostics International. Anti-ferroportin (MAP 23, 
1:1000) was kindly provided by Dr. Bruce Wong (Department of Pathology, 
University of Melbourne). Anti-ISCU (Cat#14812-1-AP, 1:1000) and anti-p16 
(Cat#10883-1-AP, 1:500) was purchased from Proteintech. Anti-phospho S6 
ribosomal protein (pS6) was purchased from Cell Signalling Technologies 
(Cat#2211S). HRP conjugated goat-anti-mouse (Cat#P0447) and goat-anti-rabbit 
(Cat#P0448) antibodies were purchased from Dako. The membranes was 
subsequently developed using ECL reagent (Millipore, Cat#WBKLS0500) and 
bands visualized on Gel DockTM XR+ system (Bio-Rad).  At least three 
independent experiments were used for all comparisons.  
 
Determination of total intracellular iron  
Total metal concentration was measured using inductively coupled plasma mass 
spectrometry (ICP-MS, Agilent 7700, Varian). Tissue culture cells were prepared 
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for ICP-MS analyses as previously described (Denoyer et al., 2016). In brief, the 
cells were washed with 5 ml of trypsin-EDTA solution before being harvested 
with 5 mL of trypsin-EDTA solution for a 10 cm dish or 75 cm2  flask. Suspended 
cells were counted using a Beckman Coulter Z Series Cell Count and Size 
Analyser.  Four 1 ml aliquots of the cell suspension were centrifuged at 1000 × g 
for 5 min at room temperature to pellet the cells and subsequently stored at -80°C 
until required. Tissue samples were weighed and prepared for ICP-MS analyses 
as previously described (Denoyer et al., 2016). Quadruplicate determinations of 
iron concentration was performed for each sample. Unit conversions from raw 
ppb values were performed as follows: Cell culture (ng/million cells) = (raw ppb 
values × dilution factor/cell number); Tissue (µg/g) = (raw ppb value × dilution 
factor × reduced digest volume / tissue wet weight g).  
 
Immunohistochemistry 
Cryosections 5 μm thick were fixed in formalin. Endogenous peroxidase was 
quenched with 3% hydrogen peroxidase in distilled water. Non-specific binding 
was blocked using TNB buffer (0.1M Tris-HCl, pH 7.5, 0.15M NaCl, 0.5% (w/v) 
blocking reagent, PerkinElmer FP1020). Sections were incubated in Rabbit 
polyclonal anti-ferritin antibody (Santa Cruz, Cat#sc-25617) or a Rabbit IgG 
control (Abcam, Cat#ab27478) at a dilution of 2 μg/ml. To visualise the 
distribution of ferritin, sections were incubated with ImmPRESSTM HRP anti-
rabbit IgG (Vector Laboratories, Cat#MP-7401) and 3, 3’-diaminobenzidine 
(DAKO, Cat# K3468) according to the manufacturer’s instructions. Sections were 
counterstained in haematoxylin before coverslipping. 
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Cell viability assay 
Adhered cells were harvested using trypsin-EDTA solution (0.025% trypsin and 
0.02% EDTA) and then combined with their corresponding conditioned medium 
in 5 mL flow cytometry tubes. Cells were pelleted by centrifugation at 1000 × g 
for 5 min at 4°C. To determine cell viability, cell pellets were resuspended in 200 
µL of PBS containing 5 µg/mL propidium iodide (PI, excitation 538 nm/emission 
617 nm) and immediately analysed with a FACS Canto II flow cytometer (BD 
Biosciences). 10,000 events were measured and the percentage of dead cells (cells 
positive for PI) was determined. 
 
Statistical and image analyses 
Statistical analyses were performed using two-tailed unpaired t tests, calculated 
on GraphPad PRISM (version 6.0b) software. All data are represented as mean ± 
SD; probabilities of P < 0.05 were considered significant.  
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Results and Discussion 
Relevant experimental controls for inducing cellular senescence 
We initially assessed the gamma irradiation (IR) dose required to induce the 
largest degree of senescence in MEFs without harming cell viability. Primary 
MEFs at passage (P) 4 were exposed to a range of irradiation doses (10-50 Gy) 
and then were subsequently cultured for 10 days before being stained for 
senescence-associated β-galactosidase (SA-βgal) activity (Fig. S1A). The 
majority of MEFs became senescent (>80%) equivalently across all doses (Fig. 
S1A) without harming cell viability (Fig. S1B) and therefore the lowest dose (10 
Gy) was selected for all subsequent experiments. Furthermore, the lowest dose 
(10 Gy) increased senescent markers, p16, p21 and IL-6 (mRNA transcript levels) 
(Fig. S1C) and elicited a similar iron accumulation response in MEFs when 
compared to the higher doses (20-50 Gy) (Fig. S1D).  
We next demonstrated that irradiation requires functional wild-type (wt) 
p53 protein activity to induce both senescence and iron accumulation in MEFs 
(Fig. S1E, F). Senescence-induction in response to irradiation was found to be 
impaired in primary MEFs isolated from a mouse model of the Li-Fraumeni 
syndrome, which carries a germline mutation in TP53 (G515A nucleotide 
mutation) (Lang et al., 2004) (Fig. S1E(i)). These MEFs accumulated negligible 
amounts of intracellular iron post-irradiation (10 Gy), when compared to wt p53 
MEFs exposed to the same conditions (Fig. S1E(ii)). Therefore, irradiated MEFs 
accumulate intracellular iron through a p53-driven response, presumably through 
initiating senescence. 
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Figure S1. Relevant experimental controls for inducing cellular senescence. 
(A) Primary MEFs were exposed to a range of gamma irradiation (10-50 Gy) 
doses to induce senescence. Across all doses the majority (>80%) of MEFs 
displayed positive SA-βgal activity at 10 days post-irradiation (blue staining).  
(B) The viability of MEFs exposed to a range of gamma irradiation (10-50 Gy) 
doses was determined by propidium iodide and flow cytometry at 10 days post-
irradiation. There was no change in cell viability across the doses.  
(C) Real time qPCR analyses showed elevated mRNA transcripts for senescence-
associated genes p16, p21 and IL-6 in senescent MEFs (MEF IR) at 21 days post-
irradiation (10 Gy). Levels were normalised against GAPDH and expressed as 
fold change relative to primary MEFs (MEF PRI) 
(D) ICP-MS analyses demonstrated that MEFs exposed to a range of gamma 
radiation dose (10-50 Gy) all accumulated similar levels of elevated intracellular 
iron at 10 days post-irradiation.  
(E) Irradiated p53 mutant MEFs (IR p53 mut) displayed (i) significantly lower 
SA-βgal positivity (~20%) compared to wild-type MEFs (~80%) at 10 days post-
irradiation (10 Gy) and (ii) had a negligible increase (<2-fold) in intracellular 
iron, as determined by ICP-MS analyses. Non-irradiated p53 mutant MEFs (PRI 
p53 mut) had comparable intracellular iron levels when compared to non-
irradiated p53 wild type MEFs (MEF PRI). Senescence wild-type MEFs (MEF 
IR) are included for comparison. 
(F) MEFs induced to become senescent [irradiation (IR) or replicative exhaustion 
(REP)] have increased adhered cell diameter (Feret) (≥2 fold) compared to 
primary MEFs (MEF PRI), but comparable cell diameter in suspension following 
trypsinization. Cells were imaged using a bright field inverted microscope 
(Olympus IX51) and subsequently photographed (Canon 1100D). Feret diameter 
(caliper length) was determined using ImageJ software (n = 3). Suspended cell 
diameter (post-trypsinization) was determined using a Beckman Coulter Z Series 
Cell Count and Size Analyser (n = 3). 
(G) Cellular protein content as a marker for overall cell mass and volume. 
Irradiated (MEF IR), replicative (MEF REP) and oncogenic-induced (MEF OIS) 
senescent MEFs contained ~1.3-fold, ~1.1-fold and ~1.2-fold more protein in 
comparison to primary MEFs (MEF PRI), respectively. Cellular protein 
concentrations were determined using the BCA protein assay kit (Thermo 
Scientific) as per manufacturer’s instructions. Total protein was expressed as mg 
per 106 cells and represented as mean ± SD (n = 3). 
(H) Proliferating primary MEFs lose replicative potential as a result of continual 
passaging. The population-doubling limit per day (PDL/day) reached 0.2 at 
passage 6 prior to cell cycle arrest at passage 7 (senescence). Population doubling 
was determined by the following formula: n = 3.32 (log UCY - log l) + X, where 
n = the final PDL number at end of a given subculture, UCY = the cell yield at 
that point, l = the cell number used as inoculum to begin that subculture, and X = 
the doubling level of the inoculum used to initiate the subculture being 
quantitated. 
(I) Natural variance in intracellular iron concentration between primary MEFs 
derived from different embryos (same pregnancy) ICP-MS analyses of isogeneic 
C57BL/6 MEF lines (n = 10) showed a range of intracellular iron (84.2-181.9 
ng/106 cells) concentrations. Data represented as mean ± range (n = 10).  
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001).   
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Cellular senescence is characterised by morphological changes resulting in 
an enlarged flat-cell phenotype (Kuilman et al., 2010, Serrano et al., 1997, 
Denoyelle et al., 2006, Parrinello et al., 2003). We therefore measured several 
indexes of cell size (diameters and cellular protein content) (Fig. S1F, Fig. S1G) 
in order to exclude the possibility that a cell volume increase accounted for the 
iron accumulation observed in senescent MEFs (Fig. 1). Regardless of the mode 
used to induce senescence (irradiation, replicative or oncogenic), all observed 
changes to cell size were modest and could not account for the magnitude of iron 
accumulation. 
Replicative senescence occurs in primary cells under most culturing 
conditions as a consequence of repeated cell passaging and proliferation in a high 
oxygen environment (21% O2) (Chen et al., 1995). We monitored the population 
doubling time of MEFs between successive passages in culture (Fig. S1H) as 
previously described (Chen et al., 1995), to determine when a reduction in 
replicative potential occurred signifying senescence development. In our hands, 
MEFs maintained a uniform population-doubling limit per day (PDL/Day ~0.6) 
up until passage (P) 4 and then showed a decline in proliferation across P5 and P6 
(PDL/Day <0.2), indicating cell arrest and the emergence of senescence (Fig. 
S1H). Proliferation was not observed following P6 and MEFs were designated as 
being replicative senescent at P7. Primary MEFs used for control experiments 
were obtained from P2 to P4, to ensure that replicative potential was maintain. 
 During the course of initial experiments we noticed variance in the basal 
level of intracellular iron between MEF lines derived from different embryos, 
despite originating from the same pregnancy. We therefore determined 
intracellular iron concentrations in 10 different isogenic MEF lines (C57BL/6; 
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same pregnancy) at P4 and found considerable variation (84.2-181.9 ng/ 106 cells) 
(Fig. S1I). The reason for this discrepancy is unclear and gender was not 
determined. Nevertheless, this variance was insignificant in comparison to the 
iron accumulation seen in senescent cells and therefore did not confound our 
experiments.    
 
Subcellular localization of ferroportin is altered in senescent MEFs 
Ferroportin is the only known mammalian iron export protein and predominantly 
localizes to the plasma membrane to efflux iron directly from the cell (Abboud 
and Haile, 2000, Donovan et al., 2005). Given that senescent MEFs accumulate 
such profound levels of intracellular iron, we postulated that they have reduced 
capacity to efflux iron, presumably through an alteration to ferroportin 
localization. Note that ferroportin expression was increased in senescent MEFs 
(Fig. 3A). Senescent MEFs (MEF IR) at 21 days post-irradiation had ferroportin 
localized predominantly at an intracellular compartment and not at the plasma 
membrane (Fig. S2A). Further evidence that ferroportin has reduced plasma 
membrane localization in senescent MEFs was obtained from cell fractionation 
studies (Fig. S2B, Fig. S2C). While ferroportin did increased in the NP-40 
insoluble fractions (Fig. S2B) it was significantly decreased in plasma membrane 
enriched fraction of senescent MEFs (21 days post-irradiation) (Fig. S2C), when 
compared to primary MEFs (MEF PRI). Note that the iron import protein TfR1 
was conversely enriched in the plasma membrane fraction of the senescent MEFs. 
Taken together, these results demonstrate an altered cellular localization for 
ferroportin in senescent MEFs, which conceivably would impair the cells ability 
to effectively efflux intracellular iron.  
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Figure S2. Subcellular localization of ferroportin is altered in senescent MEFs. 
(A) Senescent MEFs at day 21 post-irradiation (MEF IR) displayed ferroportin 
predominately at an intracellular localization (indicated by arrows). Ferroportin 
was detected with primary anti-ferroportin antibody (Cat#NBP1-21502, Novus 
Biologicals) and secondary goat anti-rabbit IgG Alexa 488. Nuclear staining was 
performed using ethidium bromide. Ferroportin localization in primary MEFs 
(MEF PRI) is also shown.  
(B) Fractionation of ferroportin in cytosolic and NP-40 insoluble fractions of 
primary (MEF PRI) and senescent MEFs (MEF IR) at 21 days post-irradiation (10 
Gy). Increased ferroportin in senescent MEFs was predominantly restricted to the 
insoluble fraction.   
(C) Ferroportin in plasma membrane enriched fractions of primary (MEF PRI) 
and senescent MEFs (MEF IR) at 21 days post-irradiation (10 Gy). In the plasma 
membrane fraction of senescent MEFs (MEF IR), ferroportin expression was 
significantly decreased, while TfR1 expression was increased, when compared to 
primary MEFs (MEF PRI).  
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Iron accumulation in replicative senescent MEFs is maintained and 
associated with impaired ferritinophagy 
The development of senescence (SA-βgal activity) and iron accumulation was 
surveyed in MEFs at P4, P6 and at P7 across two different culturing time points 
(10 and 21 days). Intracellular iron accumulation followed the appearance of 
replicative senescent cells at passage 6 (<10%) and was augmented when the 
majority of cells became senescent at passage 7 (>80%) (Fig. S3A, Fig. S3B). 
When replicative senescent MEFs at passage 7 were cultured for either 10 or 21 
days, the amount of accumulated iron had somewhat plateaued but was 
maintained, indicating that a possible upper threshold had been reached (Fig. 
S3A, Fig. S3B). Together, these results suggest that replicative senescent MEFs, 
analogous to irradiated senescent MEFs (Fig. 4B), reach a threshold for iron 
accumulation under normal culturing conditions.  
 In replicative senescent MEFs (MEF REP) there was a large build-up of 
LC3-II, indicating impaired lysosomal function, which was associated with 
increased TfR1 and ferritin (Fig. S3C). Therefore, analogous to irradiated 
senescent MEFs (MEF IR) (Fig. 5), lysosomal impairment is a feature of 
replicative senescence and is associated with ferritin accumulation and thus 
impaired ferritinophagy. 
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Figure S3. Iron accumulation in replicative senescent MEFs is maintained and 
associated with impaired ferritinophagy. 
(A) Intracellular iron accumulation occurred concurrent with replicative 
senescence in passaging MEFs (MEF REP). Percentage of senescent MEFs in 
passaged cultures (passages 4, 6 and 7) as determined by SA-βgal activity (blue 
staining). Images were taken at 100X magnification.  
(B) ICP-MS analyses demonstrated that iron accumulated when replicative 
senescence commenced (<10%) at passage 6 and was augmented with senescence 
enrichment (>80%) at passage 7. Note that iron accumulation somewhat plateaued 
(~18-fold) after culturing passage 7 senescent MEFs for 10 days. 
(C) Western blot analyses demonstrated that replicative senescent MEFs (MEF 
REP) have increased TfR1, ferritin and LC3-II in comparison to primary MEFs 
(MEF PRI). The large build-up of LC3-II indicates impaired lysosomal function. 
β-actin was detected as a loading control. 
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3).  
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Inhibiting mTOR in senescent cells prevented iron accumulation 
The mTOR pathway plays a crucial role in cell survival through nutrient and 
energy sensing and acts as a negative regulator of autophagy (Bayeva et al., 2012, 
La et al., 2013). Rapamycin selectively activates autophagy through inhibiting the 
mTOR pathway (Sarkar et al., 2009) and has been shown to restore lysosomal 
function in senescent cells (Tai et al., 2017). We demonstrated that sustained 
rapamycin treatment (100 nM) averted the iron accumulation phenotype of 
senescent MEFs, preventing the accumulation of TfR1, ferritin (Fig. 5E) and 
intracellular iron (Fig. 5F). To confirm that rapamycin treated cells remained non-
proliferative they were reseeded (100,000 cells/well) and cultured for an 
additional 5 days. Subsequent cell counting demonstrated that rapamycin treated 
cells remained in cell cycle arrest (Fig. S4A). We additionally treated senescent 
MEFs at 10 days post-irradiation with rapamycin (100 nM) for a shorter duration 
(4 days), which significantly reverted the intracellular accumulation of iron 
phenotype (Fig. 5H). Furthermore, this treatment regime was shown to not impact 
on the percentage of senescent cells, as determined by SA-βgal activity (Fig. 
S4B).  
 A second inhibitor of the mTOR pathway, torin 1, was further used to 
advert the iron accumulation phenotype of senescent MEFs (Fig. S4C). Torin 1 
has a different mode of action to rapamycin and inhibits mTOR through ATP 
competition (Kim and Guan, 2015). Primary MEFs were treated with torin 1 (50 
nM) while irradiated (10 Gy) to induce senescence and then subsequently for 14 
days in culture.   
 
 
114 
 
Figure S4. Inhibiting mTOR in senescent cells prevented iron accumulation. 
(A) Inhibiting mTOR does not cause escape from cell cycle arrest. Primary MEFs 
were treated with rapamycin (100 nM) while irradiated (10 Gy) to induce 
senescence and then subsequently for 10 days in culture. Treated MEFs were 
unable to proliferate when seeded in 6 well plates (100,000 cells/well) and 
cultured for additional 5 days.   
(B) Inhibiting mTOR in senescent MEFs after 10 days post-irradiation through 
rapamycin (100 nM) treatment for 4 days, had no effect on SA-βgal activity 
(>80%) (blue staining).  
(C) Primary MEFs were treated with torin 1 (50 nM) while irradiated (10 Gy) to 
induce senescence and then subsequently for 14 days in culture. Sustained torin 1 
treatment significantly prevented intracellular iron accumulation, as determined 
by ICP-MS.  
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3). 
 
 
 
 
 
 
 
 
 
 
115 
 
 
 
         
 
 
 
116 
 
Supplementary Methods 
Real-time quantitative PCR 
Total RNA was isolated using Bioline Isolate II RNA Mini Kit (Bioline, 
Alexandra, Australia; Cat#BIO-52072). cDNA was synthesized using 1 µg of 
RNA using the SensiFAST cDNA Synthesis Kit (Bioline, Alexandria, Australia; 
Cat#BIO-65053) as per manufacturers protocol. The specific primers were: 
mouse p16 5’-CCCAACGCCCCGAACT-3’ and  
5’-GCAGAAGAGCTGCTATGTGAA; mouse p21  
5’-GTGGGTCTGACTCCAGCCC-3’ and 5’- CCTTCTCGTGAGACGCTTAC-
3’; mouse IL6 5’- ACAACCACGGCCTTCCCTACTT-3’ and 5’- 
CACGATTTCCCAGAGAACATGTG-3’; Mouse GAPDH 5’- 
TCACCACCATGGAGAAGGC and 5’- GCTAAGCAGTTGGTGGTGCA. Real-
time PCR (AB 7500 Real TIME PCR System, Applied Biosystems) was 
performed in triplicate each containing 20 ng of cDNA and the Power SYBR-
Green PCR Master Mix (ThermoFisher Scientific, Scorsby, Australia; 
Cat#4367659). Results were analysed using pyQPCR Software v0.9.  
 
Immunocytochemistry  
MEFs were seeded (1.5 × 105) onto 12 mm glass coverslips in a 24-well plate and 
cultured for 24 h. The cells were then irradiated (10 Gy) as described above and 
subsequently cultured for 21 days. Cells were then fixed with 4% (w/v) 
paraformaldehyde in PBS (10 min), permeabilised with 0.1% (v/v) Triton X-100 
in PBS (10 minutes) and then blocked in PBS containing 1% (w/v) BSA, 1% 
(w/v) gelatine overnight at 4°C. Blocking solution was removed and the cells on 
coverslips were incubated with primary anti-ferroportin antibody (Novus 
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Biologicals, Cat#NBP1-21502) (diluted 1/500) in blocking solution for 1 h. The 
cells were then incubated for 1 h with secondary goat anti-rabbit IgG Alexa 488 
antibody (diluted 1/4000). Coverslips were mounted on glass slides using 
FluorSave Reagent (Merck Millipore) and cells were analysed using an Olympus 
IX51 Inverted Microscope with 40X objective (400X magnification). 
 
Cell size and morphology determination 
The diameter of cells in suspension was determined by harvesting cells as 
described previously in the main methods section. Cells in suspension were 
aliquoted (1 mL each) into four microcentrifuge tubes (Axygen) and mean 
diameters (µm) were determined (Coulter Z2 Cell Count and Size Analyser). The 
size of adherent cells was determined by analysing cell images using ImageJ 
(ver1.48) (National Institutes of Health, Bethesda, Maryland). Cells were imaged 
using a bright field inverted microscope (Olympus IX51) and subsequently 
photographed (Canon 1100D). A micrometre scale (2 mm) was used to define a 
global scale for ImageJ, the cell boundaries were traced in the image and mean 
Feret diameter (caliper length) was determined using the ImageJ software (n = 3 
for each cell type). 
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Abstract 
Cellular senescence is characterised by irreversible growth arrest incurred through 
either replicative exhaustion or by pro-oncogenic cellular stressors (radioactivity, 
oxidative stress, oncogenic activation). The enrichment of senescent cells in 
tissues with age has been associated with tissue dyshomeostasis and age-related 
pathologies including cancers, neurodegenerative disorders (e.g. Alzheimer’s, 
Parkinson’s, etc.) and metabolic disorders (e.g. diabetes). We identified copper 
accumulation as being a universal feature of senescent cells [mouse embryonic 
fibroblasts (MEF), human prostate epithelial cells and human diploid fibroblasts] 
in vitro. Elevated copper in senescent MEFs was coupled with upregulation of 
Ctr1 (copper uptake), downregulation of Atp7a (copper efflux), enhanced copper 
buffering through elevated levels of glutathione and enhanced antioxidant defence 
reflected by upregulation of SOD1 and Grx1. We further elucidated the levels of 
intracellular copper in senescent MEFs cultured in copper supplemented medium 
and in senescent Mottled Brindled (MoBr) MEFs lacking functional Atp7a. Finally 
we demonstrated how attenuation of copper accumulation by rapamycin 
correlated with the restoration/preservation of autophagic-lysosomal degradation 
in senescent MEFs. Our study thus suggests a possible link between cellular 
autophagy and copper homeostasis both of which have emerged as important 
facets of age-associated degenerative disease. Furthermore, our findings may lead 
to new molecular targets amenable to modulation through copper based 
therapeutics.  
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Introduction 
Cellular senescence represents a critical barrier against cellular transformation 
and prevents the uncontrolled proliferation of cells that are irrevocably damaged 
(Campisi and Robert, 2014, Serrano et al., 1997). Senescent cells actively secrete 
a variety of proteins, including pro-inflammatory mediators (cytokines and 
chemokines) to elicit immunological self-clearance (Campisi and Robert, 2014, 
van Deursen, 2014). Other secreted factors facilitate communication with local 
microenvironment and can establish senescence in neighbouring cells in a 
paracrine manner (Nelson et al., 2012, Mikula-Pietrasik et al., 2013). The 
beneficial roles of senescent cells, for instance in wound healing, tissue 
remodelling and against cancer development, are considered conditional on their 
efficient and timely tissue clearance (Campisi and Robert, 2014, van Deursen, 
2014). However, senescent cells accumulate in tissues and organs with age and 
contribute to age-related pathologies and dysfunctions, in part, through promoting 
chronic inflammation (van Deursen, 2014, Campisi and Robert, 2014). Why 
senescent cells accumulate with age is unclear, but it is likely to be associated 
with age-associated immunodeficiency and therefore reduced clearance (Wang et 
al., 2011, Nikolich-Zugich, 2008, Childs et al., 2015, Storer et al., 2013). Recently 
developed strategies to clear senescent cells in vivo have provided remarkable 
improvement to the healthspan of mice, by attenuating age-related pathologies 
and tissue dysfunctions (Baker et al., 2016, Baker et al., 2011, Baar et al., 2017, 
Chang et al., 2016, Zhu et al., 2015). Furthermore, a median lifespan extension 
was observed in several of these studies (Baker et al., 2016, Baker et al., 2011, 
Zhu et al., 2015).  
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We previously provided an aetiological link between senescent cell 
enrichment and iron dyshomeostasis, both of which occur in tissues with ageing 
and at sites of age-related pathologies (refer Manuscript 1). We demonstrated that 
senescent cells accumulate vast amounts of intracellular iron (up to 30-fold) as a 
result of having impaired ferritin degradation (ferritinophagy) (refer Manuscript 
1). Elevated ferritin proved to be a robust biomarker for cellular senescence and 
for associated iron accumulation (refer Manuscript 1). In this study, we further 
investigated whether other biologically relevant metals are altered in cellular 
senescence and identified a consistent and substantial change to intracellular 
copper.   
Previously, Boilan and colleagues showed that human diploid fibroblasts 
(HDFs) made senescent by passaging them to replicative exhaustion accumulated 
intracellular copper (Boilan et al., 2013). Furthermore, an increase in transcript 
levels of copper regulated genes, Hsp70, MT2A and PrP, was reported in HDFs 
made senescent by replicative exhaustion or through exposure to UV-B 
irradiation (Scheckhuber et al., 2009). In addition, treating HDFs with copper 
(500 µM as copper sulfate) increased senescence markers and induced premature 
senescence (Boilan et al., 2013, Scheckhuber et al., 2009, Matos et al., 2012, 
Matos et al., 2017). Interestingly, the pro-senescence copper effect could be 
attenuated when cells were treated with resveratrol (Matos et al., 2017), a known 
chelator of copper (Tamboli et al., 2011, Belguendouz et al., 1997). In copper-
induced senescent HDFs, resveratrol treatment activated autophagic-lysosomal 
degradation (Matos et al., 2017), a process that we have shown previously to be 
impaired in senescent cells contributing to iron dyshomeostasis (refer Manuscript 
1). Furthermore, treating human glioblastoma cells with copper (250 µM as 
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copper sulfate) resulted in an elevation of senescence markers p16, p21, and 
clusterin/ApoJ (Li et al., 2013). Notably, clusterin/ApoJ, an established 
senescence marker (Petropoulou et al., 2001), serves as a regulator of cellular 
copper homeostasis through its role in degradation of Atp7a, the major cellular 
copper export protein (Materia et al., 2011).   
Copper homeostasis is under investigation as a modifiable feature in 
several diseases, including various types of cancers (Denoyer et al., 2015) and 
neurodegenerative disorders (Squitti et al., 2014). Senescent cells have likewise 
emerged as important factors in the aetiology and progression of these disorders 
(Munoz-Espin and Serrano, 2014). Thus, we investigated copper homeostasis in 
senescent cells.  
 
Experimental 
Chemicals and reagents 
Rapamycin was purchased from Thermo Fischer Scientific (Cat#FSBBP2963-1). 
Bafilomycin A1 (Baf A1) (Cat# B1793) was purchased from Sigma Aldrich. All 
other reagents were purchased from Sigma Aldrich unless otherwise stated 
 
Isolation and culturing of primary mouse and human cells 
Primary mouse embryonic fibroblasts (MEFs) were collected from sacrificed 
pregnant mice [C57BL/6 wild-type, Li-Fraumeni syndrome C57BL/6, agouti, 
mottled brindle (MoBr) mice] at 13 day post-coitum, using a protocol modified 
from that described previously (Todaro and Green, 1963). The Li-Fraumeni 
syndrome C57BL/6 mice, which carry a germline mutation in TP53 (G515A 
nucleotide mutation), were a kind gift from Prof. Guillermina Lozano (University 
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of Texas) (Lang et al., 2004). This study was approved by the Deakin University 
Animal Ethics Committee (AEC) (Id#G01-2014). In brief, intact uteri were 
removed, washed with cold phosphate-buffered saline (PBS) (without Ca2+Mg2+) 
(Life Technologies, Cat#10010049), and each embryo individually prepared by 
removing appendages including the head and red organs.  A surgical scalpel blade 
(Size 11, Livingstone) was used to finely mince the remaining tissue, which was 
then applied through an 18-gauge needle using a 5 mL syringe. Suspended cells 
derived from each embryo were seeded into separate 10 cm (55 cm2) dishes 
(Cellstar®, Cat#664160) and cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Life Technologies, Cat#11965118) supplemented with 10% FBS, 
penicillin (20 U/mL), streptomycin (20 μg/mL), L-glutamine (2 mM), sodium 
pyruvate (1 mM), HEPES (1 mM) and non-essential amino acids (1%). When the 
adherent MEFs reached ~90% confluency they were expanded into one 14.5 cm 
(152 cm2) dish (Catalogue no. 639160, Cellstar®), at which stage they were 
referred to as being passage 2 (P2). Cells were further expanded into three 14.5 
cm dishes and subsequently cryopreserved at passage 3 (P3) in liquid N2. 
Primary human diploid fibroblasts (HDFs) (S103) isolated from skin by 
the scratch biopsy method, were obtained from the Murdoch Children’s Research 
Institute, Melbourne, and were collected from healthy control individuals as 
previously described (Michalczyk et al., 2003).  HDFs were provided at passage 
14 and were cultured in Eagle’s Basal medium (BME) supplemented with 10% 
FBS, penicillin (20 U/mL), streptomycin (20 μg/mL), L-glutamine (4 mM) and 
HEPES (1 mM). Human primary prostate epithelial cells (PrECs) were purchased 
from Lonza (Cat#CC-2555) and cultured in the recommended PrEBM growth 
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medium (Cat#CC-3166) and subcultured using reagents provided by the supplier 
(Cat#CC-5034).  All primary cells were incubated at 37°C in 5% CO2. 
 
Screening of MEFs carrying Atp7a-Mobr mutation 
MEFs were screened for presence of Atp7a-Mobr mutation by polymerase chain 
reaction (PCR) as described previously (Llanos et al., 2006). Briefly, sense 
oligonucleotides MMNK22 (5’-GGCAAAACCTCCGAGGCAAAG) specific 
for Atp7a-Mobr mutation or MMNK23 (5’- CAAAACCTCCGAGGCTCTTGC) 
specific for wild-type Atp7a and antisense oligonucleotide MMNK24L (5’-
AGGAGGAGATTTTCAGAGTTCAG-3’) were used to amplify products of 83 
bp and 87 bp, respectively, in separate reaction tubes. PCR conditions were as 
follows: 96 °C for 4 min, 63 °C for 1 min, 72 °C for 1 min for two cycles 
followed by 96 °C for 1 min, 63 °C for 1 min, 72 °C for 30 s for 35 cycles. The 
PCR products were resolved on a 4% agarose (agarose 3:1 High Resolution 
Blend, AMRESCO) gel and detected by staining with ethidium bromide. 
  
Senescence induction by ionizing radiation 
Primary mouse and human cell lines (MEFs, HDFs and PRECs) were cultured to 
~90% confluence in 25 or 75 cm2 flasks (Cellstar®, Cat#690175 or 658175, 
respectively) and subjected to 10 Gray (Gy) gamma irradiation using a calibrated 
Cesium-137 source (Gamma Cell 40, Atomic energy of Canada Limited). The 
primary cells were in their standard medium described above during irradiation. 
Control non-irradiated cell lines were cultured to equivalent confluence and 
otherwise handled in the same manner as the irradiated cells. Cellular senescence 
was assessed at various time points (in days) post irradiation by senescence-
associated β-galactosidase (SA-βgal) activity staining, as detailed in the Results.  
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Retrovirus production and transduction of primary MEFs 
HEK293T cells were cultured in DMEM medium supplemented with 10% FBS, 
penicillin (20 U/mL) and streptomycin (20 μg/mL), and were used as a packaging 
cell line for retrovirus production. The cells were seeded at 5 × 106 cells in a 10 
cm (55 cm2) dish and the following day transfected (in 5 ml of medium) with a 
500 µl mixture containing 15 µg (total) of plasmid DNA, 45 µl of FuGENE® HD 
Transfection Reagent (Promega, Cat#E2311) and Opti-MEM medium (Life 
Technologies, Cat#31985-070). To produce retrovirus containing the SV40 Large 
T antigen (SV40 LgT), equimolar amounts of pBabe-neo large TcDNA plasmid 
(Addgene, Cat#1780) along with the packaging plasmid pCl-Eco (Addgene, 
Cat#12371) were used. Retrovirus containing the oncogene H-RasV12 was 
produced with pWZL-Hygro H-Ras V12 plasmid (Addgene, Cat#18749), while 
control retrovirus was produced with empty pWZL-Hygro plasmid (Addgene, 
Cat#18750). Transfected HEK293T cells were cultured for 24 h before the 
medium was replaced (5 mL) and subsequently collected every 12 h over a 48 h 
timeframe. Viral supernatants were pooled, filtered (0.45 μm filter, Millipore) and 
frozen at -80°C until required. Retroviral transduction of MEFs was achieved by 
culturing 1.2 × 106 cells in a 10 cm (55 cm2) dish overnight, then substituting the 
medium for 3 h with neat viral supernatant (5 mL) together with polybrene (8 
μg/mL). Subsequently, the cells were cultured in fresh medium (10 mL) for 24 h 
before selection agent (G418; 500 µg/mL, or hygromycin 100 μg/mL) was 
administered.  
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Senescence-associated β-galactosidase assay in cells  
SA-βgal staining of cultured cells was performed using a protocol modified from 
that previously described (Dimri et al., 1995). Adherent cells were washed twice 
with PBS (30 sec each) and then fixed with a PBS solution containing 2% 
formaldehyde and 0.2% glutaraldehyde for 15 min at room temperature. After a 
further two PBS washes (30 sec each) the cells were incubated in staining solution 
(150 mM NaCl, 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 2.45 mM (1 mg/mL) 5-bromo-4-chloro-3-indolyl-β-D-
thiogalactopyranoside (X-Gal) in phosphate-citrate buffer, pH 6.0) at 37°C 
without CO2 for <12 h (overnight).  The percentage of cells stained for SA-βgal 
activity was determined using an inverted microscope (Olympus IX51), by 
counting cells in four random fields of view at a magnification of 200/400X. 
Images were taken with Canon 1100D digital camera. 
 
Western blotting analyses 
Cell cultures were washed once and harvested with trypsin-EDTA solution 
(0.025% trypsin with 0.02% EDTA) and pelleted by centrifugation at 5000 × g.  
RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
1% Triton X-100 and a protease inhibitor cocktail tablet (Roche)) was then used 
to lyse the cell pellet (5 × 105 cells per 150 µL of RIPA buffer), which was 
incubated on ice for 10 min before being centrifuged at 10,000 × g for 10 min at 
4°C to remove insoluble cell debris. Protein concentration was determined by the 
BCA protein assay kit (Thermo Scientific) as per the manufacturer’s instructions.  
Proteins samples (30-50 µg) were fractionated using the Novex Bolt® 
Mini-Gel system (Bio-Rad Technologies) on Bolt® 4-12% Bis-Tris Plus precast 
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gels and transferred to nitrocellulose membrane using Bolt® transfer system and 
buffer containing Tris-HCl (25mM), glycine (192 mM) and 15% methanol (5% 
for Atp7a). Membranes were blocked for 1 h at room temperature using 5% (w/v) 
skimmed milk in wash (TBS-T) buffer containing Tris-HCl [10mM, pH 8.0), 
NaCl (150mM) and 0.1% Tween-20]. The following antibody dilutions were 
used: anti-CCS (Cat#FL274, 1:1000) were purchased from Santa Cruz 
Biotechnology, USA. Anti-β-actin (Cat#A5441, 1:10000) and HRP conjugated 
anti-goat IgG (Cat#A5420, 1:5000) were purchased from Sigma Aldrich. Anti-
Ctr1 (Cat#EPR7936, 1:1000) and anti-Grx1 (Cat#AB16877, 1:1000) was 
purchased from Abcam. Anti-SOD1 (ADI-SOD-100, 1:2000) was purchased from 
Enzo Lifesciences, USA. Anti-Atp7a (R17, 1:500), goat polyclonal, was raised in-
house and affinity purified. HRP conjugated goat-anti-mouse (Cat#P0447) and 
goat-anti-rabbit (Cat#P0448) antibodies were purchased from Dako. The 
membranes was subsequently developed using ECL reagent (Millipore, 
Cat#WBKLS0500) and bands visualized on Gel DockTM XR+ system (Bio-Rad).  
At least three independent experiments were used for all comparisons. 
 
Determination of total intracellular copper 
Total copper concentration was measured using inductively coupled plasma mass 
spectrometry (ICP-MS, Agilent 7700, Varian). Tissue culture cells were prepared 
for ICP-MS analyses as previously described (Denoyer et al., 2016). In brief, the 
cells were washed with 5 ml of trypsin-EDTA solution before being harvested 
with 5 mL of trypsin-EDTA solution for a 10 cm dish or 75 cm2  flask. Suspended 
cells were counted using a Beckman Coulter Z Series Cell Count and Size 
Analyser.  Four 1 ml aliquots of the cell suspension were centrifuged at 1000 × g 
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for 5 min at room temperature to pellet the cells and subsequently stored at -80°C 
until required. Quadruplicate determination of copper concentration was 
performed for each sample. Unit conversions from raw ppb values were 
performed as follows: (ng/million cells) = (raw ppb values × dilution factor/cell 
number).  
 
Total GSH and GSSG determination 
GSH and GSSG were measured by HPLC with permanganate chemiluminescence 
detection using a GloCel detector with serpentine flow-cell (McDermott et al., 
2011, Smith et al., 2014, Terry et al., 2008). Cell pellets were homogenised 
(vortexed) in 300 L of 0.1% formic acid and then centrifuged at 5000 × g at 4°C 
for 15 min. For GSH determination, the supernatant was diluted 10-fold in 
aqueous formic acid (5%) immediately prior to analysis. For GSSG determination 
a second aliquot of the supernatant (100 L) was combined with 20 µl of 675 mM 
Tris-HCl buffer (pH 8.0) and 20 µl of 6.3 mM N-ethylmaleimide (NEM) to block 
endogenous GSH, and mixed for 30 sec. Then 20 µl of 8 mM 2-mercaptoethanol 
was added and mixed for a further 30 sec. Subsequent to adding 20 µL of 780 nM 
TCEP, the solution was gently heated at 50°C for 60 min to allow complete 
disulfide bond reduction. Finally, 20 µl of aqueous formic acid (5%) was 
introduced to re-acidify the sample prior to analysis. 
 
 
 
 
 
131 
 
Cell size determination 
The diameter of cells in suspension was determined by harvesting cells as 
described previously in the main methods section. Cells in suspension were 
aliquoted (1 mL each) into four microcentrifuge tubes (Axygen) and mean 
diameters (µm) were determined (Coulter Z2 Cell Count and Size Analyser). 
 
Statistical and image analyses 
Statistical analyses were performed using two-tailed unpaired t tests, calculated 
on GraphPad PRISM (version 6.0b) software. All data are represented as mean ± 
SD; probabilities of p< 0.05 were considered significant.   
 
Results and Discussion 
Senescent cells accumulate intracellular copper 
We initially investigated whether cellular senescence is associated with altered 
copper homeostasis using primary mouse embryonic fibroblasts (MEFs) (Di 
Micco et al., 2008) (Chapter 3). Senescence was induced by either sub-lethal 
gamma irradiation [10 Gray (Gy)] or replicative exhaustion as described 
previously (please refer Manuscript 1) and was confirmed through staining for 
senescence-associated beta-galactosidase (SA-βgal) activity (Fig. 1A). Note that 
primary MEFs underwent replicative exhaustion at passage 7 under our culturing 
conditions. More than 80% of MEFs stained positive for SA-βgal activity when 
cultured for a minimum of 10 days following either mode of senescence induction 
(Fig. 1A). Senescent cells remain metabolically active in culture for many months 
(Chapter 3) (van Deursen, 2014) and therefore we maintained senescent MEFs 
for 21 days to allow for a net change in intracellular copper to occur (Fig. 1B). 
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Both irradiated (MEF IR) and replicative senescent (MEF REP) MEFs 
accumulated a significant amount of copper (~3-4-fold, respectively) when 
compared to primary proliferative MEFs (MEF PRI) (Fig. 1B). Any variation in 
cell diameter (suspended) or total cellular protein content between senescent 
(irradiated and replicative) and primary MEFs could not account for the degree of 
increased intracellular copper (Fig. 1C). Senescence induction and maintenance 
in murine cells is reliant on wild-type p53 function, the loss of which results in 
senescence bypass/immortalization (Dirac and Bernards, 2003, van Deursen, 
2014, Harvey et al., 1993). Both irradiation and replicative exhaustion lead to 
senescence induction through p53-mediated DNA damage response (DDR) 
pathways (van Deursen, 2014). Furthermore, primary MEFs isolated from mice 
harbouring mutant p53 (G515A nucleotide mutation), which impairs senescence 
induction by irradiation (refer Manuscript 1)(Lang et al., 2004), accumulated 
negligible amounts of intracellular copper post-irradiation (10 Gy) (Fig. 1D). 
Therefore, copper accumulation concomitant with senescence, required wild-type 
p53 function, and was not indirectly caused by irradiation. Likewise, wild-type 
MEFs that we aided to spontaneously bypass senescence using the 3T3 culturing 
method [ISO(3T3)] (Todaro and Green, 1963), had intracellular copper levels 
(Fig. 1E) comparable to the normal range observed in isogenic primary MEFs 
(Fig. 1F). Note that spontaneous senescence-bypass in MEFs commonly occurs 
through alteration to p53 occurring as a random mutation in cultured cells leading 
to immortalization (Rittling, 1996, Harvey and Levine, 1991). Therefore, copper 
accumulation in replicative senescent MEFs was not sustained following 
spontaneous senescence bypass. Furthermore, intracellular copper levels in MEFs 
immortalized with SV40 large T (LT) antigen (MEF LT) (Fig. 1G) were also 
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comparable to levels seen in primary MEFs (MEF PRI) (Fig. 1F). Thus, the level 
of copper accumulated in senescent MEF (IR or REP) was significantly higher 
than primary and immortalized (spontaneously or through transduction of LT) 
MEFs.  
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Figure 1. Senescent cells accumulate copper.  
(A) Primary (non-immortalized) mouse embryonic fibroblasts (MEFs) were 
induced to senescence by either sub-lethal gamma irradiation [10 Gray (Gy)] or 
replicative exhaustion.  Senescent cell population in culture was determined 
through staining for senescence-associated beta-galactosidase (SA-βgal) activity 
(blue staining). Note that primary MEFs underwent replicative exhaustion at 
passage 7 under our culturing conditions. More than 80% of MEFs stained 
positive for SA-βgal activity when cultured for a minimum of 10 days following 
either mode of senescence induction. Images were taken at 100X magnification. 
(B) Induction of senescence in MEFs caused intracellular copper accumulation. 
ICP-MS analyses demonstrated that senescent MEFs (MEF IR) accumulated 
intracellular copper (~3-fold) at 21 days post-irradiation. Similarly, replicative 
senescent MEFs (MEF REP) when cultured for 21 days at passage 7 also 
accumulated intracellular copper (~4-fold).  
(C) Changes in cell mass and volume of senescent cells did not account for 
copper accumulation. Diameters of senescent cells in suspension (post-
trypsinization) were found to be comparable to that of their primary precursor 
cells in suspension. Suspended cell diameter was determined by Beckman Coulter 
Z Series Cell Count and Size Analyser (n = 3) for all cell types being studied.  
Cellular protein content as a marker for overall cell mass and volume was 
determined for all cell types under study. Senescent irradiated (MEF IR) and 
senescent replicative MEFs (MEF REP) contained ~1.3-fold and ~1.1-fold more 
protein when compared to primary MEFs (MEF PRI), respectively. Oncogene 
induced senescent MEFs (MEF OIS) contained ~2.3-fold more protein than 
primary MEFs treated with control viral particles (MEF VC). Senescent human 
prostate epithelial cells (PrEC IR) and senescent human diploid fibroblasts (HDF 
IR) contained ~1.5-fold more protein than primary PrECs (PrEC PRI) and HDFs 
(HDF PRI), respectively. Note that in each case the senescence associated fold 
change in copper content was higher than the fold change in total cellular protein 
content. Cellular protein concentrations were determined using the BCA protein 
assay kit (Thermo Scientific) as per manufacturer’s instructions. Total protein was 
determined as mg per 106 cells and represented as mean ± SD (n = 3).  
(D) Copper accumulation in irradiated MEFs was concomitant with senescence, 
was p53-driven and was not indirectly caused by irradiation. Primary MEFs 
isolated from mice harbouring mutant p53 (G515A nucleotide mutation), which 
impairs senescence induction by irradiation, displayed no significant increase in 
intracellular copper post-irradiation (10 Gy). Note that less than 20% of irradiated 
MEFs harbouring mutant p53 (IR p53mut) stained positive for SA-βgal activity 
when cultured for a minimum of 10 days following irradiation.  
(E) Senescence bypass in MEFs by 3T3 subculture caused a limited increase in 
intracellular copper accumulation within the normal range of intracellular Cu in 
MEFs (see Fig. 1F). ICP-MS analyses demonstrated that isogenic MEFs, which 
spontaneously bypassed senescence [ISO (3T3)], had intracellular copper levels 
comparable to that of primary MEFs (MEF PRI).  
(F) Natural variance in intracellular copper in primary MEFs between different 
embryonic linages. ICP-MS analyses of isogeneic C57BL/6 MEF lines (n = 10) 
showed a range of intracellular Cu (5.9-9.0 ng/106 cells) concentrations. Data 
represented as mean ± range (n = 10).  
(G) Senescence bypass in MEFs by immortalization caused no increase in 
intracellular copper.  
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(i) Primary MEFs were immortalised by transduction with retrovirus containing 
the SV40 large T antigen (LT) confirmed through western blot analyses. (ii) ICP-
MS analyses demonstrated that immortalised MEFs (MEF LT) at passage 7 had 
intracellular copper levels comparable to that of primary MEFs (MEF PRI). 
(H) Induction of senescence in MEFs with virus containing the oncogene H-
RasV12 caused intracellular copper accumulation. (i) Primary MEFs transduced 
with virus containing H-RasV12 (OIS) were enriched for SA-βgal positive cells 
(~50% at 8 days post-transduction) in comparison to primary MEFs transduced 
with control virus (VC) (~5%). (ii) ICP-MS analyses demonstrated that oncogene-
induced senescent MEFs (OIS) accumulated intracellular Cu (~3.5-fold) at 8 days 
post-transduction with virus containing H-RasV12. Immortalised MEFs transduced 
with virus containing H-RasV12 (MEF LT Ras) had intracellular copper levels 
comparable to that of primary MEFs (PRI) and significantly lower than MEF VC.  
 (I) Induction of senescence by sub-lethal gamma irradiation (10 Gy) caused 
intracellular copper accumulation in human diploid fibroblast (HDFs) and human 
prostate epithelial cells (PrECs). (i) The majority (>80%) of HDFs and PrECs 
displayed positive SA-βgal activity 10 days post-irradiation.  
(ii) ICP-MS analyses demonstrated that senescent HDFs (HDF IR) and senescent 
PrECs (PrEC IR) accumulated 1.7-fold and 2-fold more copper, respectively at 21 
days post-irradiation compared to their respective non-irradiated primary cell. 
Statistical analysis was performed by student-t test: significant (*p<0.05, 
**p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3) unless stated 
otherwise.  
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Oncogenes such as HRasV12 can transform immortalized cells making 
them tumourigenic, but can also induce senescence in primary (non-
immortalized) cells (Serrano et al., 1997). Oncogene-induced senescence (OIS) is 
distinct from irradiation and replicative-induced senescence that emanate from 
DDR mechanisms, as oncogenes can mediate their pro-senescence feature 
through DDR-independent mechanisms such as activation of ARF or chromatin 
remodelling (Courtois-Cox et al., 2008, Hemann and Narita, 2007). Furthermore, 
oncogene-induced senescence shares several features of programmed 
developmental senescence, such as expression of p21 and p15 that play a role in 
normal embryonic development (Storer et al., 2013). Therefore, to determine 
whether senescence induction involving different pathways was associated with 
elevated copper, we transduced primary MEFs with HRasV12 to induce cellular 
senescence, which was verified by SA-βgal activity staining at 8 days post-
transduction (MEF OIS) (Fig. 1H(i)). Despite the limited percentage of senescent 
cells (>50%), oncogene-induced (HRasV12) senescent MEFs (MEF OIS) 
accumulated intracellular copper when compared to MEFs transduced with 
control retrovirus (MEF VC) (Fig. 1H(ii)). In contrast, immortalized MEFs 
transduced with retrovirus containing HRasV12 (MEF LT Ras) had slightly 
reduced intracellular copper levels (Fig. 1H(ii)), indicating that HRasV12 itself is 
not associated with copper accumulation. Taken together, these results 
demonstrate that copper accumulated specifically in MEFs following senescence 
induction through irradiation (10 Gy), replicative exhaustion, or the HRasV12 
oncogene.  
We further demonstrated that human primary diploid fibroblast (HDFs) 
and human prostate epithelial cells (PrECs), analogous to MEFs, also 
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accumulated intracellular copper following senescence induction through 
irradiation (IR) (Fig. 1I). Senescence was confirmed by SA-βgal activity (>80%) 
(Fig.1I(i)). Therefore, our results clearly demonstrate that intracellular copper 
accumulates in senescent cells irrespective of stimuli or cell origin (mouse vs. 
human; fibroblast vs. epithelial) and is therefore likely to represent a universal 
feature of these cells. 
 
Copper accumulation in senescent cells is associated with altered homeostatic 
mechanisms 
We investigated the levels of key cellular copper homeostasis proteins in 
senescent MEFs (21 days post-irradiation) (Fig. 2A). Western blot analyses 
revealed that senescent MEFs (MEFs IR) had significantly elevated levels of the 
high-affinity copper-uptake protein 1 (Ctr1), the principle protein responsible for 
the cellular uptake of copper (Fig. 2A). Ctr1 is the major copper import protein 
and resides as a trimeric complex that creates a pore through the plasma 
membrane (Fig. S1A) (Lee et al., 2001). The export of excess intracellular copper 
is mediated by the transmembrane P-type ATPase Atp7a in most cells (e.g. 
fibroblasts & epithelial cells), which facilitates removal of excess copper across 
the plasma membrane (Monty et al., 2005, Nyasae et al., 2007). The expression of 
Atp7a was significantly reduced in senescent MEFs (21 days post-irradiation) 
(Fig. 2A), which, in combination with elevated Ctr1, likely contributes to a net 
increase in copper accumulation. Analogous changes to Ctr1 and Atp7a were 
observed in replicative senescent MEFs that could account for the net gain in 
copper observed (Fig. S1B).  
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Figure 2. Senescent cells have altered copper homeostasis and enhanced 
antioxidant defence mechanisms.  
(A) Expression of key copper homeostasis proteins was analysed in senescent 
MEFs (MEF IR) at 21 days post-irradiation (IR, 10 Gy) by western blot analyses 
and densitometry. Expression levels of Ctr1 (major copper import protein) and 
Atp7a (main copper export protein) were measured in comparison to primary 
(PRI) MEFs. β-actin was detected as a loading control.  
(B) Expression of key copper dependent and chaperone proteins was analysed in 
senescent MEFs (MEF IR) at 21 days post-irradiation (IR, 10 Gy) by western blot 
analyses and densitometry. Expression levels of superoxide dismutase (SOD1) 
(antioxidant cuproenzyme), CCS (copper chaperone for superoxide dismutase) 
and glutaredoxin 1 (Grx1) and were measured in comparison to primary (PRI) 
MEFs. β-actin was detected as a loading control.  
(C) Senescent MEFs (MEF IR) have elevated intracellular glutathione. Reduced 
(GSH) and oxidized (GSSG) glutathione were measured in primary (MEF PRI) 
and senescent MEFs (MEF IR) at 21 days post-irradiation (10 Gy) by HPLC. The 
GSH:GSSG ratio is also compared. Statistical analysis was performed by student-
t test: significant (*p<0.05, **p<0.01, ***p<0.001). Data represented as mean ± 
SD (n = 3).  
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Conceivably, the increase in intracellular copper in senescent cells would 
necessitate numerous adaptive changes by the cell, to circumvent toxicity from 
the production of reactive oxygen species (ROS). Therefore, we investigated the 
levels of known antioxidants that afford cellular protection against copper-
induced oxidative stress. Superoxide dismutase (SOD1) scavenges superoxide 
anions, utilizes copper as a cofactor (Wong et al., 2000) and is a reliable marker 
of cellular stress (Andersson-Sjoland et al., 2016). SOD1 was markedly elevated 
in senescent MEFs (21 days post-irradiation) (Fig. 2B). Interestingly, the level of 
the copper chaperone for SOD1 (CCS) (Schmidt et al., 1999, Wong et al., 2000), 
remained unchanged (Fig. 2B). Glutaredoxin 1 (Grx1) is a GSH-dependent thiol-
oxidoreductase that protects cellular proteins from oxidative damage by 
catalysing the reversible oxidation of protein thiols by GSSG to form mixed 
disulfides (P-SSG) (glutathionylation) or intramolecular disulfides (P-SS) 
(Bouldin et al., 2012, Hatori et al., 2012, Brose et al., 2014), and it protects cells 
from copper-induced toxicity (Cater et al., 2014, Singleton et al., 2010). When the 
oxidative challenge is removed, then Grx1 may catalyse the reverse reactions 
(deglutathionylation, reduction of disulfide bonds) (Brose et al., 2014). Analogous 
to SOD1, Grx1 expression is markedly elevated in senescent MEFs (21 days post-
irradiation) (Fig. 2B). GSH as the major cellular antioxidant, is rich in the cytosol 
(1-10 mM) (Dringen, 2000) and may be reversibly oxidised to its disulfide form 
GSSG. The GSSG/GSH couple constitutes a redox buffer that controls the redox 
status of cellular protein thiols among other antioxidative functions (Schmidt and 
Dringen, 2012). GSH has also been shown to play an important intermediary role 
in handling intracellular copper immediately following cellular uptake by Ctr1 
(Maryon et al., 2013, Denoyer et al., 2015, Denoyer et al., 2016) and may also 
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mediate the loading of copper onto SOD1 through a CCS- independent 
mechanism (Kim et al., 2008, Wong et al., 2000). Furthermore, the level and ratio 
of GSH (reduced glutathione) versus GSSG (oxidized glutathione) can often serve 
as an indicator of the cellular redox status (Schmidt and Dringen, 2012). Since 
oxidative stress is a well-characterised feature of senescent cells (Kuilman et al., 
2010, Freund et al., 2012), coupled with a marked increase in copper levels, we 
postulated that changes to the levels of GSH and the GSH/GSSG ratio would 
likely occur in senescent cells. In senescent MEFs (21 days post-irradiation) there 
was a substantial increase in both reduced GSH (~5-fold) and oxidised GSSG 
(~7-fold), combined with a lower ratio of GSH:GSSG (Fig. 2C). Replicative 
senescent MEFs showed similar changes in GSH and GSSG levels (Fig. S1C). 
Taken together, these results demonstrate that copper accumulation in senescent 
cells is associated with changes in the expression profile of relevant copper 
homeostatic proteins. Furthermore, a concomitant increase in major cellular 
antioxidants, SOD1, Grx1 and GSH, may protect senescent cells against the 
adverse effects of copper-induced oxidative stress.  
 
Senescent cells possess a highly enhanced but saturable limit for intracellular 
copper 
Senescent cells remain metabolically active and undergo morphological and 
biochemical changes correlating with different phases in their progression (van 
Deursen, 2014). We therefore determined whether the degree of copper 
accumulation in senescent MEFs reflected the duration of time in culture and/or 
the availability of copper in the extracellular milieu. Copper accumulation was 
monitored in irradiated MEFs following different time periods in culture (1, 7, 14 
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and 21 days) (Fig. 3A). Note that the medium was replenished weekly for each 
time point. Intracellular copper accumulated in irradiated cultures and correlated 
with the increasing percentage of senescent cells at each time point (Fig. 3A). 
However, the level of accumulated copper somewhat plateaued but was 
maintained after day 14, indicating that an upper threshold may have been 
reached (Fig. 3A).  
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Figure 3. Copper accumulation in senescent cells is saturable and limited by 
Atp7a. 
(A) Copper accumulation in irradiated (10 Gy) senescent MEFs (MEF IR) over 
prolonged culturing. ICP-MS analyses demonstrated cumulative intracellular 
copper accumulation in irradiated (10 Gy) senescent MEFs (MEF IR) over the 
culturing time points indicated (day 1, 7, 14 and 21). Note that copper 
accumulation plateaued after day 14. Baseline intracellular copper levels in 
primary MEFs (MEF PRI) are also shown. Percentage of senescent MEFs (MEF 
IR) over the culturing time points indicated as SA-βgal positive activity. 
(B) Copper accumulation in MEFs undergoing replicative senescence (MEF 
REP). ICP-MS analyses demonstrated that copper accumulated when replicative 
senescence commenced (<10%) at passage 6 and was augmented with senescence 
enrichment (>80%) at passage 7. Note copper accumulation plateaued after 
culturing passage 7 senescent MEFs for 10 days (~5-fold) following which no 
further increase in copper was reported at day 21. Percentage of senescent MEFs 
in continually passaged cultures (passages 4, 6 and 7) is indicated as percentage 
of cells with SA-βgal activity. 
(C) Capacity of senescent MEFs to accumulate copper is dependent on 
extracellular copper concentration. Irradiated senescent MEFs (MEF IR, 14 days 
post irradiation) and replicative senescent MEFs (MEF REP P7, day 10), were 
cultured for 24 hours in basal medium, or media supplemented with 20 µM 
copper (as CuCl2). ICP-MS analyses revealed a greater increase in accumulated 
copper in IR senescent MEFs compared to replicative senescent MEFs following 
copper treatment. The baseline and copper supplemented intracellular copper 
level in primary (PRI) MEFs (P4) is also shown.  
(D) Senescent irradiated Mottled Brindled (Mobr) MEFs accumulate substantial 
copper compared to senescent agouti MEFs. (i) Sub-lethal gamma irradiation (10 
Gy) caused the majority (>80%) of Mobr (MEF Mobr IR) and agouti 
MEFs[MEF(A) IR] to display positive SA-βgal activity 10 days post-irradiation. 
Images were taken at 100X magnification. (ii) ICP-MS analyses demonstrated 
that senescent Mobr  MEFs (MEF Mobr IR) accumulated intracellular copper (~2-
fold) at 21 days post-irradiation compared to primary Mobr  MEFs (MEF Mobr 
PRI). Intracellular copper levels of primary and irradiated senescent agouti MEFs 
are shown for comparison. Note that intracellular copper in non-irradiated 
primary Mobr MEFs (MEF Mobr PRI) was highly elevated compared to wild type 
MEFs of C57BL/6 or agouti background.  
(E) Replicatively senescent Mottled Brindled (Mobr) MEFs accumulate 
substantial copper post senescence induction. (i) Primary (non-immortalized) 
Mobr and agouti MEFs were induced to senescence by replicative exhaustion.  
Senescent cell population in culture was determined through staining for 
senescence-associated beta-galactosidase (SA-βgal) activity (blue staining). Note 
that primary Mobr and agouti MEFs underwent replicative exhaustion at passage 7 
under our culturing conditions. More than 80% of cells stained positive for SA-
βgal activity when cultured for a minimum of 10 days following senescence 
induction. Images were taken at 100X magnification. 
(ii) ICP-MS analyses demonstrated that replicatively senescent Mobr MEFs (MEF 
Mobr P7) accumulated intracellular copper (~2-fold) at 21 days post senescence 
induction compared to primary Mobr MEFs (MEF Mobr PRI). Statistical analysis 
was performed by student-t test: significant (*p<0.05, **p<0.01, ***p<0.001). 
Data represented as mean ± SD (n = 3).  
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Similarly, MEFs undergoing replicative exhaustion progressively accumulated 
intracellular copper in accordance with the percentage of senescent cells at each 
passage, reaching an upper limit when cells at passage 7 were cultured for 10 days 
(Fig. 3B). Further culturing of replicative senescent MEFs (21 days) did not 
augment copper accumulation (Fig. 3B). To establish whether these apparent 
upper thresholds represent copper sequestration capacity, we treated both 
irradiated (14 days post-irradiation) and replicative senescent MEFs (passage 7 
cultured for 10 days) with either basal medium or media supplemented with 20 
µM CuCl2 for 24 hours (Fig. 3C). Note that primary proliferative MEFs (passage 
4) were treated equivalently as a control (Fig. 3C). In medium supplemented with 
20 µM CuCl2 there was an increase in the capacity of senescent MEFs, regardless 
of stimuli, to accumulate intracellular copper (Fig. 3C). The reason for the greater 
copper levels accumulated by irradiated senescent MEFs compared to replicative 
senescent MEFs is currently unclear. Previously, we showed that senescent MEFs 
had reduced levels of Atp7a (Fig. 2A, S1B), which may account for the elevated 
copper to some extent. We sought to further investigate the contribution of 
defective or absent Atp7a function on copper accumulation by senescent cells. 
Skin fibroblasts from subjects suffering from Menkes disease (MD), an X-linked 
recessively inherited disease of copper deficiency due to mutations in the ATP7A 
gene (human orthologue of mouse Atp7a), show a remarkable increase in 
intracellular copper (>13-fold) compared to normal skin fibroblasts (Camakaris et 
al., 1980). These MD fibroblasts have impaired efflux of copper due to defective 
or absent ATP7A activity, however the kinetics for the uptake of copper remains 
unchanged from that of normal fibroblasts (Camakaris et al., 1980).  Furthermore, 
MD fibroblasts cultured in copper supplemented media further accumulate 
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copper, but show a markedly elevated sensitivity to copper (Camakaris et al., 
1980). These observations suggest that reduced Atp7a function would explain the 
increase in intracellular copper levels in primary and senescent MEFs. To test this 
hypothesis, we utilized brindled mouse mutants (Mobr) the animal model that 
most closely resembles MD (Grimes et al., 1997). Mobr mice harbour a mutated 
Atp7a gene with a 6 base-pair deletion (GCTCTT from nucleotides 2473 to 2478), 
corresponding to the in-frame elimination of two amino acids, an alanine residue 
(Ala799) and a completely conserved leucine residue (Leu800). While cells and 
tissue from Mobr mice display normal levels of Atp7a transcript and protein, the 
protein fails to efficiently localize to the plasma membrane for copper efflux 
(Grimes et al., 1997, La Fontaine et al., 1999) and displays greatly reduced 
residual activity compared to normal Atp7a (<5%) (Grimes et al., 1997). 
Analogous to human MD fibroblasts, several cell types isolated from Mobr mice, 
such as lung fibroblasts, kidney epithelial cells and fetal cells were reported to 
harbour elevated copper (~4-fold, ~7-fold and ~21-fold, respectively) compared 
to the corresponding normal cells when propagated in culture (Camakaris et al., 
1980). We produced MEFs from Mobr and agouti (wt Atp7a on the same 
background as Mobr) mouse embryos and irradiated them to induce senescence. 
We established that 10 days following irradiation, analogous to MEFs from 
C57BL/6 background (Fig 1A), more than 80% of MEFs from Mobr (MEF-Mobr) 
stained positive for SA-βgal activity and a similar observation was made in 
cultures of irradiated agouti MEFs (Fig. 3D(i)). These irradiated MEFs were 
cultured for an additional 11 days to allow for a net change in intracellular copper 
to occur (Fig. 3D(ii)). Notably, primary (non-irradiated) Mobr MEFs (MEF-Mobr 
PRI) showed substantially elevated intracellular copper levels (Fig. 3D(ii)), even 
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higher than those observed in senescent MEFs cultured in copper replete media 
(Fig. 3C). Furthermore senescent irradiated Mobr MEFs (MEF-Mobr IR) displayed 
a further augmentation of intracellular copper compared to primary Mobr MEFs 
(MEF-Mobr PRI) (~2-fold) (Fig. 3D(ii)). Thus, copper accumulated in senescent 
irradiated Mobr MEFs to a much greater extent than in senescent wild-type MEFs. 
In addition, senescent irradiated Mobr MEFs accumulated copper to an extent that 
surpassed the levels observed in senescent irradiated wild-type MEFs treated with 
copper, due to the almost complete abolition of Atp7a function.  
 In previous studies, premature senescence in human fibroblasts induced 
through copper treatment was accompanied by at least a two-fold increase in 
intracellular copper (Boilan et al., 2013, Matos et al., 2012, Matos et al., 2017).  
Furthermore, the copper accumulated at the end of copper treatment (~eight-fold) 
was not maintained in cells post-senescence establishment (Boilan et al., 2013). It 
is possible that this mode of senescence induction was primarily driven by 
copper-mediated ROS generation (Boilan et al., 2013). However primary Mobr 
MEFs (passage 4), which displayed at least a six-fold increase in intracellular 
copper displayed no appreciable staining for SA-βgal activity (Fig. 3A). This may 
be due to mechanisms in the Mobr MEFs that are induced to manage the gradual 
build-up of copper in these cells, in contrast to the acute stress imposed with 
copper treatment at a high concentration as performed by Boilan et al (Boilan et 
al., 2013). Furthermore, serially passaged primary Mobr MEFs displayed a 
remarkably similar senescence induction profile to wild-type MEFs (agouti or 
C57BL/6) (Fig. 3E(i)). Thus, it is unlikely that elevated intracellular copper levels 
provide a swifter transition to cellular senescence. Notably, copper accumulation 
observed in replicatively senescent Mobr MEFs (observed at passage 7) was 
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comparable to that observed in irradiated senescent Mobr MEFs (Fig. 3D, E(ii)); 
this higher level of intracellular copper may be maintained by copper buffering 
mechanisms and/or may be attributed to absence of or negligible Atp7a activity.  
 
Rapamycin treatment can attenuate senescence associated copper 
accumulation 
Previously in copper-induced senescent HDFs, the pro-senescence effects of 
copper treatment could be attenuated by subsequently treating cells with 
resveratrol, a known chelator of copper (Tamboli et al., 2011, Belguendouz et al., 
1997), through the activation of autophagic-lysosomal degradation (Matos et al., 
2017). We have shown previously that autophagic-lysosomal degradation is 
impaired in senescent cells and contributes to iron dyshomeostasis (refer 
Manuscript 1). We thus explored whether the preservation of autophagic-
lysosomal degradation was sufficient to prevent copper accumulation. 
Rapamycin, an mTOR inhibitor (Kim and Guan, 2015), activates autophagy and 
preserves lysosomal function in senescent cells (Tai et al., 2017). Interestingly, 
rapamycin treatment affects other facets of senescence such as the partial 
suppression of SA-βgal activity and senescence-associated secretory phenotype 
(SASP), however the extent and the exact senescence features affected are cell 
context dependent (Xu et al., 2014). We treated primary MEFs with rapamycin 
(100 nM) while they were irradiated (10 Gy) to undergo senescence and sustained 
this treatment for 10 days. Cell culture medium was changed twice over this time 
period and rapamycin treatment was maintained with each medium change. Note 
that 10 days post-irradiation (10 Gy) is sufficient to achieve >80% senescence in 
MEF cultures. The LC3 protein in its lipidated form (LC3-II) normally builds up 
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in autophagosomes of cells and is degraded by lysosomal proteases following 
autophagosome-lysosome fusion (Mizushima and Yoshimori, 2007, Tanida et al., 
2005). Thus, the persistent accumulation of LC3-II in cells indicates an 
impairment in lysosomal degradation and the resultant accumulation of 
autophagosomes (refer Manuscript 1)(Tanida et al., 2005). We thus assessed 
LC3-II levels in rapamycin treated irradiated MEFs 10 days post-irradiation and 
found that levels of LC3-II were decreased indicating that autophagic-lysosomal 
degradation in rapamycin treated cells was preserved post-irradiation (Fig. 4A). 
In addition to decreased LC3-II, the phosphorylated form of ribosomal protein S6 
(pS6), was also diminished in rapamycin treated irradiated MEFs (Fig. 4A), 
indicating autophagosome formation and lysosomal degradation (Blommaart et 
al., 1995). Taken together these results suggests that rapamycin treatment had 
preserved autophagic-lysosomal degradation functions in irradiated MEFs.  
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Figure 4. Rapamycin treatment attenuates senescence-associated copper 
accumulation. 
(A) Sustained rapamycin treatment preserves autophagic-lysosomal function in 
irradiated MEFs. Western blot analysis demonstrated that levels of LC3-II and 
phosphorylated ribosomal protein S6 (pS6) were significantly reduced by 
sustained treatment of irradiated MEFs for 10 days post-irradiation (10 Gy) with 
rapamycin (100 nM). β-actin was detected as a loading control. 
(B) Sustained rapamycin treatment limited intracellular copper accumulation in 
irradiated MEFs. ICP-MS analyses demonstrated that irradiated MEFs subjected 
to sustained treatment with rapamycin (100 nM) showed markedly reduced 
copper accumulation at 10 days post-irradiation (10 Gy).  
(C) Rapamycin treatment after senescence establishment reversed intracellular 
copper accumulation in irradiated MEFs. ICP-MS analyses demonstrated that 
senescent irradiated MEFs treated with rapamycin (100 nM) for 4 days after 
senescence establishment (10 days post-irradiation) reversed copper 
accumulation. Statistical analysis was performed by student-t test: significant 
(*p<0.05, **p<0.01, ***p<0.001). Data represented as mean ± SD (n = 3).  
(D) Sustained rapamycin treatment did not enhance Atp7a levels. Western blot 
analysis and densitometry demonstrated that levels of Atp7a did not increase by 
sustained treatment of irradiated MEFs for 10 days post-irradiation (10 Gy) with 
rapamycin (100 nM). β-actin was detected as a loading control. 
(E) Bafilomycin A1 (Baf) treatment attenuates autophagic-lysosomal function in 
primary MEFs. Western blot analysis demonstrated that the level of LC3-II was 
significantly elevated by treatment of primary MEFs with Baf (100nM) for 16h. 
β-actin was detected as a loading control. 
(F) Inhibition of autophagic-lysosomal function enhanced intracellular copper 
accumulation in primary MEFs. Primary MEFs were cultured for 16 hours in 
basal medium, or medium supplemented with 20 µM copper (as CuCl2), with or 
without Baf (100 nM). ICP-MS analyses revealed a greater increase in 
accumulated copper in primary MEFs treated with Baf compared to primary 
MEFs without Baf treatment following 16 h of copper treatment. The baseline 
intracellular copper level in primary (PRI) MEFs (P4) is also shown.  
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Next we assessed intracellular copper levels in rapamycin treated irradiated MEFs 
and found a significant reduction in copper accumulation compared to untreated 
(basal) irradiated MEFs (Fig. 4B). In addition, once senescence was fully 
established (10 days post-irradiation) subsequent rapamycin treatment (100 nM 
for 4 days) reversed intracellular copper accumulation (Fig. 4C). However, when 
we assessed Atp7a levels in rapamycin treated irradiated MEFs 10 days post-
irradiation we found that this did not result in an increase in Atp7a and in fact the 
level of Atp7a was further diminished, possibly as a result of autophagic-
lysosomal degradation (Fig. 4D). This demonstrated that copper accumulation in 
senescent MEFs was most likely dependant on impaired autophagic-lysosomal 
degradation pathway and not solely dependent on the amount of Atp7a present. 
To confirm this hypothesis we treated primary MEFs with the lysosome inhibitor 
bafilomycin A1 (Baf) with the aim of phenocopying, to a limited extent, the 
effects of perturbed autophagic-lysosomal degradation observed in senescent 
MEFs. Interestingly, Baf is known to limit the constitutive recycling of Atp7a 
between the TGN and the plasma membrane (Petris et al., 1996).  Treating 
primary MEFs with Baf led to a concomitant build-up of LC3-II levels (Fig. 4E) 
similar to our observations of lysosomal impairment in senescent MEFs (Fig. 
4A). Interestingly, impairment of autophagic-lysosomal degradation pathway in 
primary MEFs treated for 16 h with 20 µM CuCl2 and Baf, led to a significantly 
enhanced accumulation of copper, indicating the important role of lysosomes in 
the export of copper in MEFs (Fig. 4F). Thus, preservation and possible 
restoration of the autophagic-lysosomal degradation pathway was sufficient to 
significantly prevent and revert, respectively, the copper accumulation phenotype 
in senescent cells.  
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Conclusion 
The accumulation of copper in senescent MEFs was associated with changes in 
the levels of key copper regulatory proteins. The expression of Atp7a was 
significantly reduced in senescent MEFs, which may contribute to some extent, in 
combination with elevated Ctr1, to the observed copper accumulation. GSH, 
present in millimolar concentrations, is the most abundant copper ligand in the 
cytosol. GSH has been shown to play an important role in copper uptake by Ctr1, 
and may have an intermediary role in handling intracellular copper prior to 
transfer to high affinity copper chaperone proteins (Maryon et al., 2013).  The 
substantial increase in glutathione (GSH and GSSG) levels observed in senescent 
MEFs may reflect a response to increased copper uptake by Ctr1, and/or a 
response to provide increased copper buffering capacity. The decreased 
GSH:GSSG ratio combined with the substantial increase in SOD1 and Grx1 
suggests that the cells are undergoing some level of oxidative stress.  Thus, 
copper accumulation may result from enhanced uptake and reduced export 
coupled with higher copper buffering predominantly by GSH. The reduction in 
levels of Atp7a may contribute to senescence associated copper accumulation to 
some extent. However, the reduced level of Atp7a in senescent MEFs is 
enigmatic. Atp7a, analogous to the related Atp7b, is likely to be degraded via the 
lysosomal pathway (Materia et al., 2011), however senescent cells lack efficient 
lysosomal function (Tai et al., 2017). Atp7a was therefore expected to accumulate 
in senescent cells, akin to our previous observations for other lysosomally 
degraded proteins such as ferritin, ferroportin, and autophagosome marker LC-
3II, all of which show substantial increase in protein levels (please refer 
Manuscript 1). There was no change in Atp7a transcript levels post senescence 
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induction (not shown), making it likely that Atp7a protein levels are affected at a 
translational/post-translational level. However, restoration of lysosomal function 
also did not rescue Atp7a levels. Atp7a may also be degraded via the proteasomal 
pathway (Materia et al 2012), which may be intact in senescent MEFs 
(Deschenes-Simard et al., 2013, Deschenes-Simard et al., 2014). Therefore, other 
mechanisms leading to loss of Atp7a stability or other pathways leading to Atp7a 
degradation may be activated as a consequence of lysosomal dysfunction in 
senescent cells and remain to be clarified. 
 Our finding that the preservation and reactivation of autophagic-lysosomal 
degradation by rapamycin in irradiated MEFs resulted in the reduction of copper 
levels suggests a possible and yet undefined association between cellular 
autophagy and copper export.  One possible mechanism for this may through the 
build-up of copper in endocytic structures called multivesicular bodies (MVB). 
Autophagosomes can fuse with MVBs to generate amphisomes prior to fusion 
with lysosomes (Fader and Colombo, 2009). These MVBs may thus serve as 
temporary sinks for elevated copper under normal conditions. Subsequent export 
of copper then may occur following exocytic fusion with the plasma membrane 
(Cater et al., 2006). However, in senescent cells due to lack of lysosomal turnover 
of these structures, these accumulating autophagosomes/amphisomes may 
continue to sequester copper, functioning as a reservoir of copper. Supporting this 
hypothesis, intracellular multivesicular compartments have been observed to 
accumulate in ATP7B-expressing CHO-K1 cells under conditions of elevated 
copper (La Fontaine et al., 2001). ATP7B, a P-type transmembrane ATPase 
similar to Atp7a, is expressed highly in hepatocytes, is involved in copper efflux, 
and is localized to these compartments suggesting that it may traffic copper to 
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these MVBs (Polishchuk et al., 2014). As we did not detect any expression of 
Atp7b transcript in primary or senescent MEFs (not shown) it may be possible 
that Atp7a follows a similar pathway in these cells. 
 Why senescent cells sequester copper remains unclear, but the data 
presented here point to a role for altered copper homeostasis and impaired 
autophagy in this phenomenon. The observation that senescence induction is 
accompanied by impaired autophagy and leads to a change in copper homeostasis 
is important for understanding the role copper plays in disorders of ageing, in 
which senescent cells are increasingly seen as key drivers.  
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Supplementary Information 
Figure S1. Senescent MEFs have altered key copper homeostasis proteins.  
(A) Protein levels of the main copper import protein, Ctr1 was analysed in 
irradiated senescent MEFs (MEF IR) by western blot analyses. The multimeric 
and monomeric forms of Ctr1 are shown. Protein levels of Ctr1 monomeric and 
multimeric forms in primary MEFs are shown for comparison. 
(B) Protein levels of the main copper import protein, Ctr1, and export protein, 
Atp7a, were analysed in replicative senescent MEFs (MEF REP) by western blot 
analyses. Protein levels of Ctr1 and Atp7a in primary (MEF PRI) MEFs are 
shown for comparison. β-actin was detected as a loading control.  
(C) Replicative senescent MEFs have elevated intracellular glutathione. Reduced 
(GSH) and oxidized (GSSG) glutathione were measured in primary (MEF PRI) 
and replicative senescent MEFs (MEF REP) by HPLC (n = 2). The GSH: GSSG 
ratio is also compared.  
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CONCLUDING REMARK AND FUTURE DIRECTIONS 
 
Lysosomal dysfunction, associated with senescence-associated metal 
dysfunction, may be a therapeutic target for age-related pathologies 
It is now clear that accumulation of iron and copper in senescent cells is linked to 
lysosomal dysfunction. Lysosomal dysfunction resulting in impaired 
ferritinophagy, perceived cellular iron deficiency and “iron hunger” appeared to 
drive senescence-associated iron accumulation. The mechanism behind copper 
dyshomeostasis, on the other hand, remains unclear but appeared to stem from a 
role of lysosomes in copper export; a function presumably impaired in the 
lysosomes of senescent cells.    
Senescence-associated dysfunction in iron and copper homeostasis 
provides an aetiological link between the increases in the levels of these metals in 
tissues where senescent cells are enriched. Pathologies that are of immediate 
interest are dementias such as Alzheimer’s and Parkinson’s, where iron and 
copper are important players (Lovell et al., 1998, Ward et al., 2014, Ayton et al., 
2014, Dexter et al., 1987, Lhermitte et al., 1924, Bartzokis et al., 2004, Bush, 
2013, Davies et al., 2016), and where there is also evidence of accumulation of 
senescent/senescent-like cells in diseased tissue (Golde and Miller, 2009, Chinta 
et al., 2013, Bhat et al., 2012, Chinta et al., 2015). Furthermore, till date, drugs 
developed to treat these disorders have met with limited clinical success. Thus, it 
may be of interest to explore molecules that can ablate senescent cells in the 
context of these disorders or that can preserve or repair lysosomal function in 
affected tissue. A potential class of drugs that may be explored are rapamycin 
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analogs (rapalogs) that are being trialled for safety and efficacy as anti-cancer 
drugs (Lamming et al., 2013, Meng and Zheng, 2015).   
Cellular senescence and evasion of programmed cell death  
An important aspect of senescent cell biology is their evasion of cell death 
mechanisms such as apoptosis, and as we described, ferroptosis. The role of iron 
in modulating the function of p53, a regulator of apoptosis, ferroptosis and 
senescence, would be important to explore in this respect. Additionally, the 
profoundly elevated levels of iron observed in senescent cells may offer unique 
ways for selectively ablating them by: 
a) Re-sensitizing senescent cells to ferroptotic death.  
b) Redistribution and release of stored iron to generate ROS to induce 
apoptosis 
Role of iron and copper accumulation in physiological function of wound 
healing by senescent cells 
Senescent cells are involved in optimal wound healing, appear at the site of injury 
and accelerate wound closure (Demaria et al., 2014). These cells are subsequently 
cleared by the immune system.  The clearance of senescent cells involves 
elements of both innate [macrophages (Munoz-Espin et al., 2013, Storer et al., 
2013, Kang et al., 2011), natural killer cells (NK) (Sagiv et al., 2016, Sagiv et al., 
2013, Krizhanovsky et al., 2008)] and adaptive immunity [CD4+ T-cells (Kang et 
al., 2011)] and is dependent on the pro-inflammatory SASP that both maintains 
the senescent phenotype by autocrine signalling and marks these cells for 
immunological clearance (senescence surveillance) (Hoare and Narita, 2013). The 
final clearance appears to be mediated by macrophages that infiltrate the vicinity 
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of senescent cells (Munoz-Espin et al., 2013, Storer et al., 2013). Macrophages 
have a functional role in maintaining a hypoferremic environment at the site of 
injury and inflammation, in part, to impede infection (Wessling-Resnick, 2010, 
Ganz and Nemeth, 2015). This phenomenon, commonly referred to as anaemia of 
inflammation (AI) or of chronic disease (ACD), is a protective adaptive response 
at the site of injury/inflammation (Wessling-Resnick, 2010). We postulate that 
senescent cells, through accumulating iron and with subsequent clearance by 
macrophages may function to help deliver AI/ACD. Senescent cells being 
programed to sequester profound levels of iron may provide further means to 
promote and maintain a hypoferremic environment in tissues during 
injury/inflammation. The subsequent clearance of iron-laden senescent cells by 
macrophages would then maintain the protective AI/ACD. Furthermore, iron 
recovered by macrophages through phagocytosing senescent cells may be 
recycled in a similar manner to iron from expired erythrocytes. Macrophages may 
also efflux or utilise the copper accumulated in senescent cells for their 
bactericidal activity. In contrast to iron, copper accumulates at sites of 
injury/inflammation (relative to serum level) to aid against infection (e.g. potent 
bactericide) (Hodgkinson and Petris, 2012). The phagosomes of macrophages also 
require copper (in addition to iron) for bactericidal activity and accumulate copper 
during inflammation (Hodgkinson and Petris, 2012). Nevertheless, studies on the 
impact of senescence associated metal accumulation in wound healing and by 
extension its wider role in sterile chronic inflammation are warranted.  
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Targeting copper in cancer therapy: ‘Copper That
Cancer’
Delphine Denoyer,a Shashank Masaldan,a Sharon La Fontaineab and
Michael A. Cater*ac
Copper is an essential micronutrient involved in fundamental life processes that are conserved throughout all
forms of life. The ability of copper to catalyze oxidation–reduction (redox) reactions, which can inadvertently
lead to the production of reactive oxygen species (ROS), necessitates the tight homeostatic regulation of
copper within the body. Many cancer types exhibit increased intratumoral copper and/or altered systemic
copper distribution. The realization that copper serves as a limiting factor for multiple aspects of tumor pro-
gression, including growth, angiogenesis and metastasis, has prompted the development of copper-specific
chelators as therapies to inhibit these processes. Another therapeutic approach utilizes specific ionophores
that deliver copper to cells to increase intracellular copper levels. The therapeutic window between normal
and cancerous cells when intracellular copper is forcibly increased, is the premise for the development of
copper-ionophores endowed with anticancer properties. Also under investigation is the use of copper to
replace platinum in coordination complexes currently used as mainstream chemotherapies. In comparison
to platinum-based drugs, these promising copper coordination complexes may be more potent anticancer
agents, with reduced toxicity toward normal cells and they may potentially circumvent the chemoresistance
associated with recurrent platinum treatment. In addition, cancerous cells can adapt their copper
homeostatic mechanisms to acquire resistance to conventional platinum-based drugs and certain copper
coordination complexes can re-sensitize cancer cells to these drugs. This review will outline the biological
importance of copper and copper homeostasis in mammalian cells, followed by a discussion of our current
understanding of copper dysregulation in cancer, and the recent therapeutic advances using copper
coordination complexes as anticancer agents.
1. Biological importance of copper
1.1. Copper: an essential element for life
Copper is an essential micronutrient for all organisms. It is
required as a catalytic cofactor or as a structural component for
proteins, with roles in critical biological functions such as
enzyme activity, oxygen transport and cell signaling. Copper
is highly redox active, readily donating and accepting electrons
to shift between its two valence states (Cu+ 3 Cu2+). Many
critical enzymes harness this activity and hence copper plays
important roles in biological oxidation–reduction (redox) reactions.
In prokaryotes, over 10 proteins that require copper for their
function have been identified. These include cytochrome c oxidase
(COX), NADH dehydrogenase-2 (ND2), Cu/Zn–superoxide dismutase
(SOD1) and tyrosinase, to name a few of the key proteins.
Remarkably, no other metal can functionally substitute for copper
in these ‘cuproproteins’.1 Likewise, copper is critical for the activity of
eukaryotic orthologs of these proteins and in mammals acts as a
catalytic cofactor (or allosteric) for numerous proteins involved in
multiple facets of our biology, free radical scavenging, erythropoiesis,
iron metabolism, connective tissue synthesis, pigment formation,
immunity, cell signaling to neurotransmission.2–17 The functional
role of copper in COX-mediated ATP production illustrates the
importance of copper in sustaining life.18 Examples of cuproproteins
in mammalian cells are listed in Table 1.
While the redox activity of copper is essential for enzymatic
reactions, this property also renders it potentially toxic. Copper
can catalyze the production of free radicals and this can be
damaging to lipids, proteins, DNA and other biomolecules.8,19
Copper can also interfere with proteins containing iron–sulfur
clusters and can displace other metals such as zinc from
metalloproteins inhibiting their activity.20 Therefore, copper
cannot exist free in the cytosol, but must be complexed at all
times.21,22 All organisms have evolved sophisticatedmechanisms to
strictly regulate both copper levels and the delivery of copper to
copper-requiring proteins, as described below.
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1.2. Human copper homeostasis
Any imbalance in copper bioavailability through genetically
inherited mutations or altered environmental conditions,
invariably leads to deficiency or toxicity and consequently to
pathological outcomes. Therefore, copper concentrations in the
body are maintained by homeostatic mechanisms that regulate
Table 1 Prominent cuproenzymes in mammals
Common name Major localization Enzymatic function
Ceruloplasmin Plasma Oxidation of ferrous iron (Fe2+) to ferric iron (Fe3+)
Lysyl oxidase Extracellular fluid, cartilage, bone and blood Connective tissue synthesis (cross-linking of collagen and
elastin)
Tyrosinase Melanocytes of eye and skin Pigment (melanin) synthesis
Dopamine-b-hydroxylase Catecholamine storage vesicles in neuron Neurotransmitter synthesis, conversion of dopamine to
acetylcholine (noradrenaline)
Cu/Zn superoxide dismutase (SOD) Cytoplasm and mitochondria Free radical detoxification, dismutation of superoxide
radicals
Cytochrome oxidase Inner mitochondrial membrane Electron-transport enzyme
Methionine synthase Cytoplasm Catalyzes the conversion of homocysteine to methionine
Vascular adhesion protein 1 (VAP-1) Cell surface, expressed in endothelial cells,
smooth muscle cells and adipocytes
Oxidative conversion of amine to aldehydes
Aka, semicarbazide sensitive amine
oxidase (SSAO)
Adhesion of leukocytes to endothelial cells
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its absorption, excretion and bioavailability. Copper is absorbed by
the intestinal mucosa (enterocytes), and the liver is primarily
responsible for regulating the copper status of the body, controlling
copper distribution to serum and tissues and excretion of excess
copper into the bile. A negligible amount of copper is excreted in
the urine.6 In the body, most bioavailable copper is bound to
proteins and free copper is estimated at less than 1 atom per cell.22
In the general circulation, copper is transported by plasma proteins
and not by lowmolecular weight complexes such as amino acids as
previously thought.23 Plasma cuproproteins include ceruloplasmin,
a multicopper ferroxidase that is synthesized and secreted by
hepatocytes and binds approximately 70% of the copper in plasma,
albumin and the macroglobulin transcuprein.23 Administration of
radioactive copper in animals results in rapid binding of Cu2+ to
albumin and transcuprein. Most of the radioactive copper is then
distributed to the liver before returning to the blood incorporated
into ceruloplasmin.24
The mechanisms by which copper is taken up by mammalian
cells have not been completely elucidated. The current view is
that plasma proteins (albumin, transcuprein and ceruloplasmin)
deliver Cu2+ to transporters located at the plasma membrane
and that enzymes (reductases) are responsible for the reduction
of copper (Cu2+ to Cu+) prior to uptake into cells.25,26 Potential
cupric reductases involved are the metalloreductases from the
Steap family.23 In particular, Steap 3 and Steap 4 are implicated
in the reduction of copper in hepatocytes and embryonic fibro-
blasts, respectively.27 Ctr1 (SLC31A1) has been established as the
major copper import protein.28–31 However, studies in mouse
embryonic fibroblasts lacking Ctr1 and in human kidney, hepa-
tic and mammary cells, have revealed the existence of additional
uptake systems for copper. Among these are the divalent metal
transporter 1, DMT1 (DCT1, Nramp2)32,33 and Ctr2 (SLC31A2).34
A small fraction of Ctr2 was associated with the plasma
membrane and promoted copper accumulation in COS-7 cells.35
However, other reports suggested that the involvement of Ctr2 is
unlikely since the protein mainly localizes in lysosomes and late
endosomes and functions as a regulator of intracellular copper,
transporting copper from intracellular vesicles to the cyto-
plasm.23,25,36,37 Further studies will be necessary to clarify the
exact involvement of Ctr2 in copper uptake and to identify
additional sources of copper entry into cells.23
Once inside the cell, copper is bound and traﬃcked by
cytosolic metallochaperones (e.g. ATOX1, CCS) for delivery to
specific cellular destinations. It has been speculated that these
chaperones acquire copper from Ctr1 and earlier in vitro studies
demonstrated that copper could be exchanged between yeast
Cu+-Atx1 and the cytoplasmic C-terminal fragment of yeast
Ctr1.38 However, copper acquisition directly from Ctr1 has
not been demonstrated for any of the mammalian chaperones,
and recent evidence does not support a direct interaction
between the mammalian chaperones (e.g. ATOX1, CCS) and
Ctr1.39 GSH is an abundant intracellular tri-peptide and at
millimolar concentrations can buﬀer free Cuaq
+ concentrations
towards femtomolar levels.40 Evidence is building in support of
the idea that upon copper entry into cells, GSH may serve as an
initial copper acceptor. Early studies of the kinetics of 67Cu
uptake suggested that GSH bound 67Cu before it was complexed
with metallothioneins.41,42 Subsequent studies supported a
role for GSH as a potential physiological Cu+ carrier, showing
that metallothioneins could acquire copper from Cu+–GSH,43
and that GSH played a role in copper delivery to SOD1 in the
absence of CCS, the copper chaperone for SOD1.44 Based on
in vitro copper binding affinities, more recent studies proposed
a model whereby copper is transported along an affinity
gradient from GSH (millimolar concentrations with low copper
affinity) to copper chaperones (micromolar concentrations with
higher copper affinity) and then to target proteins with the
highest copper affinities.39,40,45 CCS is the chaperone that
delivers copper to Cu/Zn–SOD1. COX17 mediates copper trans-
fer within the mitochondrial intermembrane space to SCO1/
COX11 for metallation and assembly of cytochrome c oxidase.
ATOX1 (HAH1) directly exchanges copper with the ion (copper)
transporting P1B-Type ATPases (copper-ATPases), ATP7A and
ATP7B, for delivery to the secretory pathway and for efflux
of excess copper from the cell (reviewed in ref. 46). ATOX1
was originally identified in the mid-1990s as an antioxidant
molecule,47 but this function was overshadowed by the discovery
of its role as a copper delivery molecule.48,49 There is renewed
attention to the interplay between these dual roles of Atox1 and its
expanding range of functions, which include copper-dependent
nuclear localization, DNA binding and transcriptional activation
of secreted SOD3 and cyclin D1, the latter promoting cell
proliferation (reviewed in ref. 48). Several lines of evidence
suggest that ATOX1 is not absolutely required for copper delivery
to copper-ATPases,48 so that other copper carriers may supple-
ment ATOX1 function. Recent evidence that the antioxidant
molecule glutaredoxin 1 (GRX1) binds Cu+ with high affinity
and regulates the redox sulphur chemistry of ATOX1,50 supports
a potential copper-chaperone function for this protein.
The copper-ATPases ATP7A and ATP7B are critical components
of cellular copper transport and of physiological copper regula-
tion.46,51 ATP7A and ATP7B are closely related in structure and
function, with approximately 60% amino acid sequence identity.
They are large polytopic transmembrane proteins with eight trans-
membrane domains, highly conserved catalytic domains and large
cytoplasmic N-termini containing six metal-binding domains
(MBD). They undergo ATP-dependent cycles of phosphorylation
and dephosphorylation to catalyze the translocation of copper
across cellular membranes for the metallation of many essential
cuproenzymes, as well as for the removal of excess cellular
copper to prevent toxicity. An important functional aspect of
the copper-ATPases is their copper-responsive traﬃcking
between the trans-Golgi network (TGN) and the cell periphery,
a key mechanism by which cellular copper levels are regulated.
Copper-binding together with other N- and C-terminal signals
regulate their activity, intracellular location and copper-induced
intracellular traﬃcking. Their structure, biochemistry, regula-
tion and copper-responsive traﬃcking have been thoroughly
reviewed.28,46,51,52 ATP7A and ATP7B have a dual role in cells; a
biosynthetic role delivering copper to the secretory pathway for
metallation of cuproenzymes, and a homeostatic role that
involves exporting excess copper from the cell. Under normal
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physiological conditions, ATP7A and ATP7B reside at the TGN
supplying copper to copper-dependent enzymes synthesized within
the secretory pathway. For ATP7A, these include enzymes such
as peptidylglycine a-amidating monooxygenase (PAM)53,54
tyrosinase55,56 extracellular SOD3,57 dopamine-b-hydroxylase
(DBH)58 and lysyl oxidase.59–62 Copper delivery to apo-cerulo-
plasmin in hepatocytes63 and mouse cerebellum64 is mediated
by ATP7B, and by ATP7A in macrophages in response to
hypoxia-mediated increased copper uptake.65 The trafficking
of ATP7A and ATP7B in response to elevated copper has been
described in a wide range of non-polarized and polarized cell
types.51 In the latter, there is vectorial transport of copper
across the cell. For instance, in intestinal enterocytes ATP7A
traffics from the TGN to a rapidly recycling pool of basolateral
vesicles, in order to transport copper across this surface and
into the general circulation.66,67 Conversely, ATP7B traffics to
vesicles near the apical surface of hepatocytes, which constitutes
the biliary canalicular membrane, to mediate the secretion of
excess copper into the bile.68–72 When copper levels return to
normal ATP7A and ATP7B recycle back to the TGN.67,68,73
Recently, Ctr2 was shown to regulate Ctr1 function. In
particular, the absence of Ctr2 induced the accumulation of
copper in endosomal compartments, whereas the presence of
Ctr2 increased the biogenesis of a truncated form of Ctr1 (tCtr1)
that lacked the metal-binding ecto-domain. This truncated form
of Ctr1 was involved in the mobilization of copper from endo-
somal compartments, thereby decreasing intracellular accumu-
lation of copper.74 The mode of uptake, distribution and removal
of copper in mammalian cells is summarized in Fig. 1.
1.3. Copper deficiency and clinical manifestations
Copper ingested daily in the diet is estimated to be between 0.6
and 1.6 mg.24 Despite some reports of copper deficiency in
babies as a result of malnutrition and in geriatric and pediatric
cases due to various medical conditions,75 severe dietary copper
deficiency in humans is very rare.76 In some cases, acquired
copper deficiency resulted in myelopathy with patients presenting
with spastic gait and prominent sensory ataxia. This was associated
with excessive zinc ingestion, gastric surgery or malabsorp-
tion.77 In the case of excess zinc ingestion, zinc interferes with
copper absorption in the intestine via induction of MTs. MTs
preferentially bind copper which is subsequently lost when
enterocytes are shed.78
The most severe case of copper deficiency is due to Menkes
disease (MD), the genetically inherited X-linked recessive dis-
order that results from mutation of the ATP7A gene.79 This
disease presents in males within the first few months of life,
and in severe cases is fatal in early childhood. Reduced or loss
of function of the ATP7A protein is responsible for impaired
intestinal copper absorption leading to intestinal copper accu-
mulation and systemic copper deficiency. The consequential
reduced activity of critical copper-dependent enzymes leads to a
clinical presentation that can vary in severity, but commonly
includes abnormal neurodevelopment, seizures associated with
cerebral atrophy and demyelination, a range of connective
tissue and vascular abnormalities, fragile bones, an unusual
kinky hair structure (pili torti), hair and skin pigmentation
defects and failure to thrive (reviewed in ref. 79 and 80). The
neurological symptoms have been attributed to impaired
ATP7A-mediated copper transport across the blood–brain barrier
(BBB) leading to deficiencies of enzymes such as cytochrome c
oxidase, SOD1, BDH, PAM, lysyl oxidase and tyrosinase, some of
which require ATP7A for metallation in the TGN (reviewed in
ref. 81). Treatment with various copper complexes including
copper histidine has been met with variable clinical outcomes,
and depends heavily on early diagnosis and treatment.80 In
addition, the clinical phenotype of MD patients and the response
to copper-replacement therapy seems to be also determined by
the effect of the ATP7A mutation on the amount of protein
produced, the level of activity of the protein, its correct location
in the cell, and its ability to traffic in response to copper
(reviewed in ref. 51 and 80). To better understand the reasons
for the treatment failure, a clinical trial investigating the
correlation of specific molecular defects with response to
Fig. 1 Copper homeostasis in mammalian cells. After reduction to its Cu+
form, copper enters the cell via the copper importer Ctr1. Copper is then
passed on to the chaperones CCS, COX17 and ATOX1, which deliver
copper to cytosolic SOD1, COX in the mitochondria and to ATP7A/B at
the trans-Golgi network (TGN), respectively. Additionally, binding of copper
to MTs and GSH, two cellular antioxidants, helps prevent free copper
catalyzing the formation of reactive oxygen species. At the TGN, copper is
incorporated into copper-dependent enzymes such as ceruloplasmin,
which migrate through the secretory pathway. When intracellular copper
is elevated (m Cu), Ctr1 is internalized and is subsequently degraded,
whereas ATP7A and ATP7B traﬃc from the TGN to the plasma membrane
to facilitate copper excretion. Ctr2 can increase the generation of a
truncated form of Ctr1 (tCtr1), which transports endosomal copper to the
cytoplasm resulting in decreased intracellular copper accumulation.
ATOX1 = antioxidant protein, ATP7A/B = copper transporting ATPase A/B,
COX = cytochrome c oxidase, CCS = copper chaperone for SOD1, COX17 =
cytochrome c oxidase copper chaperone, Ctr1/2 = copper transporter 1/2,
Cu = copper, GSH = glutathione, MT = metallothioneins, SOD1 = Cu/Zn–
superoxide dismutase, tCtr1 = truncated Ctr1.
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copper replacement therapy is in progress (clinicaltrials.gov id#
NCT00001262).
Occipital horn syndrome is a milder disease also caused by
mutations in ATP7A, with primarily connective tissue defects
and moderate neurological symptoms.82,83 Causative muta-
tions are often splice site mutations that result in reduced
levels of normal ATP7A mRNA.80 The milder phenotype sug-
gests that suﬃcient residual ATP7A is produced that is func-
tional, but the prominent connective tissue defects indicate
that copper delivery to lysyl oxidase is severely disrupted.80
A third clinical phenotype, distinct fromMD but associated with
ATP7A missense mutations was recently described as a form of
distal hereditary motor neuropathy.84,85 The phenotype of this
ATP7A-related motor neuropathy includes a variable age of onset
that ranges from the first to the sixth decade of life, with no overt
abnormalities of copper metabolism, and typically distal muscle
weakness and atrophy of the lower extremities leading to hand and
foot deformities.80 The causative mutations lie outside of the
conserved ATP7A functional domains and cause abnormal ATP7A
traﬃcking, aﬀecting specifically motor neuron function.84–86
1.4. Hypercupremia and copper toxicity
Wilson disease (WD) is an autosomal recessive copper overload
disorder that manifests primarily in the liver and brain. Mutations
that inactivate ATP7B lead to impaired biliary copper excretion,87
and consequently cause hepatic copper overload, apoptotic cell
death, liver damage, and spillage of copper into the plasma and
CSF.88–91 Hence, copper also accumulates in extrahepatic tissues,
notably the brain, kidneys and cornea.79,92,93 Approximately 60% of
WD cases present with neurological symptoms and typically have a
later onset than those with the liver disease.94,95 Clinical variability is
also a feature of Wilson disease (WD) and genotype/phenotype
correlations are complicated by the fact that many WD patients
are compound heterozygotes.95,96 Defects in the copper transport
activity, localization and/or trafficking of ATP7B variants may explain
some of the biochemical features of the disease, but the clinical
severity ofWDmay also be affected by environmental factors such as
copper intake and allelic variants of modifying genes such as the
metallothioneins.51,95,96 The current treatments include the use of
chelators to eliminate excess copper from the body, or the admin-
istration of dietary zinc to prevent the absorption of copper from
enterocytes.78 Patients are usually treated with chelators as first-line
treatment. Copper binds to the chelator and is excreted in the urine.
D-Penicillamine (D-pen) is commonly used for the treatment of
Wilson disease, but its serious side effects prompted the develop-
ment and use of alternative chelators such as trientine hydrochloride
and tetrathiomolybdate (TM), which have milder adverse reactions.
Once copper levels are under control, zinc acetate is given to
maintain stable copper levels in the body.78,97
2. Elevated copper in cancer
The involvement of copper in cancer has been studied for several
decades and there have been numerous reports on copper levels
being aberrant in cancerous tissues of tumor-bearing mice and
in cancer patients.98–102 In 1975, Schwartz reviewed the role of
trace elements including copper, in the context of cancer, under-
lining their potential roles as carcinogens and as diagnostic/
prognostic markers.103 More recently, Gupte and Mumper (2009)
provided an updated review on copper dysregulation in can-
cer.104 High serum copper concentrations are associated with a
variety of cancers including lymphoma, reticulum cell sarcoma,
bronchogenic and laryngeal squamous cell carcinomas, cervical,
breast, stomach and lung cancers.103,104 Strikingly, elevated
serum copper correlated with the stage of the disease and its
progression in colorectal and breast cancers.101,105 In a clinical
study on patients with hematological malignancies, including
chronic lymphoid leukemia, non-Hodgkin’s lymphoma, multi-
ple myeloma and Hodgkin’s lymphoma, the level of serum
copper decreased during periods of remission, sometimes reach-
ing normal levels, then it rebounded to pre-therapy levels during
relapses.106 In patients with advanced breast, lung or colon
cancer, in those treated with various chemotherapeutics (e.g.
doxorubicin, etoposide or 5-fluorouracil) as single agents or in
combination, serum copper levels were clearly linked to drug
resistance.107 Non-responders had approximately 130–160%
more copper in their serum.107 The mechanism(s) that cause
copper concentrations to increase in the serum of cancer
patients is not known. In a mouse model of carcinoma, the
occurrence of elevated serum copper was found to be concomi-
tant with a decrease in copper within the liver.108 This suggests
that copper distribution around the body, which is mediated by
the liver, may be fundamentally altered by cancer. Collectively,
these observations led to the hypothesis that serum copper level
may provide a biomarker of cancer recurrence and may be
measured to monitor treatment efficacy. Interestingly, unlike
copper, the levels of zinc, iron and selenium are often lower in
the serum of cancer patients.99,101,102,105 In fact, the Cu/Zn,
Cu/Fe and Cu/Se ratios all appear to be better indicators of the
presence of cancer than Cu, Zn, Fe or Se levels alone.99
As described by Gupte and Mumper (2009), elevated copper
in malignant tissues has also been established in a range of
cancer types, including breast, ovarian, cervical, lung, stomach
and leukemia.104 Surprisingly, leukemic and breast cancer
cells can have up to four-fold and three-fold more copper,
respectively.99,109 We recently demonstrated that only a small
subset of patients with prostate cancer harbor elevated intratumoral
copper despite previous reports of a more general occurrence.104,110
While there are clear demonstrations of elevated copper in several
cancer types (e.g. leukemia, breast and colorectal cancers), larger
scale studies are needed to validate many other reports on other
cancer types.104 Despite numerous reports dating back to the 1970s
and 80’s demonstrating that certain malignant tissues harbor
elevated copper, there is still no information on whether cellular
transformation to malignancy can drive copper accumulation, or on
the mechanisms by which cells adapt to tolerate the ensuing
oxidative pressure.
Copper concentrations have also been reported to increase
in nails and/or hair of patients with acute lymphoblastic
leukemia,111 prostate,112 breast113 or cervical cancers.114 However,
in other studies looking at the same cancer types, copper levels
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are lower115,116 or do not change116 in nails and/or hair. The
variability of copper levels in nails and hair is likely due to
diﬀerent dietary habits and occupational activities and as such,
precludes utilization as a biomarker for cancer diagnosis.
Intriguingly, ocular deposition of copper is associated with
lung adenocarcinoma,117 multiple myeloma118 and chronic
lymphocytic leukemia.119 Ocular copper depositions occur in
patients with hypercupremia (see Section 1.4). As shown in the
patients with leukemia, cancerous cells can secrete elevated IgG and
consequently copper binds erroneously to IgG and accumulates in
eyes rather than being eliminated by the liver.119
Is the metal dyshomeostasis seen in cancer patients a cause
or a consequence of cancer? Copper is a redox active metal that
can enhance the production of ROS, which subsequently can
damage most biomolecules.93 Oxidative stress and chronic
inflammation are intrinsically linked to malignant transformation
of cells.120 Therefore, it has been proposed that elevated copper in
tissues or serum may be a risk factor for carcinogenesis.112,121,122
Nevertheless, no clear association between copper level and cancer
incidence has been found to corroborate this hypothesis. Exposure
of wild type mice to 20 mM copper (CuSO4) in drinking water for up
to 2 years did not increase the incidence of cancer, suggesting that
copper is not carcinogenic.123 However, this copper concentration
in drinking water is unlikely to increase systemic copper levels in
mice, as they are proficient at eliminating surplus copper.124,125
Controlled studies that actually measure serum copper levels
achieved through supplementation are required to properly
ascertain whether copper can be carcinogenic.
3. Copper importance in cancer
development and progression
Copper is a key component of many cellular functions and
increasing evidence places copper as a central modulator of
cellular signaling (reviewed in ref. 126). Not surprisingly, copper
is involved in cancer development and progression and can
facilitate cancer growth, angiogenesis and metastasis.
3.1. Cancer growth and copper
Studies investigating the influence of copper on the growth of
cancers in mice have yielded discordant results. Over a century
ago, it was demonstrated that copper (0.75 mg) administered
daily as a colloidal solution over 10 days is able to retard cancer
growth in a mouse model of carcinoma.127 Additionally, cupric
acetate (2 mg per kg per week) administered by subcutaneous
injection for 26 weeks significantly reduced the initiation of
liver carcinogenesis caused by chemical (dimethylnitrosamine)
induction in rats.128 These findings contrast starkly with a more
recent study, where copper (CuSO4) administered daily by oral gavage
(42.6 mg kg1 for 14 weeks) increased cancer growth in a rat model
of chemically induced (7,12-dimethylbenz[a]anthraces [DMBA])
mammary tumourigenesis.129 Likewise, adding 20 mM copper
(CuSO4) to the drinking water of mice genetically engineered to
develop pancreatic islet cell carcinoma (RIP1-Tag2 model),
accelerated cancer growth.123 Mice bearing BRAFV600E-driven
lung cancer also had accelerated cancer growth when supplied
drinking water supplemented with high levels of copper
(125 mM CuSO4).
130 As previously mentioned, elevated copper
(20 mM CuSO4) in drinking water did not increase the incidence
of cancer in wild type mice.123 Unfortunately, in all of these
studies the level of serum copper achieved was not measured,
neither was the eﬀect of copper supplementation on the uptake
of other metals considered. The quantity and formulation of
copper given to the mice, the cancer type investigated, and
whether copper supplementation preceded or succeeded cancer
initiation, might all be responsible for the discordant results.
Intriguingly, one group demonstrated that a low copper diet
increased cancer incidence and cancer burden in a transgenic
mouse model of spontaneous multiple intestinal neoplasia.131
One of the first physiological signs of severe copper deficiency
is bone marrow suppression and anemia.132,133 Therefore,
copper deficiency likely aﬀects the immune system, which plays
a central role in preventing cancer development. Similarly, cell-
mediated immunity against leukemic cells is impaired in mice
severely copper deficient,134 outlining another way copper can
aﬀect immunological clearance of malignant cells.
3.2. Angiogenesis and copper
Angiogenesis involves the migration, proliferation and diﬀerentia-
tion of endothelial cells to form new blood vessels. Angiogenesis is
controlled by angiogenic stimulating factors (e.g., angiogenin,
vascular endothelial growth factor [VEGF], basic fibroblast growth
factor [bFGF] and transforming growth factor b [TGFb]) and
cytokines (interleukin [IL]-1, 6 and 8) as well as through inhibitors
(e.g., angiostatin and endostatin) (reviewed in ref. 135 and 136). The
inability of cancers to grow larger than 1–2 millimeters in diameter
without angiogenesis, illustrates the importance of new blood
vessel formation in cancer progression, and accordingly, this
knowledge has led to the development of anti-angiogenic agents
for cancer therapy.137 The pro-angiogenic properties of copper was
first reported by McAuslan and Reilly (1979), who established that
copper salts, and copper extracted from tumors, both induced
migration of endothelial cells, an early step of angiogenesis.138,139
Strikingly, adding copper to the cornea of rabbits induced the
formation of new blood vessels140 and copper enhanced prolifera-
tion of human endothelial cells in the absence of serum and
growth factors.141 In contrast, copper had little impact on the
proliferation of both human fibroblasts and arterial smoothmuscle
cells.141 Furthermore, zinc or iron used at the same concentration
as copper decreased endothelial cell growth. These findings
unquestionably place copper as a potent inducer of the angiogenic
process.141
The molecular pathways that copper influences to induce a
pro-angiogenic response are varied. Copper can directly bind to
the angiogenic growth factor angiogenin and enhance its aﬃnity
for endothelial cells.142,143 Copper can also regulate the secretion
of angiogenic molecules, such as FGF and IL-1a.144,145 FGF-1 and
IL-1a are secreted only following copper-dependent formation of
a multi-protein complex.144,145 FGF-1 and IL-1a lack the signal
sequence for endoplasmic reticulum (ER)-Golgi mediated secre-
tion. Finally, copper is required for the expression of certain
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angiogenic factors. For instance, copper deficiency inhibits
the activity of the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB), which in turn decreases expression
of five pro-angiogenic mediators (VEGF, bFGF, IL-1a, IL-6 and
IL-8).146 Copper is also transported into the nucleus of cells by
the copper chaperone CCS, where it can regulate formation of
the hypoxia-inducible factor 1 (HIF-1) transcriptional complex
and thus regulate expression of VEGF, a potent angiogenic
factor.147,148 Likewise, ATOX1 can enter the nucleus of cells to
serve as a copper-dependent transcription factor149 and has been
shown to regulate platelet-derived growth factor (PDGF) signaling
and thus potentially malignant angiogenesis and vascular remo-
deling.150 Indeed, compelling evidence that copper is essential for
malignant angiogenesis comes from studies demonstrating that
copper chelation can impede cancer growth and progression
in vivo. This is discussed in Section 4.1.
3.3. Metastasis and copper
An obvious role for copper in metastasis is through regulating
angiogenesis, which is a fundamental process required for
metastatic potential. However, there is growing evidence that
copper also directly influences the ability of cancerous cells to
invade and metastasize.
Copper is essential for the activities of both lysyl oxidase
(LOX) and lysyl oxidase-like (LOXL) proteins, which are involved
in the crosslinking of collagen and elastin.3,4 Cancer cells
secrete LOX to remodel the extracellular matrix and by doing
so create a pre-metastatic niche where bone marrow-derived
cells are recruited prior to the development of metastases.151
The expression of LOXL2 is elevated in highly invasive cancers
(reviewed in ref. 152) and correlates with metastasis and poor
survival in estrogen receptor negative breast cancer patients.153
One proposed mechanism is that LOXL2 induces epithelial–
mesenchymal transition (EMT). EMT is an early step of cancer
cell invasion and is partly activated through down-regulation of
E-cadherin; a protein involved in tight junctions. LOXL2 inter-
acts with a repressor of E-cadherin called Snail, increasing the
stability of Snail to inhibit E-cadherin expression.154 Based on
these studies, blocking the activity of LOX and LOXL is an
attractive therapeutic approach to inhibit cancer metastases.
More recently, a copper-dependent redox protein called
Memo has also been shown to play a role in breast cancer cell
migration and metastasis, by increasing intracellular ROS
levels.155 More aggressive breast cancers express elevated levels
of Memo and Memo appears to be a reliable prognostic marker
of early distant metastases.155
4. Copper as a target for cancer
therapy
Elevated copper in malignant tissues coupled with the realiza-
tion that copper promotes angiogenesis, cancer growth and
metastasis, has led to the development of copper-coordination
compounds for anticancer therapies. Copper chelating to
decrease copper bioavailability has been and continues to be
investigated in clinical studies as a strategy to inhibit angiogenesis
for multiple cancer types (e.g. clinicaltrials.gov id# NCT00003751,
NCT00176800, NCT01837329, NCT02068079, NCT00405574). By
definition, copper chelators remove copper ions from the body,
and as such their therapeutic premise involves impeding the
copper-dependent malignant processes to limit cancer progression.
Copper-ionophores that raise intracellular copper levels, and other
copper complexes that exert direct cytotoxic eﬀects, are also the
focus of intense research and clinical trials (e.g. clinicaltrials.gov id#
NCT00742911, NCT01907165, NCT01777919). These compounds
are mechanistically distinct from copper chelators and rather than
removing copper instead elevate and/or redistribute intracellular
copper levels. How these biological properties deliver anticancer
activity is discussed below. Herein, we give an overview of the
latest advances in the field with a particular focus on how
copper coordination compounds alter cancer cell biology and
their potential use in the clinic. The better-known anticancer
activities of several classes of copper coordination compounds
are summarized in Fig. 2. For structural information on the
diﬀerent copper coordination compounds the reader is referred
to the following excellent reviews.156–162
4.1. Impeding cancer growth with copper chelators
Historically, copper chelating agents were developed to treatWilson
disease, an autosomal recessive genetic disorder that causes copper
accumulation primarily in the liver (see Section 1.4).97 The same
agents were later investigated for their capacity to control angio-
genesis and thus by inference, to impair cancer growth and
metastasis. The depletion of bioavailable copper with D-pen, trien-
tine, or TM, delayed the spread of cancers by inhibiting vascular-
ization of lesions in various animal models including, among
others, a rat gliosarcoma,163 a rabbit brain tumor model of VX2
carcinomas,164 a mouse model of hepatocellular carcinoma165 and
of head and neck squamous cell carcinoma.166 One identified anti-
metastatic activity of copper chelators is that they prevent the
recruitment of bone marrow-derived endothelial progenitor cells
(EPC), which are essential for the angiogenic switch that occurs
prior to the development of macroscopic metastases.167,168 Consis-
tently, copper depletion in a breast cancer mouse model (HER2/
neu) inhibited the progression of microscopic to macroscopic
tumors.146,169 Furthermore, administration of TM (1 mg) daily for
3 weeks to a transgenicmousemodel of pancreatic neuroendocrine
tumor (RIP1-Tag2 mice) also delayed the angiogenic switch
observed in premalignant lesions and reduced late-stage tumor
growth.123 Likewise, in a mouse model of mesothelioma tumor,
lowering bioavailable copper by using D-pen, TM or trientine,
also reduced tumor growth and impeded tumor blood vessel
formation.170 TM-induced copper deficiency is also thought to
inhibit angiogenesis through activation of the transcription factor
NF-kB, in turn decreasing secretion of angiogenic factors (VEGF,
FGF2) and interleukins (IL-1a, IL-6, IL-8), as demonstrated in vivo
using a human inflammatory breast carcinoma cell line (SUM 149
xenograft).171 Similarly, trientine has been shown to reduce IL-8
production in hepatocellular carcinoma.172 Inhibition of lysyl oxidase
activity by D-pen, impaired collagen crosslinking and reduced
VEGF expression, resulting in delayed progression of glioblastoma
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multiforme in vivo.173 However, it is important to note that these
studies collectively highlighted the cytostatic rather than cytotoxic
properties possessed by copper chelators on both tumor and
endothelial cells.123,146,169,170
Certain copper chelators have also been reported to possess
direct anticancer activities. In murine models of cancer (fibro-
sarcoma and hepatocellular carcinoma), trientine induced
apoptosis through the generation of ROS, attributed to the
interaction of the drug with redox active copper.165,174
As previously mentioned, copper not only regulates enzymes
critical for angiogenesis, but also modulates the activity of cell
metabolic and proliferative enzymes such as cytochrome c
oxidase and MEK1/2 kinase. Therefore, is not surprising that
lowering intracellular copper, and thus lowering cuproenzy-
matic activity, could alter tumor biology. In a mouse model of
pancreatic islet cell carcinoma, the anti-proliferative eﬀect of
TM observed was believed to be mediated by cytochrome c
oxidase inhibition, and thus by decreasing ATP production.123
Lowering copper levels with TM impacts on MEK1/2 kinase
activity and BRAF-driven tumorigenesis thus decreases tumor
(xenograft) growth of BRAFV600E transformed cells.130 Consistent
with a cytostatic eﬀect, tumors rapidly develop after the copper
chelation treatment ceases.130
A least a dozen clinical trials investigating the anticancer
activities of D-pen and TM have been conducted. These copper
coordination complexes have been prescribed to Wilson disease
patients for decades and thus their toxicity profiles are quite well
known (see Section 1.4). In the context of treating cancer
patients, TM was found to be well tolerated, however, anemia
and neutropenia have been reported but are reversible with
cessation of the drug.132,175,176 In contrast, D-pen produced
severe adverse eﬀects including hematologic and renal toxicities
in some studies.133 In a phase II clinical trial, D-pen did not
improve survival of patients with brain tumor, specifically glio-
blastoma multiforme, despite producing a marked reduction in
the level of bioavailable copper in the serum of patients.177 The
lack of clinical activity was somewhat surprising given the very
encouraging preclinical results obtained in a rabbit model of
brain tumor.164 These authors suggest that preclinical success
was due to pretreatment with D-pen before tumor cell implanta-
tion, and thus lowering serum copper levels may be more
eﬀective before the onset of the angiogenic switch.163,164,177 This
is consistent with other studies demonstrating that chelating
copper perturbs the angiogenic switch and may be ineﬀective on
late stage vascularized tumors.123,170 Indeed most studies indi-
cate chelating copper is best used as a strategy to inhibit the
progression of micrometastases to macroscopic nodules. This
suggestion has been tested in a recent clinical trial on breast
cancer patients with high risk of relapse and no sign of disease at
enrollment.175 The investigators of this trial concluded that TM-
induced copper deficiency decreased circulating EPCs and might
prevent recurrence by promoting tumor dormancy.175 However,
a larger cohort of breast cancer patients is needed to validate
these findings. Consistently, another trial demonstrated that
TM stabilizes tumors in patients with various metastatic
cancers, including breast, colon, lung and prostate cancers and
Fig. 2 Copper coordination compounds targeting cancer cells. Chelators sequester copper making it unavailable for tumor growth, angiogenesis and
metastasis. In contrast, ionophores facilitate copper entry into cells, often providing bioavailable intracellular copper. Amongst the diﬀerent copper
coordination compounds there have been a myriad of anticancer activities ascribed, including but not limited to, proteasome inhibition, ROS production,
DNA interactions, topoisomerase inhibition, paraptosis and apoptosis. COX = cytochrome c oxidase, Ctr1 = copper transporter 1, FGF2 = fibroblast
growth factor 2, IL-1a, -6, -8 = interleukin-1a, -6, -8, LOX = lysyl oxidase, MEK1/2 = mitogen-activated protein kinase/ERK (extracellular-signal-
regulated-kinase) kinase 1/2, NF-kB = nuclear factor-kappa B, UPR = unfolded protein response, VEGF = vascular endothelial growth factor, XIAP =
X-linked inhibitor of apoptosis.
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melanoma.132 Furthermore, the investigators of this trial provided
valuable parameters on TM treatment, including the dose
therapeutic window and the level of copper deficiency required
in patients’ serum for eﬃcacy. Ceruloplasmin activity served as
a surrogate measure of serum copper status and was used to
adjust TM dose during treatment.132 TM is seemingly not toxic
providing ceruloplasmin levels are reduced to no lower than
15–20%, which represents a mild stage of copper deficiency.
These investigators also reported that there were no combined
drug toxicities when TM was used in combination with radio-
therapy, trastuzumab or IFN-a, opening new avenues for combi-
nation therapies.132 More recent phase II clinical trials showed
that TM used as a single agent did not provide significant
survival benefit for patients with kidney cancer,176 hormone
refractory prostate cancer178 or malignant mesothelioma,179 but
might be more effective if used in combination with standard
therapies or other antiangiogenic therapies. TM analogs (e.g.
ATN-224) are currently being trialed in patients with prostate
cancer (clinicaltrials.gov id# NCT00405574).
There is compelling evidence that copper chelation alone is
insuﬃcient to kill malignant cells, necessitating its use in
combination with other agents to be an eﬀective therapeutic
option.180–182 Supporting this approach, TM and doxorubicin
together are more potent at delaying SUM149 breast carcinoma
xenograft growth and at inducing apoptosis, than either treat-
ment administered alone.182 Similarly, treating mice bearing
head and neck squamous cell carcinoma180 or lung cancer181
with TM in combination with radiation therapy improves
tumor growth inhibition. The use of standard antiangiogenic
therapies in combination with radiation therapy has also
shown promise in clinical trials (reviewed in ref. 183). However,
current standard antiangiogenic drugs often target only one
component of the angiogenic process (e.g. VEGF) leading to the
emergence of drug resistance. TM targets multiple angiogenic
factors, making this drug potentially more effective in long-
term treatment regimes. Beyond its mode in inhibiting angio-
genesis, TM also impairs mitochondrial energy metabolism
and decreases ATP levels as explained above.123 This is accom-
panied by increased glycolysis, presumably in an attempt to
compensate for the lack of energy production quashed by TM.
Combining TM with an inhibitor of glycolysis and thereby
blocking the two major ATP production pathways, provided
greater tumor growth inhibition thanwith TM alone.123 Additionally,
copper chelators in combinationwith BRAF inhibitors have potential
for the treatment of cancers harboring the BRAFV600E mutation,
given that copper is required for oncogenic BRAF signaling and
BRAF-driven tumourigenesis.130 Nevertheless, clinical trials will
be necessary to validate these promising preclinical findings
with combination therapies involving TM (or analogs thereof).
4.2. Targeting cancer with copper ionophores
Another therapeutic approach involves the use of copper-specific
ionophores. Distinct from the sequestering nature of a chelator,
an ionophore transports specific metal(s) into cells, often allowing
them to become bioavailable.157 Three structurally diﬀerent
compounds, Cu2+(gtsm)[bis(thiosemicarbazone) analog], clioquinol
(hydroxyquinoline analog) and disulfiram (dithiocarbamate
analog), all commonly release coordinated copper under the
reductive intracellular environment,184 and display anticancer
activity in vitro and in mouse models.184–193 The therapeutic
efficacy of clioquinol and disulfiram has been studied in
numerous clinical trials.185,194–197 While these compounds
transport copper into mammalian cells and display selective
toxicity towards cancer cells, the basis for this selectivity has
not been elucidated. Elevated copper in malignant cells may
predispose them to ionophoric-copper toxicity, but this has not
been confirmed. Ionophoric-copper can also be toxic due to
redox activity (ROS production) and by displacing other metals
from binding sites within critical proteins.
Both clioquinol and disulfiram reduced tumor growth in
preclinical models of breast and prostate cancer.192,193,198
Amongst the myriad of biological activities ascribed to these
compounds, clioquinol, disulfiram and Cu2+(gtsm) inhibit
proteasomal chymotrypsin-like activity,186,199,200 a feature we
established as being common to copper-ionophores that increase
intracellular bioavailable copper.184 The anticancer activities of
these three ionophores are completely dependent on copper as
the ligands alone (metal-free compounds) display negligible
activity.184 We have also previously shown that clioquinol induces
nuclear translocation of the X-linked inhibitor of apoptosis protein
(XIAP), a modulator of caspase activity, thereby allowing caspase-
dependent apoptosis of hyperplastic and carcinoma prostate cell
lines.186 In this study, the anticancer activity of clioquinol increased
concomitantly with the level of copper in the extracellular medium
and could be abrogated by removing bioavailable copper through
copper chelator (TM).186 Accordingly, disulfiram is only active
against prostate cancer xenografts when co-administered with
copper.192 The treatment of human breast cancers both in vitro
and in vivowith disulfiram and copper, decreased PTEN expression
and activated AKT signaling, providing a strong rational to combine
copper ionophore treatment with PI3K-AKT inhibitors in future
clinical trials.193 The disulfiram–copper complex has also been
shown to inhibit aldehyde dehydrogenase (ALDH), displaying
cytotoxicity toward ALDH expressing cancer stem cells (CSCs).201
ALDH has emerged as a target for anticancer therapy and
inhibiting ALDH has the potential to sensitize CSCs to standard
chemotherapeutic drugs.201
The first clinical evidence that disulfiram possesses anticancer
activity goes back to the late 1970s. Ditiocarb, a metabolite of
disulfiram which forms the copper complex in the body,194 cured a
patient with bone metastases from breast cancer.195 More recently,
a patient with liver metastases from ocular melanoma was success-
fully treated with disulfiram.185 Disulfiram used in combination
with cisplatin and vinorelbine increased survival in patients newly
diagnosed with non-small cell lung cancer and appeared to be well
tolerated when administered at a dose of 40 mg three times
daily.202 In contrast, disulfiram did not show clinical benefit in
patients with non-metastatic recurrent prostate cancer.197 Addition-
ally, disulfiram was found to be extremely toxic in these patients
and the authors advised that further development of disulfiram
should not be continued for patients with non-metastatic prostate
cancer after local therapy.197 However, it should be noted that
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patients received either 250 mg or 500 mg of disulfiram daily,
doses well above that administered in previous trials. Other
clinical trials in cancer patients evaluating disulfiram as a single
agent or in combination with other drugs are near completion
and results should be available soon to the public (clinicaltrials.
gov id# NCT00742911, NCT01907165, NCT01777919).
Despite promising preclinical data, clioquinol failed to elicit
pharmacodynamic or clinical activity in a recent clinical trial in
patients with advanced hematologic malignancies.196 The
investigators in this trial suggested that insuﬃcient concentrations
of clioquinol reached the general circulation,196 consistent with
a previous report demonstrating that most ingested clioquinol
transits through the gut.203 Elesclomol (formely STA-4783) is
another promising copper ionophore with a unique mechanism
of action.204 This compound forms a complex with Cu2+ that is
subsequently transported to the mitochondria, where Cu2+ is
reduced to Cu+, which can result in oxidative stress and subsequent
cell death.205 Following intra-mitochondrial dissociation from
copper, elesclomol can diﬀuse out of the cell and transports
more extracellular copper into the cell, amplifying the generation
of ROS within the mitochondria. Initially, elesclomol enhanced
paclitaxel therapeutic eﬃcacy in patients with refractory solid
tumors and in stage IV metastatic melanoma.206,207 Unfortu-
nately, subsequent results published from a phase III clinical
trial in patients with advanced melanoma, demonstrated that
combining elesclomol with paclitaxel did not significantly
improve progression-free survival.208 The lack of encouraging results
in this particular trial might be explained by inadequate selection
criteria for enrolling patients, since higher lactate dehydrogenase
levels were systematically found in non-responders.208
Many other classes of copper ionophores have been synthe-
sized and tested for their potential as anticancer drugs, includ-
ing copper bis(thiosemicarbazone) complexes.184,189,190,209–211
The first bis(thiosemicarbazone) analogs tested demonstrated
potent therapeutic effects in preclinical studies and their
activity was dependent on coordinated copper or zinc.184,190,209
However, these compounds displayed severe hepatic toxicity in
mouse models.212 Considerable effort is now underway to synthe-
size and characterize new copper bis(thiosemicarbazone) analogs
with similar biological activity and reduced toxicity. Interestingly,
some of these copper bis(thiosemicarbazone) analogs retain their
coordinated metal under the reductive intracellular environment
[e.g. Cu2+(atsm)].184,213 These copper coordination complexes are
discussed in the next section, as we focus here on ionophores that
increase intracellular bioavailable copper. Analogous to elesclomol,
some copper bis(thiosemicarbazone) analogs, such as Cu2+(gtsm),
dissociate their coordinated copper intracellularly and the
ligand (H2gtsm) can recycle out and back into cells with more
re-coordinated copper.184 This property explains how increasing
extracellular copper significantly enhances Cu2+(gtsm) anticancer
activity184 and may be applicable for the clinical setting where many
patients with cancer have elevated serum copper levels. Some copper
bis(thiosemicarbazone) complexes also inhibit mitochondrial
respiration by specifically targeting Complex I in the mitochondrial
electron transport chain.214 This biological activity seems to be
independent of increasing intracellular bioavailable copper and
rather is due to the binding of the compound to the site of
ubiquinone binding in Complex I.214 Recently, we have shown
that Cu2+(gtsm) selectively destroys cancerous prostate cells
in vitro and significantly reduced prostate cancer burden in
an orthotopic mouse model.184 However, like most other copper
bis(thiosemicarbazone) analogs, Cu2+(gtsm) produced acute side
effects in mice, specifically renal toxicity.
As mentioned above, Cu2+(gtsm), clioquinol and disulfiram
inhibit proteasomal chymotrypsin-like activity,186,199,200 a feature
common to copper-ionophores that increase intracellular bio-
available copper.184 Several conventional proteasome inhibitors,
such as Bortezomib, are approved for the treatment of multiple
myeloma and others are currently in clinical trials (reviewed in
ref. 215). However, due to their limited activity in solid tumors,
these agents are currently restricted to hematological malignancies.
Copper ionophores may oﬀer both enhanced selectivity towards
cancer cells and activity against a broader range of cancer types.
However, most often encouraging preclinical results are coupled
to subsequent disappointing results obtained in patient clinical
trials. This likely reflects the need for a better understanding of
both the mechanism-of-action and the pharmacokinetics of
these compounds before commencing eﬃcacy studies in
patients. Furthermore, experience from the elesclomol trial208
highlights the importance of selecting patients that would be
more likely to benefit from treatments with copper-ionophores.
However, there are currently no reliable biomarkers to accurately
predict or assess treatment eﬃcacy. One possibility is to use
positron emission tomography (PET) radiopharmaceuticals to
allow for noninvasive visualization of cellular functions, which
may prove particularly useful for the development and validation
of biomarkers, as well as for the assessment of tumor response
to copper-based therapies.216–219
4.3. Targeting cancer with other copper complexes
The success of platinum-based therapeutics, such as cisplatin
and carboplatin, as treatments for various cancer types has
prompted the development of further metal coordination com-
pounds to target DNA, with the aim of reducing side eﬀects
and overcoming chemoresistance. To this end, many classes
of copper coordination compounds have been designed and
characterized in vitro, but only a few have been evaluated in
preclinical animal models.160,161 Platinum-based therapeutics
exert their action by binding to nitrogens on adjacent DNA
bases, which interferes with the binding of essential proteins
for transcription. Recently, a group of researchers have developed
new complexes containing two copper centers, which target two
neighboring phosphates on the DNA backbone that provide active
sites for metalloenzymes such as nucleases.220 These copper con-
taining compounds inhibit DNA synthesis and induce the cell
death of multiple cancer cell types with much higher potency than
cisplatin. These results are promising and we look forward to the
in vivo studies.
Endeavoring to overcome the chemoresistance observed
with cisplatin, Pivetta and colleagues (2015) evaluated the eﬀect
of three copper coordination compounds containing either one
or two 1,10-phenathroline molecules used in binary combination
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with cisplatin.221 A clear synergistic eﬀect was observed with the
combination therapy, even against cells identified as being resistant
to cisplatin. Encouraging also was the fact that when administered
in combination each drug could be used at a reduced dose
in comparison to when utilized as single agents. Lowering
administered drug concentrations reduces side eﬀects. While
the mechanism of action was not established, these authors
suggested that the formation of mixed copper-platinum complexes
may be responsible for the synergistic antiproliferative eﬀects seen
in both cisplatin-sensitive and -resistant cell lines.221
As mentioned above, many copper bis(thiosemicarbazone)
analogs have demonstrated encouraging anticancer properties.
Some of these compounds retain their coordinated metal under
the reductive intracellular environment [e.g. Cu2+(atsm)].184,213
Palanimuthu and colleagues (2013) selected two analogs,
Cu(gtsc) and Cu(gtscHCl), for their strong cytotoxic eﬀect that
was similar to the potency of the mainstream chemotherapeutic
drug Adriamycin.210 These compounds were shown to inhibit DNA
synthesis and to induce apoptotic cell death in various human
cancer cell lines.210 In addition, Cu(gtscHCl) was able to cleave DNA
and inhibit topoisomerase II.210 In mice, Cu(gtsc) significantly
delayed the growth of colorectal carcinoma xenografts.210 Another
copper bis(thiosemicarbazone) compound, Cu(atsm), displays anti-
cancer activity and is selectively accumulated in hypoxic cells.184,213
This interesting property led to the radiolabeled synthesis of
64Cu(atsm), which can be used both for targeted radionuclide
therapy and for diagnosis.216,218 The principle of radionuclide
therapy is to deliver cytotoxic radiation specifically to cancer cells
and by doing so limit inadvertent toxicity to normal tissues/organs.
As such, 64Cu(atsm) showed significant anticancer activity in an
explant model of human colon cancer in hamsters.222 Since 64Cu
has decay characteristics that allow PET imaging, 64Cu(atsm) also
has diagnostic applications, allowing the selection of patients that
are likely to benefit from 64Cu(atsm) therapy. In addition, to
increase selectivity towards cancer cells while reducing toxicity to
normal cells, copper bis(thiosemicarbazone) compounds have been
conjugated to specific peptides for targeting delivery. This includes
bombesin, which has cell surface receptors highly expressed in
cancers.223
In recent years, heterometallic complexes containing copper
and tin (Sn) have gained much attention. These compounds com-
bine the potential of both copper and tin coordination compounds
as anticancer agents.224,225 One such heterometallic complex,
CuSn2(Trp), induces apoptotic cells death in various cancer cell lines
in vitro.224,225 In rat, the maximum tolerated dose for CuSn2(Trp) is 8
times higher than for cisplatin.225 At equivalent doses, CuSn2(Trp)
shows less toxic side eﬀects than cisplatin, with no signs of kidney,
liver or brain toxicity and thus CuSn2(Trp) is being investigated as a
promising alternative to cisplatin.225
5. Copper transporters and resistance
to platinum-based cancer treatments
The primary reason standard chemotherapeutic treatments
fail is due to cancer cells acquiring resistance. A number of
molecular mechanisms exist, but there is amassing evidence
that copper transporters play a central role in drug resistance,
in particular towards platinum-based therapeutics. A significant
overlap exists between cellular copper homeostatic mechanisms
and those involved in the uptake and detoxification of platinum-
based compounds. Changes in the expression, activity, or the
cellular localization of the copper transporters have been linked
to cancer cells, in particular ovarian and non-small cell lung
cancers, developing resistance to platinum drugs such as cisplatin.
A better understanding of the interplay between the copper trans-
porters and acquired chemoresistance is essential for the identifi-
cation of new biomarkers of resistance and for the prediction of
therapeutic eﬃcacy (reviewed in ref. 226 and 227).
5.1. Copper transporters in acquired resistance against
chemotherapeutics
The high-aﬃnity copper transporter Ctr1 can mediate the
cellular uptake of platinum-based therapeutics, including
cisplatin.228 Many cell types when lacking Ctr1 expression
accumulate less platinum-based drugs and therefore are more
resistant to these drugs.228–230 Additionally, the organic cation
transporter 2 (OCT2) can mediate the cellular uptake of cisplatin
and tissues where OCT2 is expressed are sites of severe side
effects in patients, such as oto- (ear) and nephrotoxicity.231,232 In
kidney cells where OCT2 expression is high Ctr1 is not required
for the cellular uptake of cisplatin.232,233 In human ovarian
cancers, high levels of Ctr1mRNA are associated with sensitivity
to platinum-based therapy and correlates with increased disease-
free survival following treatment.234 Similarly, in patients with
non-small cell lung cancers, tumor response is reduced in
patients with no detectable Ctr1 expression in comparison to
patients with Ctr1 at any level.235 However, for both ovarian and
non-small cell lung cancers, the level of cellular uptake of
platinum-based drug does not usually correlate well with the
level of Ctr1 expression.235,236 One explanation is that cisplatin
treatment may rapidly down-regulate the activity of Ctr1 in
certain cells types, as previously described in human ovarian
carcinoma cells.236 This could mimic how copper regulates Ctr1
expression and thus its own uptake in certain cells, such as
kidney epithelial cells.237 In other cell types such as hepatocytes
copper does not regulate Ctr1 expression.232,237 Therefore, for
certain cancer types internalization of Ctr1 from the plasma
membrane by macropinocytosis and its subsequent proteasomal
degradation may have important clinical implications for the
success of platinum-based therapies.236,237
The copper transporter Ctr2 has also been implicated in
cancer cells acquiring resistance to platinum-based therapeutics
(reviewed in ref. 227). In contrast to the correlation with Ctr1,
loss of Ctr2 expression increased the accumulation of either
cisplatin or carboplatin in human ovarian cancer cell lines and
conferred sensitivity to these drugs.34 Moreover, low levels of
Ctr2 expression increased the success rate of platinum treatment
in patients with ovarian cancer.238,239 One way that Ctr2 may
exert its eﬀect on drug sensitivity is through modulating the
activity of Ctr1.74 Ctr2 can increase the generation of a trun-
cated form of Ctr1 that lacks the copper and cisplatin-binding
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ecto-domain,74 thus the more Ctr2 expressed the less cisplatin
will enter the cell. Conceivably, Ctr2 expression in conjunction
with Ctr1 should be examined, since patients with a Ctr2/Ctr1
ratio greater than 1 have a poorer prognosis.239 Adding another
level of complexity, Eljack and colleagues recently proposed
a non-protein mediated solubility-diﬀusion mechanism for
cisplatin transfer across the plasmamembrane.240 Using unilamellar
lipid vesicle preparations, cisplatin when holding a neutral charge
(e.g. in high chloride concentration) could passively traverse the lipid
bilayer. Note that high chloride ion concentrations present in blood
may promote the persistence of the electroneutral complex. These
authors did not rule out active pathways for cisplatin internaliza-
tion240 and future studies are required to ascertain the contributions
of Ctr1, Ctr2, OCT2, and passive diﬀusion in the cellular uptake of
cisplatin (and other platinum-based drugs); in a cell specific manner
as expression of each transporter varies considerably between
cell types.
The copper eﬄux transporters, ATP7A and ATP7B, are also
reported to be involved in certain cancer types acquiring
chemoresistance. ATP7B expression is associated with poor
overall survival in oral squamous cell carcinoma patients241 and
could predict recurrence in patients where ovarian carcinoma
was treated with platinum-based therapy.242 In vitro, ATP7B has
been shown to modulate cisplatin resistance in human epider-
moid carcinoma and prostate cancer cell lines.243 A functional
interaction between cisplatin and up-regulated ATP7B results in
the active transport of cisplatin into exocytic vesicles, however,
there have also been suggestions that ATP7B can mediate
active eﬄux directly across the membrane.244,245 Platinum-
based drugs can directly bind to the six N-terminal metal-
binding domains of ATP7B.246 Analogous to ATP7B, ATP7A
can mediate resistance to platinum-based drugs in ovarian,
colon and non-small cell lung cancer cells.247–250 In patients,
ATP7A expression correlates with a poorer survival in non-
small cell lung cancers.248 In addition to platinum-based
therapeutics, ATP7A confers cellular resistance to SN-38, taxol,
mitoxantron, doxorubicin, etoposide and vincristin in an
ex vivo assay using human patient colon cancer samples.249
ATP7A induces the compartmentalization of cisplatin, doxor-
ubicin and SN-38 in the Golgi apparatus249,250 preventing the
drugs from reaching their nuclear target, DNA. ATP7A also
enhances the efflux rates of doxorubicin and SN-38 by a
mechanism dependent on the vesicle transport system.249
Supporting the notion that cisplatin efflux occurs via vesicle
trafficking, fluorescein-labeled cisplatin is sequestered into
lysosomes, the Golgi apparatus and vesicles of the secretory
pathway.251
5.2. Overcoming acquired resistance with copper modulating
agents
The strong link described above between copper transporters
and resistance to chemotherapeutic drugs provides a rationale
for moderating this association during cancer treatment. One
possibility might be to prevent Ctr1 degradation, and thus
increase the uptake of platinum-based drugs into applicable cancer
cells to enhance their eﬃcacy. Ctr1 expression is regulated by
copper availability at both the transcriptional and post-
translational levels. When the bioavailable (exchangeable) pool
of copper is low, the transcription factor Sp1 binds to the Ctr1
promotor and up-regulates Ctr1 expression.252 When copper is
high, Ctr1 is internalized and degraded in certain cell types.236
Based on these observations, a clinical trial was performed on
5 patients with platinum-resistant high-grade epithelial ovarian
cancers using a combination of trientine, a copper lowering
agent (chelator), and carboplatin, a second-generation platinum
drug.253 One patient had partial remission, three had stable
disease and one had progressive disease after two cycles of
therapy.253 The greater response to therapy was observed in
patients where low serum copper levels were achieved, as
measured by ceruloplasmin. An exploratory phase I clinical trial
was then performed on a larger cohort of patients (n = 55,
including 45 patients with tumors resistant to platinum-based
agents) with various advanced malignancies including head and
neck, non-small cell lung and epithelial ovarian cancers.254 The
combination of carboplatin and trientine was well tolerated and
had improved anticancer activity when compared to carboplatin
used alone, but again only in a subset of patients who achieved a
significant decrease in serum copper level.254 A separate study
using xenografts of human ovarian cancers in mice, provided
additional evidence that platinum-based drugs (cisplatin) and
copper chelation (D-pen) together decreased tumor growth more
eﬀectively than either treatment alone.255 Furthermore, D-pen
treatment was found to be more eﬀective on cisplatin resistant
cells, where it up-regulated Ctr1 expression by 20-fold in com-
parison to 2-fold in cisplatin sensitive cells.255 Therefore, it is
possible that patients with low Ctr1 expression associated with
cisplatin resistance might benefit more from the combination
therapy with a platinum-based therapeutic and a chelator.
Similarly, the copper chelator TM enhanced cisplatin treatment
eﬃcacy in a mouse model of cervical cancer, by increasing
cisplatin-DNA adduct levels and by impairing angiogenesis.234
However, Ctr1 expression and localization did not change
in cervical cancers treated with TM and cisplatin, indicating
diﬀerent mechanisms for Ctr1 regulation in cervical cancer.
Another proposed way to modulate Ctr1 expression is to increase
intracellular GSH levels.256 Sequestration of intracellular copper
by GSH has been suggested to lower the bioavailable copper
pool, in turn up-regulating Ctr1 expression and increasing
cisplatin sensitivity.256 A potential problem with this approach is
that GSH already exists in millimolar concentrations, far exceeding
the concentration of intracellular copper.39 However, it is important
to note that enhancing the toxicity of platinum-based therapeutics
in any manner, requires specificity towards cancer cells, as such
therapies are already extremely toxic systemically.
6. Concluding remarks
Preclinical and clinical studies have marshaled enough evidence
to merit the thorough investigation of copper coordination
compounds as anticancer therapies, both as single agents and
in combination with other treatments. Eﬀorts are now clearly
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underway to better categorize the diﬀerent types of copper
coordination compounds and to define the biological features
ideal for their anticancer activity. However, also essential is the
need to better understand the role copper plays in cancer
etiology and pathogenesis, and to delineate which cancer types
are appropriate for treatments that target or utilize copper. Also
required is the development of accurate biomarkers for both
personalize treatment strategies and for evaluating clinical
activity. Therefore, the future success of copper coordination
compounds in the clinic necessitates close collaborations between
biomedical scientists, chemists and clinicians.
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Heterogeneous Copper Concentrations in Cancerous
Human Prostate Tissues
Delphine Denoyer,1 Sharnel A.S. Clatworthy,1 Shashank Masaldan,1 Peter M. Meggyesy,1
and Michael A. Cater1,2*
1Centre for Cellular and Molecular Biology, School of Life and Environmental Sciences, Deakin University,
Burwood, Victoria, Australia
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BACKGROUND. Therapeutics that target copper for the treatment of prostate cancer are
being evaluated in human clinical trials. Elevated intracellular copper is considered to
sensitize prostate cancer cells to certain copper-coordination compounds, especially those
with ionophoric properties. While there is compelling in vitro evidence that prostate cancer
cells accumulate intracellular copper, a corresponding status for copper in patient tissues has
not been corroborated. We therefore established whether copper concentrations increase in
cancerous prostate tissues, and in sera, in patients throughout disease progression.
METHODS. Human prostate tissue samples were obtained from patient prostatectomies
(n¼ 28), and together with patient-matched sera, were analyzed for copper content by
inductively coupled plasma mass spectrometry.
RESULTS. When grouped together, cancerous prostate tissues exhibiting moderate disease
severity (Gleason Score 7) (n¼ 10) had 1.6-fold more copper than age-matched normal tissues
(n¼ 10) (P< 0.05). Those with more aggressive disease (Gleason Score 9) (n¼ 8) had 1.8-fold
more copper (P< 0.05). In both disease stages however, the copper concentrations between
individual samples were rather variable (0.55–3.02mg/g), with many clearly within the
normal range (0.52–1.28mg/g). Additionally, we found that there was no change in serum
copper concentrations in patients with either moderate or aggressive prostate cancer (Gleason
Score 7 or 9), compared with reference intervals and to age-matched controls.
CONCLUSIONS. The heterogeneous nature of copper concentrations in cancerous prostate
tissues, suggest that a small subset of patients may respond to treatments that target elevated
intratumoral copper. Therefore, such approaches would likely require personalized treatment
strategies. Prostate 75:1510–1517, 2015. © 2015 Wiley Periodicals, Inc.
KEY WORDS: prostate cancer; copper; benign prostatic hyperplasia; ionophore;
treatment
INTRODUCTION
Indirect evidence suggests that prostate cancer cells
in vivo may accumulate intracellular copper [1–6].
Human prostate cancer cell lines propagated in mice
(xenografts) show increased uptake of radioactive
64CuCl2 [1], which was linked to enhanced cellular
copper uptake mediated by the human copper trans-
porter 1 (hCtr1) protein [2]. Numerous studies have
also shown that patient prostate cancer cell lines
harbor elevated intracellular copper (two- to six-
fold) [3–5]. However, whether intratumoral copper is
actually elevated in prostate cancer patients has not
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been established. This is despite considerable research
focus on the development of therapeutics that target
copper for their anti-prostate cancer activity.
Human clinical trials are evaluating the therapeutic
efficacy of several copper-coordination compounds
for the treatment of prostate cancer (ClinicalTrials.gov
Id: NCT00405574 & NCT01118741), and many others
are in early development (reviewed in [6]). One
therapeutic approach is to sequester bioactive copper
from the body, and chelators such as tetrathiomolyb-
date (TTM) analogues (e.g., ATN-224) are being trialed
in patients (ClinicalTrials.gov Id: NCT00405574).
Another approach is with compounds that instead
deliver copper to cells (copper-ionophores), increasing
intracellular levels of the redox active metal. The
differential response between primary (normal) and
cancerous cells to elevated intracellular copper is the
premise for the development of copper-ionophores
endowed with anticancer properties. Three chemically
distinct copper-coordination compounds, CuII(gtsm),
clioquinol, and disulfiram, that commonly release
their coordinated copper under the reductive intra-
cellular environment [7], all display anti-prostate
cancer activity in vitro and in mouse models [4,5,7,8].
Despite promising preclinical data, disulfiram failed
to elicit pharmacodynamic, or clinical activity in a
recent clinical trial in patients with non-metastatic
recurrent prostate cancer [9]. Conceivably, a lack of
understanding of the copper status in prostate cancer
patients and within their cancerous tissue, may have
contributed to the failure of this trial. Another clinical
trial evaluating disulfiram as a treatment for prostate
cancer is in the pipeline [5].
The copper content of the prostate does not change
with age in healthy individuals, being comparable in
13–60-year-old men [10]. This is apparently despite the
incidence of benign prostatic hyperplasia (BPH), which
develops from 30 years of age and manifests in 50% of
men by the age of 50 [11]. However, serum copper
concentration has been shown to increase with age,
and together with declining zinc, has been associated
with a heightened risk of several malignancies [12–15].
Nevertheless, Habib and colleagues (1980) demon-
strated that there is no difference in serum copper
concentrations between men with prostate cancer
(untreated) and aged-matched controls (BPH) [16].
However, hormonal (endocrine) treatments (e.g.,
stilboestrol and Estracyt) used for prostate cancer
therapy were shown to significantly elevate serum
copper levels [16]. It was also reported that serum
copper concentrations are elevated in aged-matched
individuals with either BPH or prostate cancer, in
comparison to a healthy young population (20–30 years
old) [16]. However, this likely reflects the normal
increase in serum copper concentration with age.
We report that cancerous prostate tissues, taken
from independent patient prostatectomies, are
heterogeneous with respect to copper concentration
(0.55–3.02mg/g). Many patients, irrespective of dis-
ease severity (Gleason Score 7 or 9), had copper
levels within the normal range (0.52–1.28mg/g).
There were also no correlations between intratu-
moral copper concentration and either prostate-
specific antigen (PSA) level (measured preopera-
tive), or patient-matched serum copper concentra-
tion. Serum copper concentration in patients with
prostate cancer (Gleason Score 7 or 9) was unal-
tered. The implications for developing prostate
cancer therapies that target copper are discussed.
MATERIALS AND METHODS
Sampling of Tissue From Patient Prostatectomies
The Victorian Cancer Biobank (Melbourne, Aus-
tralia) coordinated the isolation of human prostate
tissue samples and provided patient pathology
reports containing the information presented in
Table I. This study was approved by the Deakin
University Human Ethics Advisory Group (HEAG)
(Id# STEC-14-2013-CATER). Patients undergoing rad-
ical prostatectomies consented for their tissue to be
used for research at the time of admission for surgery.
Importantly, no patient had undergone any form of
cancer treatment (e.g., radiotherapy or chemotherapy)
prior to the prostatectomy. Sampling of tissues (core
extraction) from within the prostatectomies was per-
formed immediately following surgery, as detailed in
Results. The extracted tissue cores were divided into
two, with one part embedded in Optimal Cutting
Temperature (OCT) compound (Sakura Ltd, Japan)
for histological sectioning, and the other snap frozen
in a cryovial and stored at 80°C until required.
Prostate cancer staging, including Gleason, and pros-
tate-specific antigen (PSA) grading, were performed
at Austin Pathology (Heidelberg, Australia, 3084); an
accredited laboratory with the National Association of
Testing Authorities Australia (NATA) and the Royal
College of Pathologists of Australia.
Serum Collection
Patients at preadmission for radical prostatectomy
surgery provided consent for additional blood collec-
tion in conjunction with routine bloods taken by
Austin Pathology services. Whole blood was collected
into Vacuette serum collection tubes (Greiner Bio-one,
Austria; Cat#455071) and allowed to clot by standing
for 30 minutes at room temperature. These collection
tubes have been validated for use in divalent metal
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determination in serum (see product description).
Serum was collected by centrifugation initially at
1200g for 10min at room temperature, to separate
from the clotted fraction. The cleared serum super-
natant was then decanted into a fresh tube and
centrifuged again at 1800g for 10min. The serum was
then divided into 500ml aliquots in 1.5ml Cryovials
(Nunc, Denmark) and stored at 80°C until required.
Copper Analysis
The Victorian Cancer Biobank directly transferred
collected tissue (core extractions) and serum sam-
ples to the Biometals Facility, The University of
Melbourne (Parkville, Australia), for copper analy-
sis. Copper concentration was measured using
inductively-coupled plasma mass spectrometry
(ICP-MS, Agilent 7700, Varian). Tissues samples
were weighed and prepared for ICP-MS analysis as
previously described [17], however, reduced digest
volumes from sample heating were consistently at
10%. Quadruplicate determination of copper con-
centration was performed for each tissue sample.
Serum was diluted (1/10) in triplicate with 1%
nitric acid diluent. Unit conversions from raw ppb
values were performed as follows: Tissue copper
(mg/g)¼ (raw ppb valuedilution factor reduced
digest volume/tissue wet weight g). Serum copper
(mmol/l)¼ (raw ppb valuedilution factor/molec-
ular weight of copper). Statistical analyses were
performed using two-tailed unpaired t-tests, calcu-
lated on GraphPad PRISM (version 6.0b) software.
RESULTS
Patients presenting at the clinic with significantly
elevated prostate-specific antigen (PSA) levels
(>4 ng/ml) and palpable hardness of the prostate
posterior surface, were assessed for the prospect of
requiring radical prostatectomies. Tissue core extracts
TABLE I. Patient Information
Patient code Age PSA (ng/ml, preoperative) Diagnosisa Gleason grade
BPH A1 72 N/A High grade urethral carcinoma BPH
BPH A2 50 N/A Low grade urethral carcinoma BPH
BPH A3 62 N/A High grade urethral carcinoma BPH
BPH A4 79 N/A Prostate benign nodular hyperplasia BPH
BPH A5 80 N/A High grade urethral carcinoma BPH
BPH A6 80 N/A Prostate benign nodular hyperplasia BPH
BPH A7 80 N/A Prostate benign nodular hyperplasia BPH
BPH A8 83 N/A High grade urethral carcinoma BPH
BPH A9 75 N/A Prostate benign nodular hyperplasia BPH
BPH A10 60 N/A Prostate benign nodular hyperplasia BPH
Gle 7 B1 60 8.5 Acinar adenocarcinoma 3þ 4¼ 7
Gle 7 B2 67 9 Acinar adenocarcinoma 4þ 3¼ 7
Gle 7 B3 43 15.3 Acinar adenocarcinoma 4þ 3¼ 7
Gle 7 B4 60 9.1 Acinar adenocarcinoma 3þ 4¼ 7
Gle 7 B5 51 5.6 Acinar adenocarcinoma 3þ 4¼ 7
Gle 7 B6 65 6 Acinar adenocarcinoma 4þ 3¼ 7
Gle 7 B7 57 21 Acinar adenocarcinoma 3þ 4¼ 7
Gle 7 B8 53 17 Acinar adenocarcinoma 4þ 3¼ 7
Gle 7 B9 68 11.3 Acinar adenocarcinoma 4þ 3¼ 7
Gle 7 B10 49 b Acinar adenocarcinoma 4þ 3¼ 7
Gle 9 C1 64 12.1 Acinar adenocarcinoma 4þ 5¼ 9
Gle 9 C2 60 17.4 Acinar adenocarcinoma 5þ 4¼ 9
Gle 9 C3 69 18.85 Acinar adenocarcinoma 4þ 5¼ 9
Gle 9 C4 52 9.2 Acinar adenocarcinoma 4þ 5¼ 9
Gle 9 C5 69 10.64 Acinar adenocarcinoma 4þ 5¼ 9
Gle 9 C6 79 b Acinar adenocarcinoma 4þ 5¼ 9
Gle 9 C7 56 40 Acinar adenocarcinoma 4þ 5¼ 9
Gle 9 C8 48 b Acinar adenocarcinoma 4þ 5¼ 9
N/A, Not Applicable.
aReason for prostatectomy based on clinical diagnosis.
bNot recorded in clinical file.
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Fig. 1. Sampling of tissue from human prostates (following prostatectomy). (A) Representative images of the core extraction procedure.
Patients undergoing radical prostatectomies consented for their tissue to be used for research purposes. Descriptions for each main stage
of the core extraction procedure are provided. Images were taken with a conventional compact digital camera with an image resolution of
14 megapixels. (B) Representative images of the histological sectioning of the reassembled prostate. Clinical diagnosis including Gleason
grading was performed as described in the Materials and Methods, on tissue surrounding the extracted cores as shown. (C) Representative
images of patient tissues with either BPH, Gleason grade 7, or Gleason grade 9 pathology. Typically prostate adenocarcinomas present as a
heterogeneous mixture of differential grades (patterns) and are morphologically distinct from benign prostatic hyperplasia (BPH). Gleason
grade is determined by identifying the two most prevalent tissue patterns. Tissue patterns shown are as follows: BPH, typical benign
prostatic hyperplasia with florid proliferation of well formed glandular structures; Pattern 3, characterized by numerous small discrete
glands invading into the prostatic fibromuscular stroma; Pattern 4, glandular structures become fused into disorganized chains, with
occasional lumen formation; Pattern 5, foci comprise of single flat cells with an absence of glandular features, such as luminal spaces or
organized rings of cells; Gleason grade 7, Typical mixed tumor patterns for Gleason grade 7 (3þ4), with pattern 3 (left arrow) adjacent to
fused pattern 4 (right arrow); Gleason grade 9, Typical mixed tumor patterns for Gleason grade 9 (4þ5), with pattern 4 (top arrow) and
pattern 5 (bottom arrow). Images were captured using ``ScanScope XT`` manufactured by Aperio Ltd, at 20 magnification with an image
resolution of 0.5mm/pixel and a RGB color depth of 24 Bit.
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from within removed patient prostates were isolated
immediately following surgery by a qualified pathol-
ogist (Austin Pathology) (Fig. 1A). Competent han-
dling is important to ensure that subsequent clinical
diagnosis, performed on the reassembled prostate
specimen, is not compromised by the core extraction
procedure. The position of the tumor foci was ascer-
tained from patient Transrectal ultrasound (TRUS)
biopsy reports prior to sampling. The pathologist
performs a single horizontal slice from the posterior
face of the prostate gland at the level of the tumor
(Fig. 1A(i)). Note that in accordance with anatomical
pathology standard procedure, the anterior and pos-
terior surfaces of the fresh surgical specimen
(unsliced) are labeled with blue and black tissue dye
respectively. The dye layers mark specifically and
indelibly the periprostatic fascial layer and highlights
important diagnostic margins to the pathologist dur-
ing microscopic review. Utilizing a 6mm biopsy
punch (Stiefel Ltd, UK), a vertical core is cut into the
central/peripheral zones containing tumor/benign
tissue, whilst avoiding diagnostic margins (Fig. 1A(ii)).
The extracted cores (Fig. 1A(iii)) were prepared for
copper analysis as described in the Materials and
Methods sections. The prostate specimen was then
reassembled with the cut edges joined with surgical
staples (Fig. 1A(iv)) and was subsequently utilized for
clinical diagnosis. Histological assessment, with hem-
atoxylin and eosin (H&E) staining, of tissue surround-
ing the 6mm biopsy cores (Fig. 1B) was used to
ascertain whether disease resided within the extracted
tissue. The Gleason grade of the tumor surrounding
the core was determined by two independent pathol-
ogists (registrar and senior consultant). Representa-
tive images of the typical histological lesions seen in
both Gleason score 7 and 9 are shown, in comparison
to aged-matched prostate tissue designated as BPH
(Fig. 1C).
The extracted patient prostate tissue samples
together with the corresponding patient serum were
given a generic code for de-identification purposes, as
shown in Table 1. Patient information, including their
age, clinical diagnosis, Gleason grade (if appropriate),
and preoperative PSA levels are also shown in Table 1.
It is important to note that healthy prostate tissues
isolated for age-matched controls were all found to
harbor BPH (Table 1), consistent with its development
in most men by the age of 50 [11]. While the BPH
control tissues were extracted from men ranging
between 50 and 83 year old (Table 1), all were found
to have comparable prostate tissue copper levels
(Fig. 2A). Therefore, copper content of the prostate
does not seemingly change over this 30-year time-
frame, in addition to not changing between 13 and 60
year-old men as previously reported [10]. Patient
tissue samples exhibiting moderate disease severity
(Gleason Score 7) (n¼ 10), when analyzed together,
had 1.6-fold more copper than age-matched control
(BPH) tissues (n¼ 10) (P< 0.05) (Fig. 2A(i)). Similarly,
those with aggressive disease (Gleason Score 9) (n¼ 8)
had 1.8-fold more copper (P< 0.05) (Fig. 2A(i)). There
was no difference in intratumoral copper content
between patient samples with moderate and aggres-
sive disease pathology (Gleason Score 7 or 9), indicat-
ing that copper levels do not correlate with disease
grade. Despite there being a significant (P< 0.05)
elevation in intratumoral copper in patients, large
standard deviations (Gleason Score 7 or 9) indicated
that there was a considerable range in tissue copper
concentrations between patients (Fig. 2A(i)). The
extent of this range is more clearly evident from
individual patient tissue copper concentrations
(Fig. 2A(ii)). Precisely half of the eighteen patient
samples with either moderate or aggressive disease
pathology (Gleason Score 7 or 9) had copper concen-
trations greater than the normal (BPH) range (>0.52
to 1.28mg/g). Many individuals with disease clearly
had intratumoral copper concentrations well within
the normal range Figure 2A(ii).
We next analyzed patient-matched sera to deter-
mine whether serum copper levels are elevated in
patients with prostate cancer (Fig. 2B). There was no
difference in serum copper concentrations in patients
with either moderate or aggressive prostate cancer
(Gleason Score 7 or 9), compared with the age-
matched controls. This was despite that fact that
many of the same patients had elevated intratumoral
copper concentrations (Fig. 2A(ii)). Therefore, there
was no clinical correlation between serum and intra-
tumoral copper concentrations in patients with pros-
tate cancer.
DISCUSSION
A number of copper-coordination compounds are
being investigated on the basis that elevating intra-
cellular copper may be less toxic to normal cells than
to prostate cancer cells [2–9,18]. Elevated copper in
cancerous tissue and serum has been established for
several cancer types, including breast, ovarian, lung,
stomach, and leukemia (reviewed in [18]), but not in
prostate cancer patients. Increased intracellular cop-
per may predispose cancerous cells to ionophoric-
copper sensitivity [4,5,8,19], but this has not been
confirmed. We report here that patients with prostate
cancer are heterogeneous with respect to copper
concentrations in their cancerous tissues, with a small
percentage of patients exhibiting appreciably higher
levels (>twofold) (Fig. 2A). Therefore, a subset of
patients may be appropriate for treatments that target
1514 Denoyer et al.
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Fig. 2. Prostate cancer patients exhibit heterogeneous intratumoral copper concentrations. (A) Copper analysis of human prostate
tissues. Prostate tissue copper concentration was compared between individuals with BPH (n¼ 10), Gleason grade 7 (n¼ 10), or Gleason
grade 9 (n¼ 8) by using ICP-MS. Cohorts were grouped together for statistical analysis (i) and also had their individual results presented
(ii). Asterisk indicates significant difference between samples (P< 0.05), while error bars represent standard deviations. Actual
concentration values are shown in Supplementary Table S1. (B) Copper analysis of patient-matched sera. Serum copper concentration was
compared between the above individuals with BPH (n¼ 10), Gleason grade 7 (n¼ 10), or Gleason grade 9 (n¼ 8) by using ICP-MS.
Cohorts were grouped together for statistical analysis (i) and also had their individual results presented (ii). Asterisk indicates significant
difference between samples (P< 0.05), while error bars represent standard deviations. Actual concentration values are shown in
Supplementary Table S1.
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elevated intratumoral copper and thus such
approaches would likely require personalized treat-
ment strategies.
Published reports have stated that serum copper
levels are elevated in patients with prostate cancer,
but this is actually not the case. The commonly cited
article, written by Habib and colleagues (1980),
reported that serum copper concentrations are higher
in aged-matched individuals with either BPH or
prostate cancer, in comparison to a healthy young
population (20–30 years old) [16]. However, the
appropriate control group for prostate cancer patients
was in fact the age-matched BPH group, where the
authors showed no discernable difference in serum
copper level [16]. Notably, serum copper concentra-
tions have been shown to increase with age [12–15].
We have verified in this study, that there was no
difference in serum copper concentration in patients
with either moderate or aggressive prostate cancer
(Gleason Score 7 or 9), in comparison to published
reference intervals (10–27mM copper) [12] and to our
age-matched controls (Fig. 2B).
Enhanced copper uptake in human prostate cell
lines, mediated by the human copper transporter 1
(hCtr1) protein, has been suggested to confer elevated
intracellular copper and subsequent sensitivity to
disulfiram [2]. However, immunohistochemical studies
on patient tissue microarrays have revealed that hCtr1
is not detected in normal prostate and is not aug-
mented in prostate cancers [20]. Our results suggest
that if hCtr1 were involved in elevating copper levels
in prostate cancer, then it would be in a small subset of
patients that have elevated intratumoral copper. We
and others have also demonstrated that several human
prostate cancer cell lines used in studies (e.g., PC3,
Du145, & LNCaP) possess elevated levels of intra-
cellular copper [3–5]. Our results here suggest, that
these commonly used prostate cancer cell lines, includ-
ing mouse xenograft models derived from these cells,
likely represent the small subset of patients that harbor
elevated intratumoral copper. It is envisaged that
human explant tissue models might prove to be more
appropriate for translational research pertaining to
copper (reviewed in [21]).
In conclusion, we have demonstrated that a small
subset of prostate cancer patients may be suitable for
treatments and imaging techniques (PET) that target
elevated intratumoral copper.
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ABSTRACT
Copper-ionophores that elevate intracellular bioavailable copper display 
significant therapeutic utility against prostate cancer cells in vitro and in TRAMP 
(Transgenic Adenocarcinoma of Mouse Prostate) mice. However, the pharmacological 
basis for their anticancer activity remains unclear, despite impending clinical trails. 
Herein we show that intracellular copper levels in prostate cancer, evaluated in vitro 
and across disease progression in TRAMP mice, were not correlative with copper-
ionophore activity and mirrored the normal levels observed in patient prostatectomy 
tissues (Gleason Score 7 & 9). TRAMP adenocarcinoma cells harbored markedly 
elevated oxidative stress and diminished glutathione (GSH)-mediated antioxidant 
capacity, which together conferred selective sensitivity to prooxidant ionophoric 
copper. Copper-ionophore treatments [CuII(gtsm), disulfiram & clioquinol] generated 
toxic levels of reactive oxygen species (ROS) in TRAMP adenocarcinoma cells, but not 
in normal mouse prostate epithelial cells (PrECs). Our results provide a basis for the 
pharmacological activity of copper-ionophores and suggest they are amendable for 
treatment of patients with prostate cancer. Additionally, recent in vitro and mouse 
xenograft studies have suggested an increased copper requirement by prostate cancer 
cells. We demonstrated that prostate adenocarcinoma development in TRAMP mice 
requires a functional supply of copper and is significantly impeded by altered systemic 
copper distribution. The presence of a mutant copper-transporting Atp7b protein 
(tx mutation: A4066G/Met1356Val) in TRAMP mice changed copper-integration into 
serum and caused a remarkable reduction in prostate cancer burden (64% reduction) 
and disease severity (grade), abrogating adenocarcinoma development. Implications 
for current clinical trials are discussed.
INTRODUCTION
Prostate cancer is a major cause of morbidity and 
mortality among elderly men worldwide and is rapidly 
becoming more prevalent as life expectancy increases 
[1, 2]. Early detection is paramount, and treatment 
regimes are disease stage-dependent and can include 
combinations of radical prostatectomy, brachytherapy 
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(implanted radioactive seeds) and androgen deprivation 
(hormone therapy). Unfortunately, these therapies 
are often not curative and the majority of patients 
relapse into castration-resistant (hormone-refractory) 
disease. While attention is still focused primarily 
on developing androgen deprivation, a number of 
additional pharmacological targets have emerged (e.g. 
protein tyrosine kinases [3], mitochondrial metabolism 
[4] or prostate-specific membrane antigen [5]), 
highlighting the growing consensus that alternative 
therapies for prostate cancer are needed [6]. We recently 
established that prostate cancer cells, both in vitro and 
in the orthotopic TRAMP mouse model, are remarkably 
sensitive to a family of lipophilic compounds 
categorized as copper-ionophores [7–9]. Ionophores 
bind and transport specific metal(s) indiscriminately into 
cells, often allowing the ions to become bioavailable 
(exchangeable) [8, 10, 11]. Importantly, copper is a 
potent prooxidant and excess causes the generation of 
cytotoxic reactive oxygen species (ROS) in cells [9, 
12]. The differential response between normal (healthy) 
and cancerous cells to select copper-ionophores is 
the basis for their development against a variety of 
cancer types, including melanoma and breast cancer 
[13–15]. Nevertheless, the pharmacological mechanism 
responsible for their selective toxicity against cancerous 
cells remains unclear.
Physiological copper interchanges between 
oxidized cupric (CuII) and reduced cuprous (CuI) 
states, enabling it to serve as a rate-limiting cofactor 
for enzymes fundamental for cellular growth and 
development (reviewed in [9]). Cellular acquisition 
and utilization of prooxidant copper is tightly 
regulated by molecular transporters and chaperones 
to prevent deleterious ROS production while satiating 
cuproenzyme metallation [9]. Nevertheless, several 
reports describe copper levels being characteristically 
elevated (2-6 fold) in prostate cancer patient cell lines 
in vitro [7, 16, 17] and in xenograft mouse models [17, 
18], suggesting that patients might harbour elevated 
intratumoral copper. Raised intracellular ROS is a 
well-defined feature of human prostate cancer and 
clinical studies have unequivocally confirmed a role for 
oxidative stress in the development and progression of 
this disease [19–22]. Therefore, it has been postulated 
that elevated endogenous copper may predispose 
prostate cancer cells to copper-ionophore sensitivity, by 
possibly underpinning a heightened state of oxidative 
stress [8, 14, 17, 23]. However, copper ions can exert 
toxicity through a myriad of mechanisms, including 
protein iron-sulfur cluster interference, proteasome 
inhibition and by displacing functional metals 
(e.g. zinc and iron) from metalloproteins [9, 24, 25]. 
Furthermore, we recently established that only a small 
subset of prostate cancer patients actually harbour 
elevated intratumoral copper levels, irrespective of their 
disease stage (Gleason Score 7 or 9) [26]. Therefore, 
clarification on the importance of intratumoral copper 
for the pharmacological activity of copper-ionophores 
is required.
The anticancer activity of bis(thiosemicarbazone) 
copper ligands was established in numerous in vitro and 
in vivo studies mid last century [27–29], originating with the 
demonstration that H2gts [glyoxalbis(thiosemicarbazone)] 
inhibited sarcoma growth in Swiss brown mice [29]. 
We recently established that CuII(gtsm) [glyoxalbis(N4-
methylthiosemicarbazonato)CuII] significantly reduced 
prostate cancer burden (~70%) and severity (lesion grade) in 
the orthotopic TRAMP mouse model [8]. Pharmacokinetic 
analyses in mice confirmed that CuII(gtsm) did not exchange 
coordinated copper with other divalent metals in vivo 
[8]. Mechanistically, CuII(gtsm) undergoes intracellular 
reduction causing copper (CuI) to dissociate into a 
bioavailable (prooxidant) pool. Remarkably, the resultant 
ligand (H2gtsm) continues to re-coordinate and redistribute 
accessible copper [8]. This property renders CuII(gtsm) 
highly toxic toward human prostate cancer cell lines (e.g. 
PC3, DU145, LNCap), while normal cells (e.g. human 
primary prostate epithelial cells) remained refractory [8]. 
The anticancer activity of CuII(gtsm) was copper-dependent, 
positively correlated with milieu copper level and could 
be abrogated with copper chelation [tetrathiomolybdate 
(TTM)] [8]. Stefani and colleagues (2015) more recently 
demonstrated that CuII(gtsm) generates intracellular ROS 
and again validated the requirement for copper for its 
anticancer activity [23]. Two structurally unrelated copper-
ionophores, disulfiram [1-(diethylthiocarbamoyldisulfanyl)-
N,N-diethyl-methanethioamide)] and clioquinol 
(5-chloro-7-iodo-8-quinolinol), likewise display selective 
pharmacological activity against prostate cancer in vitro and 
in mouse models [8, 16, 17]. Analogous to CuII(gtsm), their 
anticancer potency correlated with an intrinsic ability to 
release coordinated copper under the reductive intracellular 
environment [8]. Disulfiram was identified in a screen for 
prostate cancer therapeutics and was subsequently evaluated 
in clinical trials on patients with non-metastatic recurrent 
prostate cancer (500 mg/day) [30]. Disulfiram failed to 
demonstrate clinical activity in these patients, but its 
pharmacokinetics in relation to copper was not evaluated 
and its apo (copper-free) structure was administered. 
Disulfiram, and clioquinol, absolutely require coordinated 
copper for anticancer activity [7, 8]. Another clinical trial 
evaluating disulfiram in the setting of parenteral copper 
supplementation is in the pipeline [17].
Clinical trials of copper-ionophores for prostate 
cancer treatment are clearly outpacing our understanding 
of their mechanism of action. In this study, we aimed to 
delineate the role of elevated intratumoral copper and 
ROS production and establish how copper-ionophores are 
selectively toxic toward prostate cancer cells. Additionally, 
recent in vitro and mouse xenograft studies have suggested 
an increased copper requirement by prostate cancer cells 
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[7, 8, 16-18, 31]. Therefore, we sought to determine the 
importance of copper in prostate cancer development and 
progression in the orthotopic TRAMP mouse model.
RESULTS
Copper homeostasis is maintained during 
prostate cancer progression in TRAMP mice
We previously demonstrated that prostate cancer 
cells in vitro and in the orthotopic TRAMP mouse model 
are highly sensitive to copper-ionophores that increase 
intracellular bioavailable copper [7, 8]. We, and others, 
postulated that endogenous elevated intracellular copper 
predisposed the cancer cells to sensitivity, by possibly 
underpinning a heightened state of oxidative stress [8, 
14, 17, 23]. However, we recently established that only a 
small subset of prostate cancer patients’ harbour elevated 
intratumoral copper [26] and thus sought to clarify 
whether copper is indeed the critical, and targetable, 
factor. To address this question, we surveyed copper levels 
during prostate cancer development in TRAMP mice 
(Figure 1 & 2), having previously obtained significant 
copper-ionophore [CuII(gtsm)] utility in this model [8]. 
Heterozygous male TRAMP mice develop prostate 
adenocarcinoma through the expression of the SV40 large 
T antigen (Tag), which is driven by the prostate epithelial 
specific promoter, probasin. Probasin is androgen-
driven and therefore both Tag expression and cancer 
initiation are developmentally regulated in the mice, 
beginning at 6-weeks of age [32]. Disease development 
in TRAMP mice is well-characterized [8, 32–35], with 
progressive cancer burden monitored by the cumulative 
weight of the genitourinary (GU) tract (includes prostate, 
seminal vesicles, testicles and empty urinary bladder) 
(Figure 1A & 1B). Histological examination of prostate 
lobes [anterior prostate (AP), dorsolateral prostate (DLP) 
and ventral prostate (VP)] with hematoxylin and eosin 
(H&E) staining, verified that prostate cancer develops 
uniformly in the TRAMP mouse model (Figure 1C & 1D); 
initiated with hyperplasia (6-10 weeks), then progressing 
through low-grade prostate intraepithelial neoplasia (PIN) 
(10-14 weeks), high-grade PIN (14-18 weeks), to prostate 
adenocarcinoma (18-22 weeks). The most advanced 
proliferative lesion in each lobe signified the grade of 
disease. Representative images (H&E-stained sections) of 
the various stages of disease severity (grades) can be seen 
in Figure 1D.
Inductively coupled plasma mass spectrometry 
(ICP-MS) was used to establish whether the concentration 
of copper, and of other metals (e.g. zinc and iron), 
changed in the prostate lobes of TRAMP mice during 
disease progression (Figure 2). At no stage during prostate 
cancer development (6, 10, 14, 18 and 22-weeks of age) 
did copper levels fluctuate in comparison to wt mice 
(Figure 2A–2C). These results are analogous to our recent 
findings with human patient prostatectomy samples [26], 
where the vast majority of patients regardless of disease 
severity (Gleason Score 7 or 9) had intratumoral copper 
levels within the normal range. Additionally, serum copper 
level measured across disease progression in TRAMP 
mice did not change (Figure 2D), as likewise noted in 
human prostate cancer patients [26]. In contrast, zinc 
levels were significantly lower in the ventral prostates of 
18 and 22-weeks old TRAMP mice (Figure 2G), which 
is the first prostate lobe where adenocarcinoma arises in 
this model (Figure 1C) [35]. The zinc level in the other 
prostate lobes (anterior and dorsolateral), and in serum, 
did not vary between TRAMP and wt mice at any stage 
(Figure 2E, F & 2H). These findings are consistent with 
those by Costello and colleagues (2004 & 2011), who 
established that as in human prostate cancer, zinc levels 
are markedly decreased in TRAMP adenocarcinomas [33, 
36]. The level of iron in anterior and dorsolateral prostate 
lobes was also significantly reduced in TRAMP mice at 
22 weeks of age (Figure 2I & 2J), consistent with lower 
iron accumulation observed in prostate cancer patients 
compared to healthy subjects [37]. Note that serum iron 
could not be reliably measured due to varying degrees 
of hemolysis between samples, as ruptured erythrocytes 
change iron concentrations (not shown). There were no 
changes to the concentrations of other biologically relevant 
metals, such as selenium and manganese, in prostate 
tissues or serum (not shown). Taken together, these results 
position TRAMP mice as being a clinically relevant 
model to investigate metal homeostasis during prostate 
transformation to malignancy. Moreover, the significant 
copper-ionophore [CuII(gtsm)] utility previously observed 
in this model [8] could not be explained by predisposing 
high intratumoral copper levels.
Copper-ionophores induce oxidative stress in 
TRAMP prostate cancer cells
Three distinct copper-ionophores, CuII(gtsm) 
[bis(thiosemicarbazone) analog], disulfiram (dithiocarbamate 
analog) and clioquinol (hydroxyquinoline analog), all 
release coordinated copper under the reductive intracellular 
environment [8] and display selective anticancer activity in 
vitro and in mouse models (reviewed in [9]). The differential 
response between healthy (normal) and cancerous cells 
to these copper-ionophores is the premise for their further 
development and conceivably, is due to a disparity in handling 
and detoxifying elevated prooxidant copper. To investigate 
this possibility, we compared prostate epithelial cells (PrECs) 
derived from wt mice to cancerous prostate epithelial cells 
(TRAMP-C1) derived from TRAMP mice (Figure 3). 
Prostate tissue used to establish the TRAMP-C1 cell line 
was obtained from a 32-week old TRAMP mouse bearing 
adenocarcinoma, as previously described [38]. The PrEC and 
TRAMP-C1 cell lines had comparable levels of intracellular 
copper (Figure 3A), consistent with our observations using 
Oncotarget37067www.impactjournals.com/oncotarget
ex vivo prostate tissues derived from wt and TRAMP mice 
(Figure 2A-2C). Nevertheless, TRAMP-C1 cells had 
markedly elevated levels of intracellular ROS (measured 
with H2DCF-DA probe) (Figure 3B), which is a well-defined 
feature in both human [22] and TRAMP prostate cancers 
[39]. Additionally, TRAMP-C1 cells were remarkably more 
sensitive in comparison to prostate epithelial cells (PrECs) 
to copper-ionophore treatments [CuII(gtsm), disulfiram & 
clioquinol] (Figure 3C & 3D), indicating a large therapeutic 
window. Note that the proliferation of PrECs during the 
copper-ionophore treatments was unaffected (not shown). 
These results are consistent with our previous finding using 
human cells, where CuII(gtsm) selectively killed prostate 
hyperplasia and carcinoma cell lines (BPH-1, PC3, DU145 
& LNCaP), while not affecting the viability or proliferation 
of primary prostate epithelial cells [8]. To be consistent with 
our previous studies [7, 8], copper-ionophore treatments were 
in media supplemented with a physiological level in copper 
(20 µM CuCl2). Milieu copper is required for the anticancer 
activities of both disulfiram (DSF) and clioquinol ligands 
[7, 8]. Taken together, these results provide further evidence 
that intracellular copper status does not govern cellular 
sensitivity to copper-ionophores.
To establish if copper-ionophore toxicity correlated 
with oxidative stress, we compared both ROS production 
(Figure 3E) and antioxidant capacity (Figure 3F) between 
the PrEC and TRAMP-C1 cells. Strikingly, copper-
ionophore treatments [CuII(gtsm), disulfiram & clioquinol] 
caused ROS production only in TRAMP-C1 cells 
(Figure 3E[i] & 3[ii]). ROS was measurably elevated after 
6 hours of treatment and was considerably augmented 
after 18 hours of treatment. The same copper-ionophore 
concentrations were associated with TRAMP-C1 cell 
death following 18 hours of treatment (Figure 3C & 3D). 
Glutathione (GSH) is the major cellular antioxidant and 
plays an essential role in protecting cells against ROS 
accumulation and toxicity [40, 41]. An imbalance in 
cellular GSH homeostasis caused by either GSH oxidation 
Figure 1: Prostate cancer develops uniformly in the TRAMP mouse model. A. Progressive cancer burden in TRAMP mice 
monitored by the cumulative weight of the genitourinary (GU) tract (includes prostate, seminal vesicles, testicles and empty urinary 
bladder). GU tracts were weighed from both wild type and TRAMP mice at the indicated ages (6-22 weeks) and normalised to respective 
mouse body weights (n=5-15 at each age). Horizontal black lines represent the mean GU tract weight at the indicated age. B. Representative 
photographs of harvested GU tracts from wild type and TRAMP mice at 10, 18 and 22 weeks of age. C. Histological examination of 
prostate lobes [anterior prostate (AP), dorsolateral prostate (DLP) and ventral prostate (VP)] with hematoxylin and eosin (H&E) staining, 
verifying disease grade in TRAMP mice at the indicated ages (6-22 weeks) (n=5 at each age). The most advanced proliferative lesion 
in each lobe signified the grade of disease. D. Representative H&E-stained sections displaying grades of prostate disease in TRAMP 
mice from hyperplasia, low-grade PIN, high-grade PIN, adenocarcinoma and invasive adenocarcinoma. H&E-stained normal prostate was 
obtained from wild type mice. (***p < 0.001).
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(to GSSG), or by GSH efflux, can diminish the antioxidant 
capacity of the cell and often contributes to cell death [40–
42]. We determined the GSH:GSSG ratio in both PrEC 
and TRAMP-C1 cells, as a well-established marker for 
antioxidant capacity (Figure 3F[iii]) [40, 41]. The basal 
GSH:GSSG ratio was significantly lower in TRAMP-C1 
cells than in PrEC cells (Figure 3F[iii]), meaning that there 
is less protective GSH (Figure 3F[i]) and more oxidized 
GSSG (Figure 3F[ii]) in the cancerous cells. Furthermore, 
sublethal copper-ionophore treatments [CuII(gtsm), 
disulfiram & clioquinol] stimulated an increase in the level 
of protective GSH in PrEC cells (Figure 3G[i]), while in 
stark contrast, caused a reduction in GSH in TRAMP-C1 
cells (Figure 3G[ii]). These results can account for there 
being ROS production observed only in TRAMP-C1 
cells following copper-ionophore treatments (Figure 
Figure 2: Metal levels in prostate tissue and serum during cancer development in TRAMP mice. Inductively coupled 
plasma mass spectrometry (ICP-MS) was used to determine whether copper, zinc or iron concentrations change in prostate lobes and sera of 
TRAMP mice throughout disease progression. A-D. Copper concentrations in anterior prostate (AP), dorso-lateral prostate (DLP), ventral 
prostate (VP) and serum from both wild type and TRAMP mice at the indicated ages (6-22 weeks). Zinc E-H. and iron I-K. concentrations 
are also shown. Results represent mean ± STDEV (bar) and are shown as either µg/g wet weight for tissues (n=5-10 at each age) or µM for 
serum (n=10-17 at each age). (*p < 0.05; ***p < 0.001).
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Figure 3: Copper-ionophores generate intracellular ROS and selectively target TRAMP adenocarcinoma cells 
through a disparity in their antioxidant capacity.  A. TRAMP adenocarcinoma cells (TRAMP-C1) have normal intracellular 
copper levels. Total intracellular copper was measured in both TRAMP-C1 and mouse primary prostate epithelial cells (PrECs) cultured 
under basal conditions. Results are shown as copper (ng) per 106 cells. B. TRAMP adenocarcinoma cells (TRAMP-C1) have elevated 
intracellular ROS levels. Intracellular ROS was measured using the cell permeable fluorogenic probe H2DCF-DA and flow cytometry. 
Results represent mean fluorescence intensity (MFI) (geometric mean). C. Copper-ionophores potently kill TRAMP adenocarcinoma cells 
(TRAMP-C1). TRAMP-C1 cells were treated for 18 hours with CuII(gtsm), disulfiram (DSF) or clioquinol alone or in combination with 
20 μM CuCl2. Ionophore concentrations are shown and cell viability was determined by the propidium iodide exclusion assay and flow 
cytometry. D. Copper-ionophores selectively kill TRAMP adenocarcinoma cells while not affecting the viability of mouse primary prostate 
epithelial cells (PrECs). Both cell lines were treated for 18 hours with CuII(gtsm), disulfiram or clioquinol in combination with 20 μM 
CuCl2. Ionophore concentrations are shown and cell viability was determined by the propidium iodide exclusion assay and flow cytometry. 
E. Copper-ionophores generate intracellular ROS in TRAMP adenocarcinoma cells (TRAMP-C1) (i), but not in mouse primary prostate 
epithelial cells (PrECs) (ii). Both cell lines were treated for 2, 4, 6 or 18 hours with CuII(gtsm), disulfiram or clioquinol in combination 
with 20 μM CuCl2. Ionophore concentrations are shown and intracellular ROS was measured using the cell permeable fluorogenic probe 
H2DCF-DA and flow cytometry. Results represent mean fluorescence intensity (MFI) (geometric mean) F. TRAMP adenocarcinoma cells 
(TRAMP-C1) have markedly reduced antioxidant capacity. Reduced (GSH) (i) and oxidised (GSSG) (ii) glutathione were measured in 
TRAMP adenocarcinoma cells (TRAMP-C1) and mouse primary prostate epithelial cells (PrECs) by HPLC. (iii) The GSH:GSSG ratio is 
compared between both cell lines. G. Differential GSH expression in TRAMP adenocarcinoma cells (TRAMP-C1) treated with copper-
ionophores. Reduced glutathione (GSH) was measured in mouse primary prostate epithelial cells (PrECs) (i) and TRAMP adenocarcinoma 
cells (TRAMP-C1) (ii) following treatment for 18 hours with sublethal concentrations of CuII(gtsm) (20 nM), disulfiram (150 nM) or 
clioquinol (2 µM) (with 20 μM CuCl2). Glutathione (GSH & GSSG) was measured by HPLC. Results represent mean ± STDEV (bar) of 
triplicate determinations for each measurement. (*p < 0.05; **p < 0.01).
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3E[i] & 3E[ii]). Taken together, these data demonstrate 
that adenocarcinoma TRAMP-C1 cells have diminished 
capacity to handle and detoxify auxiliary ROS compared 
to wt prostate epithelial cells (PrECs), providing a premise 
for how copper-ionophores are selective toward prostate 
cancer cells.
Altered systemic copper distribution impedes 
prostate cancer growth
Despite intratumoral copper levels being normal in 
the vast majority of prostate cancer patients [26], and in 
the TRAMP mouse model (Figure 2A,B & 2C), we wanted 
to establish whether copper is nevertheless important 
for prostate cancer growth. However, manipulating diet 
to regulate systemic copper levels in mice is extremely 
difficult, as mice are proficient at maintaining strict 
homeostatic copper levels [12, 43]. Therefore, we decided 
to instead alter copper supply to the prostate by genetically 
modifying copper release from the liver; the central organ 
controlling systemic copper distribution. The toxic milk 
mouse (tx), a well-characterised model for Wilson’s 
disease, has an autosomal recessive mutation in the Atp7b 
gene (A4066G/Met1356Val) that causes substantial 
changes to systemic copper distribution [44, 45]. The gene 
encodes the copper-transporting P-type ATPase expressed 
primarily in the liver (Atp7b), which mediates both 
copper incorporation into serum components (systemic 
distribution) and the excretion of excess copper into 
bile [46]. The tx mutation in Atp7b hinders both of these 
functions [44, 45], therefore we assessed whether it could 
influence prostate cancer growth in the TRAMP mouse 
model (Figure 4 & 5).
The original tx mouse was on the inbred DL strain 
[44, 45, 47, 48], while the tx mice used in this study 
had been backcrossed to the C57BL/6 background for 
10 generations. Therefore, we first verified that our 
tx C57BL/6 model retained the same characteristics 
(Figure 4). Consistently, tx C57BL/6 mice (22-weeks 
old) accumulated substantial levels of hepatic copper 
(~35-fold increase) (Figure 4A) and had elevated 
serum copper content (~1.8-fold increase) (Figure 
4B) [44, 47, 48]. Likewise, TRAMP mice harbouring 
the tx mutation (22-weeks old) had equivalent copper 
manifestations (Figure 4A & 4B). To substantiate 
that copper integration into serum components was 
also perturbed due to the tx mutation, we measured 
ceruloplasmin (CP) oxidase activity (Figure 4C). 
Ceruloplasmin coordinates 6 atoms of allosteric copper 
that are supplied during its biosynthesis by Atp7b (in 
hepatocytes) and accounts for more than 70% of the 
copper found in blood (serum) [9]. Consistent with the 
lack of fully functional Atp7b, mice harbouring the tx 
mutation (tx and tx/TRAMP) had significantly reduced 
serum ceruloplasmin oxidase activity, as measured 
with the conventional o-dianisidine dihydrochloride 
substrate (Figure 4C). A further feature of tx mice is 
copper dyshomeostasis in extrahepatic tissues [47, 48], 
presumably due to the altered serum copper content. 
Elevated copper was found to occur in all extrahepatic 
tissues examined, even those that are not believed 
to express Atp7b [47, 48]. We confirmed that mice 
harbouring the tx mutation (tx and tx/TRAMP) have 
elevated copper in their brain (1.3 to 1.8-fold increase) 
(Figure 4D), kidneys (2-fold increase) (Figure 4E) 
and spleen (7.5 to 12-fold increase) (Figure 4F) and 
further established the same dyshomeostasis in lungs 
(1.4 to 2.2-fold increase) (Figure 4G) and the prostate 
lobes (1.8 to 2.4-fold increase) (Figure 4H[i-iii]). 
Importantly, we demonstrated that normal prostate 
(wtC57BL/6), analogous to most extrahepatic tissues, 
does not express Atp7b at the mRNA (Figure 4I[i]) or 
protein level (Figure 4I[ii]), reducing the possibility of 
a direct influence of the tx mutation on prostate cancer 
growth. Therefore, together these results demonstrate 
that the tx mutation significantly alters systemic copper 
distribution, providing a unique model to explore the 
importance of copper in prostate cancer development 
and progression.
The impact of the tx mutation and associated 
systemic copper misdistribution on prostate cancer 
growth was assessed in 22 and 26-week old male TRAMP 
mice (Figure 5). These ages represent when TRAMP 
mice first develop adenocarcinoma (Figure 1) and 
when considerable prostate cancer growth had occurred 
(Figure 5A), respectively. Notably, there was no difference 
in GU tract weight between tx and wt mice at both 22 
and 26-weeks of age (Figure 5A), demonstrating that the 
tx mutation does not alter normal prostate size. TRAMP 
mice exhibited prostate cancer burden across both age 
groups, with GU tract weights increasing 1.6–fold at 22 
weeks and 2–fold at 26-weeks, when compared to age-
matched wt mice (Figure 5A). Remarkably, TRAMP mice 
harbouring the tx mutation had significantly less prostate 
cancer burden in comparison to the standard TRAMP 
mice. The difference was more pronounced at 26-weeks 
of age, where there was a staggering 64% reduction in 
prostate cancer weight (GU tract weight). Histological 
examination of prostate lobes was further used to establish 
the severity of the proliferative lesions in the 26-week old 
mice, signifying the grade of the disease (Figure 5B). In 
TRAMP mice harbouring the tx mutation there was a 
significant reduction in the severity of prostate lesions in 
both dorsolateral (DLP) and ventral (VP) lobes, with no 
distinguishable adenocarcinoma. Representative images 
(H&E-stained sections) of the mean histological lesion 
seen in each lobe, for both TRAMP and tx harbouring 
TRAMP mice, can be seen in Figure 5C. Together, these 
results demonstrate that altering systemic copper, and 
thus copper supply to the prostate, significantly impedes 
prostate cancer growth and reduces disease severity in 
TRAMP mice.
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Figure 4: The tx mutation in Atp7b substantially alters systemic copper distribution in mice. A&B. TRAMP mice 
harbouring the tx mutation (tx/TRAMP) display elevated copper in their liver and serum. Inductively coupled plasma mass spectrometry 
(ICP-MS) was used to determine copper concentrations in the liver and serum of 22-week old wild type, tx, TRAMP and tx/TRAMP mice 
(n=5-20 for each strain). Results represent mean ± STDEV (whisker plot) and are shown as either µg/g wet weight for tissue or µM for 
serum. C. Copper incorporation into serum ceruloplasmin is perturbed in TRAMP mice harbouring the tx mutation (tx/TRAMP). Serum 
ceruloplasmin oxidase activity (copper-dependent) was measured from 22-week old wild type (n=10), tx (n=11), TRAMP (n=17) and tx/
TRAMP (n=10) mice using the o-dianisidine dihydrochloride based assay. Results are expressed as unit/litre (U/L) and presented as mean 
± STDEV (bar). D-H. TRAMP mice harbouring the tx mutation (tx/TRAMP) display elevated copper in extrahepatic tissues. ICP-MS 
was used to determine copper concentrations in brain, kidney, spleen, lung and prostate lobes [anterior prostate (AP), dorsolateral prostate 
(DLP) and ventral prostate (VP)] of 22-week old wild type, tx, TRAMP and tx/TRAMP mice (n=4-20 for each strain). Results represent 
mean ± STDEV (whisker plot) and are shown as µg/g wet weight. I. Mouse prostate has no detectable level of Atp7b expression. (i) Real-
time PCR quantification of Atp7b mRNA levels in liver (LIV), kidney (KID) and prostate (PRO) of 22-week old wild type mice (n=3). The 
level of Atp7b mRNA is compared against the liver. (ii) Western blot analysis of Atp7b expression in liver (LIV), kidney (KID) and prostate 
(PRO) of 22-week old wild type mice (50 μg protein). The WND4B antibody detected Atp7b in the liver and kidney at ~170kDa. β-actin 
was detected as a loading control. (*p < 0.05; **p < 0.01; ***p < 0.001).
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DISCUSSION
Copper-ionophores are being appraised for a variety 
of therapeutic indications that require a wide range 
of copper-related pharmacological effects. Clioquinol 
analogues (e.g. PBT2) are being trialled in Alzheimer’s 
disease patients, having been shown to dissolve senile 
plaques (pathological hallmark) in mice by redistributing 
copper away from amyloid and into neighbouring 
neurons [49–51]. Similarly, CuII(atsm) [diacetylbis(N4-
methylthiosemicarbazonato)CuII] has proven to be an 
effective treatment for mice with motor neuron disease 
(ALS) [52]. CuII(atsm) releases coordinated copper in 
elevated reductive states [e.g. hypoxic tissues, electron 
transport chain (ETC) compromised cells] [8, 53, 54] and 
corrected superoxide dismutase (SOD) (cuproenzyme) 
levels in copper deficient spinal cords of ALS mice [52, 
54]. Remarkably, ALS mice treated with CuII(atsm) had 
18-months of extended survival [52]. These promising 
studies demonstrate the importance of understanding 
biological and pharmacological activities of copper-
ionophores for their therapeutic purpose. Despite extensive 
study, there is inadequate understanding of how copper-
ionophores function as anticancer agents. In this study, we 
delineated the role of elevated intratumoral copper and 
ROS and provided a premise for how copper-ionophores 
are selectively toxic toward prostate cancer cells.
Prostate tissue copper levels in TRAMP mice 
remained unchanged during prostate cancer development 
and progression (Figure 2A–2D) and thus could not 
explain the significant copper-ionophore [CuII(gtsm)] 
utility previously observed in this model [8]. Cultured 
TRAMP mouse adenocarcinoma cells (TRAMP-C1) 
were likewise susceptible to copper-ionophore treatment 
[CuII(gtsm), disulfiram & clioquinol] (Figure 3C & 3D), 
despite having normal intracellular copper levels when 
Figure 5: Altered systemic copper distribution impedes prostate cancer growth in TRAMP mice. A. The tx mutation 
significantly reduces prostate cancer burden in TRAMP mice. Genitourinary (GU) tracts were weighed from 22-week old and 26-week old 
wild type, tx, TRAMP and tx/TRAMP mice and normalised to respective mouse body weights (n=5-15 for each strain). The mean ± STDEV 
(whisker plot) for each strain is shown. B. The tx mutation significantly reduces prostate cancer disease severity (grade) in TRAMP mice. 
Histological examination of prostate lobes [anterior prostate, dorsolateral prostate and ventral prostate] with hematoxylin and eosin (H&E) 
staining, establishing disease grade in 26-week old wild type, tx, TRAMP and tx/TRAMP mice (n=5 for each strain). The most advanced 
proliferative lesion in each lobe signified the grade of disease. C. Representative H&E-stained sections displaying prostate disease grade in 
the prostate lobes [anterior prostate (AP), dorsolateral prostate (DLP) and ventral prostate (VP)] of 26-week old TRAMP and tx/TRAMP 
mice. (*p < 0.05; **p < 0.01; ***p < 0.001)
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compared to treatment-refractory mouse prostate epithelial 
cells (PrECs) (Figure 3A). These findings are consistent 
with the vast majority of patients with prostate cancer 
(Gleason Score 7 & 9) having intratumoral copper 
levels well within the normal range [26]. Enhanced 
copper uptake by prostate cancer cell lines in vitro and in 
xenografts mouse models, mediated by copper transporter 
1 (hCtr1) protein, elevates intracellular copper and has 
been suggested to underpin copper-ionophore anticancer 
activity [17, 18, 23]. Our results establish that surplus 
copper does not govern the pharmacological facility of 
copper-ionophores, but may heighten clinical activity 
in the small subset of patients found to have elevated 
intratumoral copper [26]. Additionally, surplus copper 
is not required for the altered metabolic requirement of 
prostate cancer. Consistent with malignant transformation 
causing a loss of cell specialization, zinc levels were 
found to be significantly lower following adenocarcinoma 
onset in TRAMP mice (ventral lobe) (Figure 2G) [33, 36]. 
Healthy prostate (includes BPH) contains an extremely 
high concentration of zinc, more than any other soft 
tissue in the body (Figure 2E–2H) [55] and requires 
zinc to change metabolism in order to produce citrate, 
an important component of semen. Prostate cancer 
malignancy necessitates the reduction of intracellular zinc 
to activate mitochondrial aconitase and in turn induce 
citrate oxidation and ATP production (Krebs cycle) [33, 
36, 56]. Accordingly, zinc-ionophores have recently 
emerged as potential therapeutics for prostate cancer [57]. 
Together, copper and zinc levels in TRAMP mice mirror 
those seen in patients with prostate cancer (tissue and 
serum) (Figure 2A–2H) [33, 36, 57], positioning TRAMP 
mice as being clinically relevant to investigate ionophore 
pharmacology.
We demonstrated that TRAMP adenocarcinoma 
cells (TRAMP-C1) have markedly reduced capacity 
to detoxify elevated prooxidant (ionophoric) copper 
(Figure 3E & 3F), providing a basis for their selective 
death in vitro (Figure 3C & 3D) and in mice [8] following 
copper-ionophore treatment. A hallmark of the aggressive 
phenotype of prostate cancer is oxidative stress (increased 
ROS), which has been linked to disease development and 
progression [58–60]. Clinical trials utilizing antioxidants 
have been disappointing (reviewed in [60]), and 
conceivably prooxidant agents (e.g. ionophoric copper) 
used to instead overload the cells with oxidative stress 
may prove more effective. Copper-ionophores [CuII(gtsm), 
disulfiram & clioquinol] that release coordinated copper 
within cells [8] catalysed the formation of intracellular 
ROS in TRAMP adenocarcinoma cells (TRAMP-C1), but 
not in normal prostate epithelial cells (PrECs) at the same 
concentrations (Figure 3E). The anticancer activities of 
CuII(gtsm) and disulfiram have previously been attributed 
to ROS production, as antioxidants (e.g. N-acetyl-L-
cysteine) attenuate their effectiveness [23, 61]. Ordinarily, 
cells have potent antioxidant defence mechanisms and 
one key player, glutathione [reduced (GSH) or oxidised 
(GSSG)], serves as an indicator of the cellular redox status 
[40]. Glutathione (GSH) can directly donate an electron 
(reducing equivalent; H++ e−) to unstable molecules, 
such as ROS. In turn glutathione itself becomes reactive, 
but rapidly bridges (disulfide) with another reactive 
glutathione to form the corresponding disulfide (GSSG). 
Protein glutathionylation can also increase under oxidative 
stress and protects thiols from oxidative modifications 
that can irreversibly alter protein function or stability 
[62]. However, protein glutathionylation is dependent on 
cellular redox status, typically occurring only following 
substantial disruption to the GSH:GSSG ratio [63]. The 
capacity of cells to buffer oxidative stress depends on the 
GSH:GSSG ratio and a reduced intracellular GSH level, 
through oxidation or cellular efflux, has been associated 
with cell death induction [40, 41]. There have been several 
reports that glutathione activity is perturbed in prostate 
cancer [64, 65] and indeed treatment with L-buthionine-
sulfoximine (BSO), an inhibitor of glutathione synthesis, 
potentiates prooxidant (As2O3) toxicity in prostate cancer 
cells [66]. We demonstrated that TRAMP adenocarcinoma 
cells (TRAMP-C1) have markedly elevated ROS (Figure 
3B) coupled with a reduced basal GSH:GSSG ratio that 
corresponded to considerably less protective GSH (~50%) 
(Figure 3F[I]-[III]). Furthermore, copper-ionophore 
[CuII(gtsm), disulfiram & clioquinol] treatments further 
decreased GSH levels in the prostate cancer cells (Figure 
3G[ii]), indicative of exceeding their antioxidant capacity. 
Conversely, identical treatments of normal prostate 
epithelial cells (PrECs) increased their intracellular GSH 
level (Figure 3G[i]), thereby affording protection from 
oxidative stress-induced cell death. Taken together, our 
findings clarify that the anticancer activity of copper-
ionophores is not reliant on intracellular copper level, 
but rather on a disparity in cellular ROS and antioxidant 
capacity.
Wild type mice are proficient at maintaining strict 
homeostatic copper levels and are resistant to copper 
loading through diet [12, 43]. The liver sequesters newly 
absorbed dietary copper and through Atp7b regulates both 
copper incorporation into serum components (systemic 
distribution) and biliary excretion of superfluous copper 
[46]. The tx mutation (Met1356Val) obstructs the copper-
translocation activity of Atp7b [67], causing hepatic copper 
accumulation and altered systemic copper distribution 
[43-45, 47]. The tx mouse is a well-established model 
for the hepatic manifestations seen in Wilson disease and 
exhibits overt liver pathology at around 10-months of 
age [68]. Haplosufficiency necessitates that both Atp7b 
alleles are mutated [43]. An intriguing feature of tx mice is 
copper being systemically elevated in extrahepatic tissues 
(brain, kidney, spleen, lung & prostate) (Figure 4D–4H) 
[43], even in tissues believed not to express Atp7b (lung 
& spleen). We confirmed that mouse prostate does not 
express Atp7b at the mRNA or protein level (Figure 4I). 
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Therefore, the copper dyshomeostasis in extrahepatic 
tissues is seemingly caused by altered copper supply to 
these tissues. Copper distribution to peripheral tissues is 
poorly understood, but circulating ceruloplasmin is known 
to be the major copper-carrying protein (holds >70% of 
serum copper) [9]. The oxidase activity of ceruloplasmin 
requires copper metallation during its biosynthesis, which 
in hepatocytes is mediated by Atp7b [9]. We verified that 
copper integration into serum ceruloplasmin is impeded 
due to the tx mutation (Figure 4C), but nevertheless, tx 
mice harboured elevated serum copper levels (Figure 4B). 
How copper is alternatively incorporated into serum in 
tx mice is part of future investigations. We can confirm 
however, that ceruloplasmin deficiency alone is not 
responsible for the elevated extrahepatic tissue copper 
[69], having shown that ceruloplasmin knockout mice 
have no such copper aberration (Supplementary Figure 
S1). Therefore, the tx mutation more drastically alters 
systemic copper distribution, providing a unique model 
to explore the importance of copper in prostate cancer 
development and progression.
Our study is the first to show that prostate cancer 
growth is reliant on a functional copper supply from 
the liver (Figure 5). TRAMP mice aged to 26-weeks 
harbouring the tx mutation have a remarkable reduction 
in both prostate cancer burden (64% reduction) (Figure 
5A) and disease severity (grade), with no discernable 
carcinoma development (Figure 5B). Copper was 
evidently more important for prostate adenocarcinoma 
development as appose to PIN development (low & 
high-grade), as 22-weeks old TRAMP mice harbouring 
the tx mutation showed less significant disease reduction 
(Figure 5A & 5B). Prostate cancer develops uniformly 
in the TRAMP mouse model, progressing through high-
grade PIN to prostate adenocarcinoma at 18-22 weeks 
of age (Figure 1C). Surplus intratumoral copper is not a 
feature of prostate adenocarcinoma, in both patients (e.g. 
Gleason Score 7 & 9) [26] and TRAMP mice (across all 
grades) (Figure 2A–2C) and is thus not a requirement for 
the altered metabolic needs of aggressive malignancy. 
Instead, collectively our results demonstrate that prostate 
adenocarcinoma development requires the appropriate 
delivery of copper to the prostate gland, through a 
conventional serum carrier(s). Defining the important 
serum copper carrier(s) may provide opportunity to 
pharmacologically exploit this requirement. Moreover, 
understanding the pharmacological effects of complexes 
that target copper (e.g. chelators & ionophores) may 
better tailor their design and in vivo activities, which 
may include altering serum copper distribution. The tx 
mutation by altering serum copper distribution actually 
caused an increase in intratumoral copper in TRAMP 
mice (Figure 4H). Copper is required for numerous 
cuproenzymes involved in cancer progression and 
metastasis [9], however, the surplus intratumoral copper 
caused by altered delivery from the serum did not enhance 
prostate cancer progression. We also cannot rule out the 
possibility that the increased intratumoral copper impeded 
adenocarcinoma development.
In conclusion, we provided evidence that copper-
ionophores can selectively target prostate cancer cells 
through a disparity in their antioxidant capacity and 
therefore are amendable for the treatment of patients 
with prostate cancer. Additionally, elevated intratumoral 
copper was not requisite for their anticancer activity 
and furthermore, was not associated with malignant 
transformation of the prostate in TRAMP mice as 
previously observed in patients [26]. We also demonstrated 
that prostate adenocarcinoma development requires a 
functional supply of copper, being significantly impeded 
by altered systemic copper distribution in mice. Our 
studies warrant further biological and pharmacological 
studies on copper-ionophores, aimed at tailoring their 
activities specifically for prostate cancer therapy.
MATERIALS AND METHODS
Cell culture and reagents
TRAMP-C1 mouse prostate cancer cells were 
derived from the TRAMP (transgenic adenocarcinoma of 
mouse prostate) strain (C57BL/6 background) [38] and 
were generously provided by Assoc. Prof. Michael H. 
Kershaw (Peter MacCallum Cancer Centre, Melbourne, 
Australia). Mouse (C57BL/6) primary prostate epithelial 
cells (PrECs) were purchased from Cell Biologics 
(Chicago, USA; Cat#C57-6038). TRAMP-C1 cells were 
cultured in DMEM (ThermoFisher, Scoresby, Australia; 
Cat#11965-092) supplemented with 10% foetal calf 
serum (Bovogen biologicals, Keilor East, Australia; 
Cat#SFBS-F), 2 mM L-glutamine, 100 Units/mL 
penicillin and 100 μg/mL streptomycin. Primary prostate 
epithelial cells were cultured in Epithelial Cell Medium 
(Cell Biologics, Chicago, USA; Cat# M6621) as per the 
manufacturer’s instructions. Cells were maintained at 
37°C under humidified atmosphere containing 5% CO2.
Copper-ionophores (Disulfiram; Cat#86720 
and clioquinol; Cat#24880) were purchased from 
Sigma-Aldrich (Castle Hill, Australia) or synthesized 
[CuII(gtsm)] by Assoc. Prof. Paul S. Donnelly (University 
of Melbourne, Melbourne, Australia) following published 
procedures [70]. Each copper-ionophore was prepared in 
DMSO at 5 mM immediately before each experiment. All 
other reagents were supplied by Sigma-Aldrich (Castle 
Hill, Australia) unless specified otherwise.
Mouse experiments
Experiments were conducted in accordance 
with national and international guidelines and were 
reviewed and approved by the Deakin University 
Animal Ethics Committee (AEC) (G21/2013 & 
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G01/2014). Homozygous TRAMP mice on the 
C57BL/6 background were maintained as previously 
described [8], while wild type (wt) C57BL/6 mice 
were purchased from the Australian Animal Resources 
Centre (Canning Vale, Australia). Ceruloplasmin (CP) 
knockout C57BL/6 mice and wt littermates were kindly 
provided by Dr. Scott Ayton (University of Melbourne, 
Australia). Heterozygous TRAMP males (referred 
to as TRAMP mice) were generated by crossing 
founder homozygous TRAMP males with wtC57BL/6 
females. Toxic milk mice on the C57BL/6 background 
(referred to as tx mice), containing the A4066G/
Met1356Val mutation in the Atp7b copper-ATPase 
[53], were obtained from Prof. Julian Mercer (Deakin 
University, Burwood, Australia). Several breeding 
steps were required to generate heterozygous TRAMP/
homozygous tx male mice (Tt/XX; where T = Tramp 
& X = tx alleles). Initially, both homozygous mouse 
strains were crossed to produce heterozygous TRAMP/
heterozygous tx progeny (Tt/Xx). The progeny (Tt/Xx) 
were then backcrossed with homozygous tx mice (tt/
XX) to obtain both heterozygous TRAMP/homozygous 
tx male mice (Tt/XX) and homozygous tx male mice 
(tt/XX).
Blood was collected by cardiac puncture and 
incubated on ice for 30 min before serum was isolated by 
two centrifugations at 16,000 g for 5 min and then snap 
frozen. Genitourinary (GU) tracts (includes prostate, 
seminal vesicles, testicles and emptied urinary bladder) 
were removed and their weights normalized against 
respective mouse weights.
Genotyping
The genotypes of all mouse strains were confirmed 
by PCR-based screening using DNA isolated from 
ear tags. The DNA was extracted using the Viagen 
DirectPCR® DNA Extraction System (Viagen, Los 
Angeles, USA; Cat#402-E) with 0.2 mg/mL proteinase 
K. PCR was performed using 2xGo Taq® Hot Start 
Green Master Mix (Promega, Alexandria, Australia; 
Cat#M5122) with the primer sets shown below. 
Presence of the TRAMP SV40 T antigen transgene was 
established using the forward 5’-CCGGTCGACCG
GAAGCTTCCACAAGTGCATTTA-3’ and reverse 
5’-CTCCTTTCAAGACCTAGAAGGTCCA-3’ primers 
as previously described [32]. Primers against mouse 
IL-2 were used as an internal PCR control (forward: 
5’-CTAGGCCACAGAATTGAAAGATCT-3’ and 
reverse: 5’-GTAGGTGGAAATTCTAGCATCATCC-3’). 
Reactions were run on a Biometra PCR machine (Biolabo 
Scientific Instruments, Chatel-St-Denis, Australia) 
using an amplification program of 1 cycle at 94°C for 
5 min, 40 cycles at 94°C for 30 s, 54°C for 30 s, 72°C 
for 1 min and 1 cycle at 72°C for 5 min. Primers used 
to amplify the relevant region of the Atp7b gene, to 
confirm the tx A4066G/Met1356Val mutation, were 
forward 5’-GAGCAGGGCTCTCAGTATTCCCTA
GC-3’ (complementary sequence before exon 19) and 
reverse 5’-GGATACTGAATTCCCATGGTTCAAG-3’ 
(complementary sequence before exon 21). The program 
for amplifying the Atp7b region was 1 cycle at 96°C for 
3 min, 36 cycles at 96°C for 1 min, 55°C for 1 min, 72°C 
for 1 min and 1 cycle at 72°C for 5 min. The resultant 659-
bp PCR product was then digested with NcoI restriction 
endonuclease for 2 hours at 37°C. The attainable NcoI 
profiles included 4 fragments for wtAtp7b (103, 345, 193 
and 18-bp), 3 fragments for the tx mutation (448, 193 
and 18-bp) and 5 fragments for heterozygous mice (103, 
345,448, 193 and 18-bp).
Tissue, serum and intracellular metal analysis
Metal concentrations were determined by 
inductively coupled plasma mass spectrometry (ICP-MS). 
The prostate lobe and other organs [kidney, spleen, lung, 
liver and brain (left hemisphere)] were freeze-dried before 
being digested in 65% nitric acid (50-500 µL) (Suprapur, 
Merck, Bayswater, Australia; Cat#100441) overnight 
at room temperature and then at 90°C for 20 min. An 
equivalent volume of 30% hydrogen peroxide (VWR, 
Tingalpa, Australia; Cat#87003-224) was then added to 
each sample. Samples were incubated 30 min at room 
temperature and 15 min at 70°C and were further diluted 
with 1% nitric acid (900-1000 µl). Serum samples (50 
μL) were diluted in 1% nitric acid (450 μL). Intracellular 
metal analysis of PrEC and TRAMP-C1 cells was 
performed as follows. Cellular pellets were generated as 
previously described [7] and to each pellet 50 μL of 65% 
nitric acid were added and the samples were incubated 
for 6 hours at room temperature before being heated at 
90°C for 20 min. After digestion, 455 μL of 1% nitric acid 
were added to reach a final volume of 500 μL. All metal 
measurements were made using an Agilent 7700 series 
ICPMS instrument under routine multi-element operating 
conditions using a Helium Reaction Gas Cell. The 
instrument was calibrated using 0, 5, 10, 50, 100 and 500 
ppb of certified multi-element ICPMS standard calibration 
solutions (AccuStandard, New Haven, USA; Cat#ICP-
MS-CAL2-1, ICP-MS-CAL-3 & ICP-MS-CAL-4) for a 
range of elements and a certified internal standard solution 
containing 200 ppb of Yttrium (Y89) was used as an 
internal control (AccuStandard; Cat#ICP-MS-IS-MIX1-1). 
The raw ppb values obtained were converted into either 
μg/g of wet weight for tissues (μg/g), to μmol/L for serum, 
or to ng/106 cells for tissue culture as previously described 
[26].
Histological examination
Dissected prostate lobes were fixed in 10% 
neutral buffered formalin overnight at 4°C, before being 
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transferred into 70% ethanol and paraffin-embedded. 
Sections were cut and stained with hematoxylin and 
eosin (H&E). Prostate samples were step sectioned and 
histopathology was determined from at least 6 sections 
per mouse using the TRAMP model scoring system as 
previously described [8]. The most aggressive histological 
lesion observed in each lobe was used to grade each lobe 
and therefore the severity of disease.
Serum ceruloplasmin oxidase activity assay
The oxidase activity of ceruloplasmin in serum was 
measured spectrophotometrically by using o-dianisidine 
dihydrochloride (Sigma-Aldrich, Castle Hill, Australia; 
Cat#D3252) as a substrate, as previously described [71]. 
Briefly, in duplicate 96-well plates 5 μL of sera (or water 
for blank) was added to wells containing 75 μL of 0.1 
M sodium acetate. After a 5 min-incubation at 37˚C, 20 
μL of 7.88 mM o-dianisidine dihydrochloride was then 
added to each well. One plate was incubated for 5 min 
and the other plate for 60 min at 37°C. The reaction was 
then stopped by the addition of 200 μL of 9 M sulphuric 
acid. After 5 min of incubation at room temperature, 
absorbance was read at 540 nm using a multiplate reader 
(Multiskan, ThermoFisher Scientific). Sera from each 
mouse strain (wt, tx, TRAMP & tx/TRAMP) was taken for 
at least 10 individual mice (n=10 to 17) and analysed in 
duplicate. Ceruloplasmin oxidase activity was expressed 
in International Units per litre (U/L) using the following 
formula: (U/L) = (((A60min-A5min)/55))/ε x 1/b x 60 x 1000), 
where A60min and A5min are the absorbance of the 60 min and 
5 min solutions, respectively; ε is the molar absorptivity 
of coloured solutions in terms of substrate consumed (9.6 
mL.μmol-1.cm-1); b = optical length (1 cm); 60 = volume 
correction factor and 1000 = conversion to 1L.
Cell viability and intracellular ROS analysis
Mouse primary prostate epithelial cells (PrECs) 
and TRAMP-C1 cells were seeded (120,000 cells/well) 
separately into 24-well plates and incubated overnight. 
Cells were then treated for 2, 4, 6 or 18 hours in triplicate 
with various concentrations of CuII(gtsm), disulfiram 
(DSF), clioquinol or CuII(atsm) in complete medium with 
or without 20 μM CuCl2. Following treatment, conditioned 
media were collected in 5 mL FACS tubes and adhered 
cells were harvested using 1 mL of trypsin solution 
(0.025% trypsin and 0.02% EDTA) and then combined 
with their corresponding conditioned medium. Cells were 
pelleted by centrifugation at 1,500 rpm for 5 min at 4°C. 
To determine cell viability, cell pellets were resuspended 
in 300 μL of PBS containing 5 μg/mL propidium iodide 
(PI, excitation 538 nm/emission 617 nm) and immediately 
analysed with a FACS Canto II flow cytometer (BD 
Biosciences). 10,000 events were measured and the 
percentage of dead cells (cells positive for PI) was 
determined. To determine intracellular ROS levels 
following treatment, the cells were instead incubated 
in 500 μL of PBS containing 20 μM 2′,7′-dichlorodihy
drofluorescein diacetate (H2DCF-DA) (ThermoFisher 
Scientific, Scoresby, Australia; Cat#D399) for 30 min at 
37°C in the dark. Substrate reaction with ROS results in 
the production of fluorescent dichlorofluorescein (DCF) 
(excitation 495 nm; emission 527 nm). To concurrently 
determine cell viability, PI (2 μg/mL) was added to each 
tube immediately prior to measuring ROS. ROS levels 
were determined by comparing the mean fluorescence 
of treated versus control cells and were expressed as 
percentage of control. 10,000 events were measured and 
only viable cells (negative for PI) were used for analysis. 
Data analysis was performed with BD FACSDiva software 
version 8.0 (BD Biosciences).
GSH and GSSG measurement
GSH and GSSG were measured by HPLC with 
permanganate chemiluminescence detection [72, 73] 
using a GloCel detector with serpentine flow-cell [74]. 
Cell pellets (1 x 106 cells) were homogenised (vortexed) 
in 300 μL of 0.1% formic acid and then centrifuged at 
13000 rpm for 15 min at 4°C. For GSH determination, 
the supernatant was diluted 10-fold in aqueous formic 
acid (5%) immediately prior to analysis. For GSSG 
determination, a second aliquot of supernatant (100 µL) 
was combined with 20 µL of 675 mM Tris-HCl buffer 
(pH 8.0) and 20 µL of 6.3 mM N-ethylmaleimide (NEM) 
to block endogenous GSH, and mixed for 30 s. Then 20 
µL of 8 mM 2-mercaptoethanol was added to react excess 
NEM, and mixed for a further 30 s. To allow for complete 
disulfide bond reduction, 20 µL of 0.78 mM tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) was added 
and the solution gently heated at 50°C for 60 min. Finally, 
20 µL of aqueous formic acid (5%) was introduced to re-
acidify the sample prior to analysis.
Western blot analysis
To detect Atp7b expression in mouse prostate, 
dissected lobes (AP, DLP and VP) were pooled together 
(per mouse) and homogenized as described previously 
[75]. Control organs, including the liver and kidney, 
were similarly prepared. Protein lysates were prepared 
by homogenizing approximately 20 mg of ground liver, 
kidney or prostate tissue, in buffer containing 50 mM Tris, 
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
1% Triton-X 100, and complete mini-EDTA free protease 
inhibitor cocktail tablet (Roche Diagnostics GmbH, Castle 
Hill, Australia; Cat#04693124001). Protein samples 
(50 μg) were fractionated on a 7.5% SDS-PAGE and 
transferred to a 0.45 μm nitrocellulose membrane (GE 
Health Care Life Sciences, Australia; Cat#10600002) 
using the Mini Protean Tetra system (BioRad), before 
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being blocked with 5% non-fat dry milk in TBS-T for 
1 hour at room temperature. Mouse Atp7b was detected 
using mWND4B [44] (diluted 1:5,000), followed by HRP-
conjugated donkey anti-goat secondary antibody (Sigma-
Aldrich, Castle Hill, Australia; Cat#A5420) (diluted 
1:5,000). Mouse ceruloplasmin was detected with rabbit 
anti-human ceruloplasmin (Dako, North Sydney, Australia; 
Cat#Q0121)) (diluted 1:1,000), followed by horseradish 
peroxidase-conjugated goat anti-rabbit secondary 
antibody (Dako Cat#P0448) (dilution 1:5,000). Anti-β-
actin antibody (Sigma-Aldrich, Castle Hill, Australia; 
Cat#A5441) (diluted 1:10,000) was used as a loading 
control, with goat anti-mouse HRP secondary antibody 
(Dako; Cat#A5420) (diluted 1:5,000). Bands were 
visualized using Immobilon Western chemiluminescent 
detection kit (Merck Millipore, Bayswater, Australia; 
Cat#WBKLS0500) with the ChemiDoc MP Imaging 
system controlled by ImageLab software version 5.1 
(Bio-Rad).
Real-time quantitative PCR
Tissues were homogenized as previously described 
[75] and total RNA isolated using the Bioline Isolate II 
RNA Mini Kit according to manufacturer’s instructions 
(Bioline, Alexandria, Australia; Cat#BIO-52072). 
cDNA was then synthesized from 1 ug of RNA 
using the SensiFAST cDNA Synthesis Kit (Bioline, 
Alexandria, Australia; Cat#BIO-65053) according to 
manufacturer’s instructions. The specific primers were: 
mouse Atp7b 5’-GAGGGTCCACAGCCCTACAG and 
5’-GCGGGTCCTATTGTCTGAAGTT; and mouse 
GAPDH 5’- TCACCACCATGGAGAAGGC and 5’- 
GCTAAGCAGTTGGTGGTGCA. Real time PCR was 
performed in triplicate on 20 ng of cDNA with the Power 
SYBR-Green PCR Master Mix (ThermoFisher Scientific, 
Scoresby, Australia; Cat#4367659) using the AB 7500 
Real Time PCR System (Applied Biosystems). Primer 
efficiencies were taken into consideration when comparing 
relative amounts of mRNA to the liver using pyQPCR 
Software v0.9.
Statistical analysis
Statistical significance was determined using 
Student t test or multiple t tests (Holm-Sidak method) 
with the GraphPad Prism software (Version 6.05). Unless 
otherwise stated, the data shown are means of at least 
triplicate determinations for each test condition with 
standard deviation (± STDEV).
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